name1,name2,name3,name4,name5,mean_cp,mean_odds,uniq_a,uniq_b,shared,score,treeLevel
Human Cell Line (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,266.11,14,14,0,28.0,2.0
Human Cell Line (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,265.34,14,13,0,25.07,2.0
Human Cell Line (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,277.61,14,6,0,8.57,2.0
Diagnosis (hlca),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.65e-07,215.75,4,10,0,5.6,4.0
Vitamin D (phsu),PREDISPOSES,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,277.63,18,10,0,15.56,21.0
Assessment procedure (hlca),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),2.15e-13,277.6,7,10,0,11.9,4.0
Vitamin D Deficiency (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.23e-12,185.68,59,30,0,45.25,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),8.21e-73,265.44,59,45,0,79.32,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),3.27e-22,263.12,59,14,0,17.32,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),7.62e-13,274.63,59,8,0,9.08,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,195.19,59,7,0,7.83,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.16e-08,196.99,59,8,0,9.08,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.4e-17,237.8,59,12,0,14.44,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),1.79e-22,268.49,59,14,0,17.32,1.0
Multiple Sclerosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.88e-08,9.56,12,30,0,16.8,1.0
Multiple Sclerosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),1.88e-08,89.33,12,45,0,15.2,1.0
Multiple Sclerosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),1.88e-08,87.01,12,14,0,22.29,1.0
Multiple Sclerosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),1.88e-08,98.51,12,8,0,13.33,1.0
Multiple Sclerosis (dsyn),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.61e-06,19.07,12,7,0,11.08,1.0
Multiple Sclerosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),9.04e-08,20.88,12,8,0,13.33,1.0
Multiple Sclerosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.88e-08,61.68,12,12,0,24.0,1.0
Multiple Sclerosis (dsyn),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),1.88e-08,92.38,12,14,0,22.29,1.0
Entire lumbar spine (blor),LOCATION_OF,Neck (blor),LOCATION_OF,Prostate (bpoc),8.07e-14,77.08,11,12,0,21.08,2.0
Entire lumbar spine (blor),LOCATION_OF,Neck (blor),LOCATION_OF,"Preservation, Biological (lbpr)",8.07e-14,54.49,11,63,0,12.92,2.0
Entire lumbar spine (blor),LOCATION_OF,Neck (blor),LOCATION_OF,Malignant neoplasm of prostate (neop),2.68e-09,105.78,11,6,0,9.27,2.0
Entire lumbar spine (blor),LOCATION_OF,Neck (blor),LOCATION_OF,Bladder stenosis (anab),8.07e-14,46.42,11,17,0,18.12,2.0
Entire lumbar spine (blor),LOCATION_OF,Neck (blor),LOCATION_OF,Surgical margins (bpoc),8.07e-14,79.47,11,12,0,21.08,2.0
Vitamin D (phsu),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),2.46e-15,259.19,8,16,0,12.0,21.0
Vitamin D (phsu),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),6.2e-11,266.09,8,7,0,13.12,9.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,250.71,30,15,0,22.5,8.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,174.21,30,41,0,51.95,3.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,174.0,30,1,0,1.03,3.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,262.23,30,23,0,40.63,10.0
Vitamin D3 Receptor (gngm),PART_OF,Hepatic (blor),LOCATION_OF,Medical Imaging (diap),2.24e-10,110.99,6,126,0,6.29,2.0
Rickets (dsyn),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),6.81e-09,147.13,14,23,0,22.52,1.0
Rickets (dsyn),PROCESS_OF,African American (popg),ISA,Racial group (popg),5.99e-26,148.36,14,78,0,16.51,1.0
PTH gene|PTH (gngm),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.5e-15,252.02,8,35,0,9.83,8.0
PTH gene|PTH (gngm),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),4.5e-15,243.05,8,28,0,10.29,4.0
Calcium (bacs),STIMULATES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.29e-30,261.74,16,35,0,23.31,8.0
Calcium (bacs),STIMULATES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.29e-30,252.76,16,28,0,25.14,4.0
FGF23 (gngm),COEXISTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.29e-10,308.63,5,15,0,6.67,8.0
FGF23 (gngm),COEXISTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.45e-06,232.13,5,41,0,5.61,3.0
FGF23 (gngm),COEXISTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.92e-07,231.92,5,1,0,1.2,3.0
FGF23 (gngm),COEXISTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),8.29e-10,320.14,5,23,0,6.09,9.0
Age (orga),ASSOCIATED_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),6.76e-13,236.37,7,10,0,11.9,8.0
long-term care (hlca),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.29e-30,261.74,16,35,0,23.31,6.0
long-term care (hlca),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.29e-30,252.76,16,28,0,25.14,4.0
paricalcitol (orch),compared_with,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,138.31,32,9,0,11.53,5.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),2.19e-09,137.91,6,19,0,7.89,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,135.5,6,4,0,6.67,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.77e-06,153.92,6,4,0,6.67,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),2.2e-09,143.69,6,8,0,10.5,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),4.87e-09,140.76,6,6,0,12.0,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),2.19e-09,138.57,6,10,0,9.6,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),2.19e-09,144.71,6,9,0,10.0,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),3.7e-09,153.92,6,6,0,12.0,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),4.87e-09,140.76,6,6,0,12.0,3.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.19e-09,147.34,6,13,0,8.77,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),2.19e-09,147.34,6,13,0,8.77,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),2.19e-09,188.47,6,33,0,7.09,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),2.19e-09,144.07,6,50,0,6.72,3.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),2.19e-09,142.97,6,37,0,6.97,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),4.87e-09,140.76,6,6,0,12.0,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),2.19e-09,146.66,6,35,0,7.03,5.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),2.19e-09,135.51,6,32,0,7.12,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,135.5,6,4,0,6.67,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),2.19e-09,153.92,6,10,0,9.6,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),2.26e-09,142.41,6,7,0,11.14,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),2.23e-09,153.92,6,7,0,11.14,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),4.87e-09,140.76,6,6,0,12.0,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.19e-09,139.75,6,11,0,9.27,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.77e-06,153.92,6,4,0,6.67,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),2.19e-09,131.35,6,40,0,6.9,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",2.19e-09,136.87,6,22,0,7.64,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),2.19e-09,141.64,6,13,0,8.77,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),2.19e-09,146.25,6,11,0,9.27,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,135.5,6,4,0,6.67,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),2.19e-09,147.51,6,40,0,6.9,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),2.19e-09,153.92,6,14,0,8.57,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.77e-06,153.92,6,4,0,6.67,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),4.87e-09,140.76,6,6,0,12.0,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.16e-07,138.57,6,5,0,9.17,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),4.87e-09,140.76,6,6,0,12.0,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),2.19e-09,146.66,6,35,0,7.03,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",3.7e-09,153.92,6,6,0,12.0,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),2.19e-09,139.19,6,21,0,7.71,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),2.19e-09,136.22,6,21,0,7.71,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),9.62e-09,123.22,6,6,0,12.0,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),2.19e-09,146.25,6,11,0,9.27,3.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),2.19e-09,140.34,6,138,0,6.26,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),2.19e-09,148.34,6,77,0,6.47,5.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),2.19e-09,149.92,6,22,0,7.64,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),2.19e-09,153.92,6,8,0,10.5,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),2.19e-09,137.08,6,58,0,6.62,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",2.19e-09,137.68,6,28,0,7.29,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),2.19e-09,153.92,6,10,0,9.6,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),2.19e-09,174.86,6,27,0,7.33,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),2.2e-09,143.69,6,8,0,10.5,5.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),2.19e-09,145.55,6,20,0,7.8,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.16e-07,138.57,6,5,0,9.17,3.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),2.19e-09,144.68,6,351,0,6.1,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),2.23e-09,153.92,6,7,0,11.14,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),3.7e-09,153.92,6,6,0,12.0,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),2.19e-09,144.25,6,51,0,6.71,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.93e-07,127.61,6,5,0,9.17,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.71e-08,153.92,6,5,0,9.17,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.19e-09,139.75,6,11,0,9.27,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),2.23e-09,153.92,6,7,0,11.14,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),2.19e-09,140.77,6,18,0,8.0,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.62e-08,176.94,6,5,0,9.17,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),2.19e-09,140.1,6,124,0,6.29,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),2.19e-09,148.35,6,31,0,7.16,5.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),2.19e-09,150.24,6,24,0,7.5,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",2.19e-09,136.89,6,66,0,6.55,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),2.19e-09,147.79,5,27,1,5.93,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),2.19e-09,146.52,6,57,0,6.63,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),2.19e-09,132.0,6,16,0,8.25,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),2.19e-09,149.08,6,18,0,8.0,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),2.19e-09,140.58,5,169,1,5.15,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),2.19e-09,134.19,6,11,0,9.27,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),2.19e-09,149.54,6,20,0,7.8,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),2.19e-09,142.42,6,28,0,7.29,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),2.19e-09,153.92,6,8,0,10.5,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),2.19e-09,141.4,6,76,0,6.47,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),2.19e-09,146.81,6,95,0,6.38,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),2.19e-09,124.33,6,38,0,6.95,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),2.19e-09,144.4,6,26,0,7.38,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.77e-06,153.92,6,4,0,6.67,3.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),2.19e-09,147.78,6,14,0,8.57,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),2.19e-09,153.93,6,20,0,7.8,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.71e-08,153.92,6,5,0,9.17,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),2.19e-09,116.0,6,10,0,9.6,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.71e-08,153.92,6,5,0,9.17,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),2.19e-09,145.55,6,20,0,7.8,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),2.19e-09,146.84,6,12,0,9.0,5.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.77e-06,153.92,6,4,0,6.67,8.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),2.19e-09,153.92,6,14,0,8.57,5.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,135.5,6,4,0,6.67,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),2.19e-09,148.17,6,15,0,8.4,7.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),2.19e-09,117.37,6,430,0,6.08,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),2.19e-09,113.0,6,20,0,7.8,1.0
Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",4.87e-09,140.76,6,6,0,12.0,1.0
Vitamin D (phsu),CAUSES,Toxic effect (inpo),PROCESS_OF,cohort (popg),1.59e-09,192.98,5,30,0,5.83,1.0
Vitamin D (phsu),CAUSES,Toxic effect (inpo),COEXISTS_WITH,Hormone-refractory prostate cancer (neop),1.59e-09,277.59,5,8,0,8.12,9.0
Vitamin D (phsu),CAUSES,Toxic effect (inpo),COEXISTS_WITH,Prostate cancer metastatic (neop),1.69e-09,257.13,5,7,0,8.57,9.0
Vitamin D (phsu),CAUSES,Toxic effect (inpo),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.59e-09,274.08,5,50,0,5.5,9.0
Vitamin D (phsu),COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,266.14,28,14,0,21.0,8.0
Vitamin D (phsu),COEXISTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,265.37,28,13,0,19.04,9.0
Vitamin D (phsu),COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,277.65,28,6,0,7.29,8.0
Intervention regimes (hlca),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,248.67,67,35,0,53.28,6.0
Intervention regimes (hlca),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,239.69,67,28,0,39.7,4.0
Breast Cancer Cell (cell),LOCATION_OF,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,179.28,11,9,0,16.36,2.0
Vitamin D (phsu),TREATS,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,236.94,19,6,0,7.89,4.0
Vitamin D (phsu),AFFECTS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,244.87,14,10,0,17.14,7.0
Supplementation (topp),USES,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,117.82,55,9,0,10.47,5.0
BONE MASS (dsyn),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),1.01e-07,64.08,6,25,0,7.44,1.0
dihydroxy-vitamin D3 (orch),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,253.82,62,15,0,18.63,8.0
dihydroxy-vitamin D3 (orch),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,177.32,62,41,0,68.11,3.0
dihydroxy-vitamin D3 (orch),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,177.11,62,1,0,1.02,3.0
dihydroxy-vitamin D3 (orch),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,265.33,62,23,0,31.53,10.0
Calcium supplementation (topp),USES,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),3.67e-07,194.72,4,9,0,5.78,5.0
alpha Tocopherol (phsu),ISA,Vitamin E (lipd),PREDISPOSES,Malignant neoplasm of prostate (neop),1.41e-16,75.23,30,20,0,33.33,5.0
Calcium (bacs),PART_OF,Protoplasm (celc),LOCATION_OF,Signal Pathways (celf),1.89e-06,2.65,133,60,0,87.07,2.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.85e-11,277.6,6,10,0,9.6,9.0
Exercise (dora),TREATS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),7.61e-07,76.12,6,5,0,9.17,1.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.74e-49,247.94,26,35,0,45.31,2.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,238.96,26,28,0,50.14,2.0
Entire right thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Prostate (bpoc),3.04e-16,71.34,14,12,0,22.29,2.0
Entire right thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"Preservation, Biological (lbpr)",2.71e-16,48.75,14,63,0,17.11,2.0
Entire right thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Malignant neoplasm of prostate (neop),2.68e-09,100.04,14,6,0,8.57,2.0
Entire right thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Bladder stenosis (anab),2.72e-16,40.69,14,17,0,25.53,2.0
Entire right thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Surgical margins (bpoc),2.93e-16,73.74,14,12,0,22.29,2.0
Intestines (bpoc),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.5e-15,245.48,8,14,0,12.57,2.0
Intestines (bpoc),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),4.5e-15,244.71,8,13,0,12.92,2.0
Intestines (bpoc),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,256.99,8,6,0,10.5,2.0
Vitamin D (phsu),AFFECTS,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),2.58e-09,176.91,10,12,0,18.33,2.0
Vitamin D (phsu),AFFECTS,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),6.12e-19,176.63,10,58,0,11.72,2.0
Sunscreening Agents (phsu),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,272.63,4,35,0,4.46,8.0
Sunscreening Agents (phsu),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.32e-07,263.65,4,28,0,4.57,4.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),2.24e-10,177.26,6,19,0,7.89,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,174.85,6,4,0,6.67,21.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.77e-06,193.27,6,4,0,6.67,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),2.25e-10,183.04,6,8,0,10.5,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.9e-09,180.11,6,6,0,12.0,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),2.24e-10,177.92,6,10,0,9.6,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),2.24e-10,184.06,6,9,0,10.0,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),1.72e-09,193.27,6,6,0,12.0,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.9e-09,180.11,6,6,0,12.0,3.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.24e-10,186.7,6,13,0,8.77,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),2.24e-10,186.7,6,13,0,8.77,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),2.24e-10,227.82,6,33,0,7.09,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),2.24e-10,183.43,6,50,0,6.72,3.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),2.24e-10,182.32,6,37,0,6.97,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.9e-09,180.11,6,6,0,12.0,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),2.24e-10,186.02,6,35,0,7.03,5.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),2.24e-10,174.87,6,32,0,7.12,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,174.85,6,4,0,6.67,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),2.24e-10,193.27,6,10,0,9.6,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),2.86e-10,181.76,6,7,0,11.14,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),2.58e-10,193.27,6,7,0,11.14,20.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.9e-09,180.11,6,6,0,12.0,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.24e-10,179.11,6,11,0,9.27,20.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.77e-06,193.27,6,4,0,6.67,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),2.24e-10,170.7,6,40,0,6.9,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",2.24e-10,176.23,6,22,0,7.64,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),2.24e-10,181.0,6,13,0,8.77,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),2.24e-10,185.6,6,11,0,9.27,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,174.85,6,4,0,6.67,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),2.24e-10,186.86,6,40,0,6.9,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),2.24e-10,193.27,6,14,0,8.57,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.77e-06,193.27,6,4,0,6.67,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.9e-09,180.11,6,6,0,12.0,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.14e-07,177.92,6,5,0,9.17,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.9e-09,180.11,6,6,0,12.0,20.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),2.24e-10,186.02,6,35,0,7.03,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",1.72e-09,193.27,6,6,0,12.0,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),2.24e-10,178.54,6,21,0,7.71,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),2.24e-10,175.57,6,21,0,7.71,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),7.65e-09,162.58,6,6,0,12.0,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),2.24e-10,185.6,6,11,0,9.27,3.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),2.24e-10,179.69,6,138,0,6.26,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),2.24e-10,187.69,6,77,0,6.47,5.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),2.24e-10,189.27,6,22,0,7.64,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),2.24e-10,193.27,6,8,0,10.5,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),2.24e-10,176.43,6,58,0,6.62,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",2.24e-10,177.03,6,28,0,7.29,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),2.24e-10,193.27,6,10,0,9.6,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),2.24e-10,214.21,6,27,0,7.33,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),2.25e-10,183.04,6,8,0,10.5,5.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),2.24e-10,184.91,6,20,0,7.8,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.14e-07,177.92,6,5,0,9.17,3.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),2.24e-10,184.03,5,350,1,5.07,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),2.58e-10,193.27,6,7,0,11.14,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),1.72e-09,193.27,6,6,0,12.0,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),2.24e-10,183.6,6,51,0,6.71,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.91e-07,166.96,6,5,0,9.17,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.51e-08,193.27,6,5,0,9.17,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.24e-10,179.11,6,11,0,9.27,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),2.58e-10,193.27,6,7,0,11.14,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),2.24e-10,180.12,6,18,0,8.0,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.43e-08,216.29,6,5,0,9.17,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),2.24e-10,179.45,6,124,0,6.29,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),2.24e-10,187.7,6,31,0,7.16,5.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),2.24e-10,189.6,6,24,0,7.5,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",2.24e-10,176.25,6,66,0,6.55,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),2.24e-10,187.14,6,28,0,7.29,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),2.24e-10,185.87,6,57,0,6.63,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),2.24e-10,171.35,6,16,0,8.25,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),2.24e-10,188.43,6,18,0,8.0,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),2.24e-10,179.93,6,170,0,6.21,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),2.24e-10,173.54,6,11,0,9.27,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),2.24e-10,188.89,6,20,0,7.8,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),2.24e-10,181.77,6,28,0,7.29,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),2.24e-10,193.27,6,8,0,10.5,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),2.24e-10,180.75,6,76,0,6.47,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),2.24e-10,186.17,6,95,0,6.38,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),2.24e-10,163.69,6,38,0,6.95,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),2.24e-10,183.75,6,26,0,7.38,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.77e-06,193.27,6,4,0,6.67,3.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),2.24e-10,187.13,6,14,0,8.57,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),2.24e-10,193.28,5,19,1,6.32,21.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.51e-08,193.27,6,5,0,9.17,20.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),2.24e-10,155.36,6,10,0,9.6,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.51e-08,193.27,6,5,0,9.17,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),2.24e-10,184.91,6,20,0,7.8,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),2.24e-10,186.19,6,12,0,9.0,5.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.77e-06,193.27,6,4,0,6.67,9.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),2.24e-10,193.27,6,14,0,8.57,5.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,174.85,6,4,0,6.67,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),2.24e-10,187.52,6,15,0,8.4,7.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),2.24e-10,156.72,6,430,0,6.08,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),2.24e-10,152.35,6,20,0,7.8,1.0
Calcium intake (fndg),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.9e-09,180.11,6,6,0,12.0,1.0
Calcium (bacs),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,232.23,43,35,0,63.49,8.0
Calcium (bacs),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,223.25,43,28,0,46.23,4.0
Cholecalciferol (phsu),TREATS,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),1.85e-11,268.39,6,9,0,10.0,2.0
Ligands (chem),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.85e-11,266.09,6,14,0,8.57,8.0
Ligands (chem),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.85e-11,265.32,6,13,0,8.77,10.0
Ligands (chem),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.52e-09,277.59,6,6,0,12.0,8.0
Replacement therapy (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,238.77,58,35,0,56.12,6.0
Replacement therapy (topp),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,229.79,58,28,0,41.52,4.0
Supplementation (topp),compared_with,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.77e-09,241.71,5,35,0,5.71,8.0
Supplementation (topp),compared_with,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.77e-09,232.73,5,28,0,5.89,4.0
Vitamin D (phsu),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-10,197.75,6,61,0,6.59,9.0
Vitamin D (phsu),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.47e-10,188.9,6,112,0,6.32,8.0
Vitamin D (phsu),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,CYP17A1 gene|CYP17A1 (gngm),1.78e-09,136.71,6,8,0,10.5,9.0
Vitamin D (phsu),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),PART_OF,8q24 (nusq),1.47e-10,154.28,6,14,0,8.57,3.0
Vitamin D (phsu),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Aggressive behavior (mobd),2.55e-10,150.08,6,8,0,10.5,8.0
Vitamin D (phsu),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),CAUSES,Malignant neoplasm of prostate (neop),2.77e-06,203.39,6,4,0,6.67,9.0
Vitamin D (phsu),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,PSCA gene|PSCA (gngm),2.83e-09,190.23,6,6,0,12.0,9.0
Vitamin D (phsu),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),LOCATION_OF,Malignant neoplasm of prostate (neop),1.65e-09,203.39,6,6,0,12.0,2.0
Calcium (bacs),PART_OF,Extracellular (celc),LOCATION_OF,Vesicle (acab),2.03e-09,4.42,145,68,0,99.89,2.0
Osteocytes (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.25e-07,228.98,4,14,0,5.14,2.0
Osteocytes (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),2.25e-07,228.21,4,13,0,5.23,2.0
Osteocytes (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.27e-07,240.49,4,6,0,6.67,2.0
Binding Protein (aapp),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.91e-25,259.4,13,35,0,17.83,8.0
Binding Protein (aapp),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),8.91e-25,250.42,13,28,0,19.04,4.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,SUBCUTANEOUS TUMOR (fndg),3.82e-08,74.37,13,6,0,8.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Benign Neoplasm (neop),1.51e-06,128.08,13,4,0,5.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Diffusion Magnetic Resonance Imaging (diap),3.37e-08,81.38,13,19,0,21.89,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,Participant (humn),3.35e-07,62.86,13,5,0,6.92,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Ovarian Carcinoma (neop),4.74e-06,78.97,13,4,0,5.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Glandular proliferation (patf),5.14e-08,55.54,13,6,0,8.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,melanoma (neop),1.51e-06,128.08,13,4,0,5.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,cohort (popg),4.74e-06,78.97,13,4,0,5.23,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Anatomical location (blor),3.37e-08,78.98,13,8,0,12.92,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Morphologically altered structure (anab),3.37e-08,36.7,13,15,0,24.27,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Malignant neoplasm of prostate (neop),3.37e-08,90.34,13,60,0,15.82,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Burden (diap),3.38e-08,76.93,13,7,0,10.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Toxic effect (inpo),1.01e-06,47.17,13,5,0,6.92,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,ABNORMAL GROWTH (fndg),3.37e-08,67.42,13,29,0,18.83,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Hemorrhage (fndg),3.37e-08,36.81,13,13,0,26.0,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Chronic inflammation (patf),3.37e-08,44.78,13,24,0,20.04,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Aggressive behavior (mobd),3.37e-08,88.18,13,9,0,15.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic resonance imaging guided biopsy (diap),3.37e-08,67.42,13,29,0,18.83,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Testosterone (strd),3.37e-08,29.83,13,41,0,17.12,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Neoplasm Metastasis (neop),3.37e-08,81.29,13,33,0,18.12,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Palpation (diap),3.37e-08,57.36,13,13,0,26.0,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,SCID Mice (mamm),3.63e-08,84.24,13,6,0,8.77,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Imaging (diap),3.37e-08,71.2,13,505,0,13.33,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,tomography (diap),3.37e-08,71.09,13,30,0,18.63,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,"Rats, Wistar (mamm)",3.37e-08,30.02,13,11,0,20.31,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Tumorigenesis (neop),3.37e-08,102.51,13,19,0,21.89,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Tuberculosis (dsyn),9.25e-08,16.36,13,9,0,15.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,"Tomography, Emission-Computed (diap)",4.74e-06,78.97,13,4,0,5.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Suppressor Genes (aapp),3.82e-08,74.37,13,6,0,8.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Digital Rectal Examination (diap),3.37e-08,65.75,13,42,0,17.02,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Driving While Intoxicated (mobd),3.37e-08,72.28,13,8,0,12.92,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Primary Carcinoma (neop),2.8e-06,97.39,13,4,0,5.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Atrophic (patf),3.37e-08,32.27,13,36,0,17.69,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,"Mice, Nude (mamm)",3.37e-08,83.03,13,54,0,16.13,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,Bladder (bpoc),3.37e-08,63.91,13,14,0,25.07,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Prolactin|PRL (aapp),3.37e-08,59.48,13,10,0,17.69,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Cell Invasion (fndg),3.37e-08,73.29,13,31,0,18.45,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PRODUCES,Prostate-Specific Antigen (aapp),3.37e-08,76.47,13,17,0,22.94,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Positron-Emission Tomography (diap),3.37e-08,90.31,13,12,0,23.08,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Medical Imaging (diap),3.37e-08,62.58,13,169,0,14.0,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Vitamin D (phsu),3.37e-08,80.65,13,9,0,15.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Acute inflammation (fndg),3.38e-08,76.93,13,7,0,10.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,Wild Type Mouse (mamm),9.86e-08,97.39,13,5,0,6.92,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Digital palpation (diap),3.37e-08,59.03,13,14,0,25.07,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,Gerbils (mamm),4.97e-06,20.66,13,6,0,8.77,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,Carcinoma (neop),3.37e-08,80.65,13,9,0,15.23,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,AR gene|AR (aapp),3.63e-08,84.24,13,6,0,8.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Serum specimen (bdsu),3.52e-08,97.39,13,6,0,8.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Stanolone (strd),3.37e-08,35.06,13,52,0,16.25,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Secondary malignant neoplasm of bone (neop),3.37e-08,82.05,13,25,0,19.76,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Carcinogenesis (neop),3.37e-08,120.42,13,20,0,21.45,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Functional assessment (diap),3.37e-08,78.98,13,20,0,21.45,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,"Phantoms, Imaging (medd)",3.37e-08,62.13,13,66,0,15.56,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Malacoplakia (patf),3.37e-08,23.73,13,15,0,24.27,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Lymphoma (neop),4.74e-06,78.97,13,4,0,5.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Nodule (acab),3.37e-08,72.84,13,22,0,20.68,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Prostate-Specific Antigen (aapp),3.37e-08,63.63,13,19,0,21.89,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Malignant disease (dsyn),3.37e-08,95.5,13,47,0,16.6,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Adenocarcinoma (neop),3.37e-08,108.35,13,123,0,14.37,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Needle biopsy procedure (diap),3.37e-08,60.4,13,682,0,13.25,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Transgenic Model (emod),3.37e-08,72.28,13,8,0,12.92,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Carcinogens (hops),3.37e-08,82.05,13,15,0,24.27,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Probes (medd),3.37e-08,57.93,13,12,0,23.08,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Transrectal Ultrasound (diap),3.37e-08,56.68,13,92,0,14.84,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Prostatic Intraepithelial Neoplasias (neop),3.37e-08,90.31,13,12,0,23.08,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Benign prostatic hypertrophy (neop),3.37e-08,55.54,13,18,0,22.39,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Cystadenoma (neop),4.74e-06,78.97,13,4,0,5.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Anatomical zone (blor),4.53e-08,60.56,13,6,0,8.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Primary Neoplasm (neop),3.37e-08,110.55,13,16,0,23.56,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Core needle biopsy (diap),3.37e-08,68.52,13,322,0,13.52,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,FLVCR1 (gngm),3.82e-08,74.37,13,6,0,8.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Biopsy (diap),3.37e-08,54.46,13,4533,0,13.04,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Bacteria (bact),1.27e-06,25.77,13,6,0,8.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,protrusion (anab),3.39e-08,28.33,13,9,0,15.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Fine needle aspiration biopsy (diap),3.37e-08,69.34,13,57,0,15.96,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,Rodent (mamm),3.37e-08,36.01,13,15,0,24.27,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,"[M]Adenocarcinoma, metastatic, NOS (neop)",4.11e-08,66.7,13,6,0,8.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Stiffness (sosy),3.37e-08,57.93,13,12,0,23.08,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Elastography (diap),3.35e-07,62.86,13,5,0,6.92,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Differential Diagnosis (diap),3.37e-08,80.65,13,9,0,15.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Model (emod),3.37e-08,85.26,12,419,1,12.34,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Small cell carcinoma of lung (neop),3.37e-08,123.7,13,9,0,15.23,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,Malignant neoplasm of prostate (neop),3.37e-08,83.76,13,23,0,20.35,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Abnormal shape (anab),3.43e-08,54.89,13,7,0,10.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Biopsy of rectum (diap),3.37e-08,32.94,13,18,0,22.39,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Estrogens (strd),3.37e-08,40.31,13,19,0,21.89,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),PART_OF,"Mice, Transgenic (mamm)",3.37e-08,68.33,13,52,0,16.25,3.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Ultrasonography (diap),3.37e-08,53.73,13,145,0,14.17,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Spectroscopy (diap),3.37e-08,62.33,13,52,0,16.25,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Localized Malignant Neoplasm (neop),3.37e-08,140.27,13,240,0,13.7,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Androgen Receptor|AR (aapp),3.06e-07,22.27,13,7,0,10.77,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Diagnosis (diap),3.37e-08,78.19,13,1087,0,13.16,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Infiltration (patf),3.37e-08,41.42,13,20,0,21.45,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Implants (medd),3.37e-08,71.33,13,154,0,14.1,2.0
"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),LOCATION_OF,Carcinoma (neop),3.37e-08,93.58,13,46,0,16.67,2.0
Vitamin D (phsu),INTERACTS_WITH,Lipids (lipd),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),6.2e-11,266.09,10,7,0,11.9,8.0
Analog (chvs),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,244.72,23,14,0,22.52,8.0
Analog (chvs),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,243.95,23,13,0,20.35,10.0
Analog (chvs),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,256.23,23,6,0,7.57,8.0
dihydroxy-vitamin D3 (orch),AFFECTS,Gene Expression (genf),AFFECTS,Malignant neoplasm of prostate (neop),1.07e-10,243.9,13,7,0,10.77,7.0
Vitamin D (phsu),PREDISPOSES,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.82e-07,200.63,5,5,0,10.0,1.0
Stimulation procedure (topp),USES,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,207.25,18,4,0,4.89,4.0
Mixed Function Oxygenases (aapp),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.24e-40,249.48,21,35,0,33.6,8.0
Mixed Function Oxygenases (aapp),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),8.24e-40,240.5,20,27,1,34.81,4.0
"Intestines, Small (bpoc)",LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),5.28e-17,254.09,9,35,0,11.31,2.0
"Intestines, Small (bpoc)",LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),5.28e-17,245.11,9,28,0,11.89,2.0
Calcifediol (phsu),higher_than,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,228.26,5,4,0,7.2,4.0
Muscle Fibers (cell),LOCATION_OF,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.84e-06,259.17,4,4,0,8.0,2.0
Vitamin D (phsu),INTERACTS_WITH,Transforming Growth Factor beta (aapp),ASSOCIATED_WITH,Tumorigenesis (neop),9.53e-08,169.37,6,9,0,10.0,8.0
Vitamin D (phsu),INTERACTS_WITH,Transforming Growth Factor beta (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.29e-11,234.36,6,27,0,7.33,8.0
Vitamin D (phsu),INTERACTS_WITH,Transforming Growth Factor beta (aapp),AFFECTS,Malignant neoplasm of prostate (neop),4.71e-06,232.68,6,4,0,6.67,7.0
Vitamin D (phsu),INTERACTS_WITH,Transforming Growth Factor beta (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.12e-10,223.47,6,7,0,11.14,8.0
Vitamin D (phsu),INTERACTS_WITH,Transforming Growth Factor beta (aapp),ASSOCIATED_WITH,Neoplasm progression (neop),1.4e-09,169.68,6,11,0,9.27,8.0
Vitamin D (phsu),INTERACTS_WITH,Transforming Growth Factor beta (aapp),PART_OF,Stroma (bpoc),3.84e-09,181.34,6,8,0,10.5,3.0
Cytochrome P450 (aapp),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),9.34e-17,238.91,9,35,0,11.31,8.0
Cytochrome P450 (aapp),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),9.34e-17,229.93,9,28,0,11.89,4.0
paricalcitol (orch),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,266.16,35,14,0,19.6,8.0
paricalcitol (orch),STIMULATES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,265.39,35,13,0,17.83,12.0
paricalcitol (orch),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,277.66,35,6,0,7.03,8.0
Calcitriol (horm),CAUSES,Up-Regulation (Physiology) (celf),AFFECTS,Malignant neoplasm of prostate (neop),2.46e-07,262.24,4,5,0,7.2,7.0
Calcitriol (horm),CAUSES,Up-Regulation (Physiology) (celf),AFFECTS,Neoplasm progression (neop),1.34e-07,210.91,4,8,0,6.0,7.0
Vitamin D (phsu),TREATS,Caucasoid Race (popg),ISA,Racial group (popg),9.87e-08,165.98,30,25,0,45.83,4.0
Skeletal bone (bpoc),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3e-18,116.28,13,15,0,24.27,2.0
Skeletal bone (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,39.77,13,41,0,17.12,2.0
Skeletal bone (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,39.56,13,1,0,1.08,2.0
Skeletal bone (bpoc),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),3e-18,127.79,13,23,0,20.35,2.0
Entire left thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Prostate (bpoc),4.81e-16,70.52,14,12,0,22.29,2.0
Entire left thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"Preservation, Biological (lbpr)",4.49e-16,47.93,14,63,0,17.11,2.0
Entire left thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Malignant neoplasm of prostate (neop),2.68e-09,99.22,14,6,0,8.57,2.0
Entire left thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Bladder stenosis (anab),4.5e-16,39.86,14,17,0,25.53,2.0
Entire left thigh (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Surgical margins (bpoc),4.7e-16,72.91,14,12,0,22.29,2.0
Cholecalciferol (phsu),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),9.34e-17,238.91,9,35,0,11.31,8.0
Cholecalciferol (phsu),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),9.34e-17,229.93,9,28,0,11.89,4.0
T-Lymphocyte (cell),PRODUCES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.35e-14,215.5,8,14,0,12.57,8.0
T-Lymphocyte (cell),PRODUCES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.35e-14,214.73,8,13,0,12.92,20.0
T-Lymphocyte (cell),PRODUCES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,227.0,8,6,0,10.5,8.0
loss; bone (patf),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.59e-09,277.59,5,10,0,7.5,9.0
Cholecalciferol (phsu),compared_with,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,157.62,8,9,0,15.11,5.0
Vitamin D (phsu),INTERACTS_WITH,Antioxidants (phsu),TREATS,Malignant neoplasm of prostate (neop),3.34e-19,267.38,10,16,0,16.25,4.0
Vitamin D (phsu),TREATS,CANADIAN (fndg),PROCESS_OF,Urologist (humn),3.2e-11,167.4,15,10,0,16.67,1.0
Depressed mood (fndg),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,255.79,15,10,0,16.67,9.0
Vitamin D (phsu),AFFECTS,Osteoblasts (cell),LOCATION_OF,Secondary malignant neoplasm of bone (neop),5.28e-17,213.75,9,98,0,9.83,2.0
Vitamin D (phsu),AFFECTS,Osteoblasts (cell),LOCATION_OF,Bone lesion (dsyn),5.28e-17,214.6,9,15,0,14.4,2.0
Vitamin D (phsu),AFFECTS,Osteoblasts (cell),LOCATION_OF,Neoplasm Metastasis (neop),5.28e-17,202.22,9,114,0,9.71,2.0
Vitamin D (phsu),AFFECTS,Osteoblasts (cell),PRODUCES,Glycoproteins (aapp),1.52e-07,179.89,9,8,0,15.11,7.0
long-term care (hlca),USES,Adrenal Cortex Hormones (phsu),TREATS,Malignant neoplasm of prostate (neop),4.56e-09,77.4,16,6,0,8.25,4.0
Epiphysial cartilage (tisu),PART_OF,Bone structure of tibia (bpoc),PART_OF,"Mice, Nude (mamm)",1.25e-07,48.08,14,10,0,17.14,3.0
Vitamin D Deficiency (dsyn),PROCESS_OF,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),3.14e-14,224.75,13,9,0,15.23,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Neoplasm progression (neop),PROCESS_OF,Animal Model (anim),1.97e-07,200.24,4,8,0,6.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Neoplasm progression (neop),PROCESS_OF,"Mice, Transgenic (mamm)",1.33e-07,206.76,4,9,0,5.78,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Neoplasm progression (neop),PROCESS_OF,cohort (popg),1.51e-07,212.37,4,7,0,6.29,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Neoplasm progression (neop),PART_OF,Prostate (bpoc),1.32e-07,258.78,3,2485,1,3.0,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Neoplasm progression (neop),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.32e-07,271.95,4,61,0,4.26,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Neoplasm progression (neop),PART_OF,Breast (bpoc),1.32e-07,187.24,4,58,0,4.28,3.0
Vitamin D (phsu),compared_with,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,250.71,30,15,0,22.5,8.0
Vitamin D (phsu),compared_with,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,174.21,30,41,0,51.95,3.0
Vitamin D (phsu),compared_with,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,174.0,30,1,0,1.03,3.0
Vitamin D (phsu),compared_with,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,262.23,30,23,0,40.63,17.0
Vitamin D (phsu),INTERACTS_WITH,FAVOR (phsu),TREATS,Malignant neoplasm of prostate (neop),6.13e-19,249.23,10,14,0,17.14,4.0
cohort (popg),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.03e-26,260.28,14,35,0,19.6,2.0
cohort (popg),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.03e-26,251.3,14,28,0,21.0,2.0
Fibroblasts (cell),LOCATION_OF,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),4.6e-07,157.62,4,9,0,5.78,2.0
Vitamin D (phsu),AFFECTS,physiological aspects (phsf),PROCESS_OF,Prostate (bpoc),4.21e-23,241.59,12,28,0,17.14,1.0
Prophylactic treatment (topp),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.65e-07,215.75,4,10,0,5.6,4.0
Cholecalciferol (phsu),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,251.71,33,15,0,21.82,8.0
Cholecalciferol (phsu),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,175.21,33,41,0,59.56,3.0
Cholecalciferol (phsu),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,175.0,33,1,0,1.03,3.0
Cholecalciferol (phsu),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,263.23,33,23,0,39.03,10.0
monocyte (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),5.84e-22,229.0,12,14,0,22.29,2.0
monocyte (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.5e-20,228.23,12,13,0,23.08,2.0
monocyte (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,240.5,12,6,0,9.0,2.0
Femur (bpoc),LOCATION_OF,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),9.24e-07,52.91,10,5,0,7.5,1.0
Cholecalciferol (phsu),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.88e-38,255.8,20,35,0,31.43,8.0
Cholecalciferol (phsu),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.88e-38,246.82,20,28,0,34.29,4.0
"Administration, Oral (topp)",USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.73e-19,293.26,10,35,0,12.86,6.0
"Administration, Oral (topp)",USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.73e-19,284.28,10,28,0,13.57,4.0
Vitamin D3 Receptor (gngm),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.83e-36,263.39,19,35,0,29.31,8.0
Vitamin D3 Receptor (gngm),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.83e-36,254.41,19,28,0,31.89,4.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Prostate (bpoc),3.26e-17,61.36,1108,12,0,12.13,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"Preservation, Biological (lbpr)",1.29e-78,38.76,1108,63,0,66.58,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Malignant neoplasm of prostate (neop),2.68e-09,90.06,1108,6,0,6.03,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Bladder stenosis (anab),8.3e-19,30.7,1108,17,0,17.26,2.0
Femur (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Surgical margins (bpoc),2.15e-17,63.75,1108,12,0,12.13,2.0
Cytochrome P450 (aapp),INTERACTS_WITH,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,166.43,11,4,0,5.45,4.0
Osteopenia (dsyn),ISA,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,105.56,12,6,0,9.0,5.0
Supplementation (topp),USES,Nutrients (food),PREDISPOSES,Malignant neoplasm of prostate (neop),1.5e-09,113.37,14,6,0,8.57,6.0
Calcium (bacs),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.37e-08,164.41,5,35,0,5.71,8.0
Calcium (bacs),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.37e-08,155.44,5,28,0,5.89,4.0
Epithelial Cells (cell),PRODUCES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.59e-09,266.09,4,13,1,5.23,8.0
Epithelial Cells (cell),PRODUCES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.59e-09,265.32,5,13,0,6.92,20.0
Epithelial Cells (cell),PRODUCES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.09e-09,277.59,4,5,1,7.2,8.0
physiological aspects (phsf),ASSOCIATED_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.59e-09,272.63,5,35,0,5.71,8.0
physiological aspects (phsf),ASSOCIATED_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.59e-09,263.65,5,28,0,5.89,4.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),6.79e-31,272.66,16,35,0,23.31,8.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),6.79e-31,263.68,16,28,0,25.14,4.0
Vitamin D2 (phsu),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,266.71,16,10,0,16.25,4.0
Osteoblasts (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,222.83,23,14,0,22.52,2.0
Osteoblasts (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,222.07,23,13,0,20.35,2.0
Osteoblasts (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,234.34,23,6,0,7.57,2.0
Calcium (bacs),PART_OF,Entire tibia (bpoc),PART_OF,SCID Mice (mamm),3.01e-07,92.89,8,5,0,8.12,3.0
Calcium (bacs),PART_OF,Entire tibia (bpoc),PART_OF,"Mice, Nude (mamm)",3.79e-08,59.21,8,7,0,13.12,3.0
"PTH protein, human|PTH (aapp)",INHIBITS,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.33e-18,132.4,12,15,0,21.6,8.0
"PTH protein, human|PTH (aapp)",INHIBITS,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,55.89,12,41,0,15.51,3.0
"PTH protein, human|PTH (aapp)",INHIBITS,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,55.68,12,1,0,1.08,3.0
"PTH protein, human|PTH (aapp)",INHIBITS,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.33e-18,143.91,12,23,0,18.26,13.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,251.07,31,15,0,22.26,8.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,174.56,31,41,0,54.44,3.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,174.35,31,1,0,1.03,3.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,262.58,31,23,0,40.06,10.0
dihydroxy-vitamin D3 (orch),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,272.7,32,35,0,61.26,8.0
dihydroxy-vitamin D3 (orch),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,263.72,32,28,0,52.5,4.0
Ovary (bpoc),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,266.08,4,14,0,5.14,2.0
Ovary (bpoc),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.32e-07,265.32,4,13,0,5.23,2.0
Ovary (bpoc),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.34e-07,277.59,4,6,0,6.67,2.0
Impaired cognition (fndg),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),2.25e-07,240.49,4,10,0,5.6,9.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.31e-14,149.33,9,15,0,14.4,8.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,72.83,9,41,0,10.98,3.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,72.62,9,1,0,1.11,3.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.31e-14,160.85,9,23,0,12.52,10.0
VITAMIN D AND METABOLITES (bacs),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),9.24e-23,248.0,12,15,0,21.6,8.0
VITAMIN D AND METABOLITES (bacs),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,171.49,12,41,0,15.51,3.0
VITAMIN D AND METABOLITES (bacs),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,171.28,12,1,0,1.08,3.0
VITAMIN D AND METABOLITES (bacs),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),7.91e-23,259.51,12,23,0,18.26,10.0
Rickets (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.41e-11,162.14,6,30,0,7.2,1.0
Rickets (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),3.29e-11,241.91,6,45,0,6.8,1.0
Rickets (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),3.29e-11,239.59,6,14,0,8.57,1.0
Rickets (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),3.37e-11,251.09,6,8,0,10.5,1.0
Rickets (dsyn),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,171.65,6,7,0,11.14,1.0
Rickets (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.17e-08,173.46,6,8,0,10.5,1.0
Rickets (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),3.29e-11,214.26,6,12,0,9.0,1.0
Rickets (dsyn),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),3.29e-11,244.96,6,14,0,8.57,1.0
Phosphorus (elii),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),6.99e-30,319.04,15,35,0,21.43,8.0
Phosphorus (elii),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),6.99e-30,310.06,15,28,0,23.04,4.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.23e-12,9.24,30,30,0,60.0,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),2.62e-20,89.01,30,45,0,50.0,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),2.65e-20,86.69,30,14,0,20.53,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),7.62e-13,98.2,30,8,0,10.13,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,18.76,30,7,0,8.63,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.16e-08,20.56,30,8,0,10.13,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.4e-17,61.37,30,12,0,16.8,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),2.64e-20,92.06,30,14,0,20.53,1.0
Total thyroidectomy (topp),PRECEDES,Prophylactic treatment (topp),USES,zoledronic acid (phsu),2.41e-08,112.42,5,18,0,6.39,6.0
Total thyroidectomy (topp),PRECEDES,Prophylactic treatment (topp),TREATS,Malignant neoplasm of prostate (neop),2.41e-08,168.59,5,43,0,5.58,4.0
Total thyroidectomy (topp),PRECEDES,Prophylactic treatment (topp),AFFECTS,Malignant neoplasm of prostate (neop),2.41e-08,176.4,5,10,0,7.5,7.0
Total thyroidectomy (topp),PRECEDES,Prophylactic treatment (topp),USES,Diphosphonates (phsu),2.41e-08,97.78,5,26,0,5.96,6.0
Total thyroidectomy (topp),PRECEDES,Prophylactic treatment (topp),TREATS,Secondary malignant neoplasm of bone (neop),2.41e-08,120.03,5,19,0,6.32,4.0
Intestines (bpoc),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.85e-11,153.13,7,15,0,10.27,2.0
Intestines (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,76.62,7,41,0,8.2,2.0
Intestines (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,76.41,7,1,0,1.14,2.0
Intestines (bpoc),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.85e-11,164.64,7,23,0,9.13,2.0
Overweight (sosy),ASSOCIATED_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.32e-07,277.59,4,10,0,5.6,8.0
Osteocalcin (aapp),PART_OF,Osteoblasts (cell),LOCATION_OF,Secondary malignant neoplasm of bone (neop),2.33e-17,79.82,13,98,0,14.72,2.0
Osteocalcin (aapp),PART_OF,Osteoblasts (cell),LOCATION_OF,Bone lesion (dsyn),2.33e-17,80.67,13,15,0,24.27,2.0
Osteocalcin (aapp),PART_OF,Osteoblasts (cell),LOCATION_OF,Neoplasm Metastasis (neop),2.33e-17,68.29,13,114,0,14.48,2.0
Osteocalcin (aapp),PART_OF,Osteoblasts (cell),PRODUCES,Glycoproteins (aapp),1.52e-07,45.96,13,8,0,12.92,3.0
Bone structure of ischium (bpoc),LOCATION_OF,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,75.27,40,5,0,5.62,1.0
Mixed Function Oxygenases (aapp),STIMULATES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),6.76e-13,231.41,7,35,0,8.4,8.0
Mixed Function Oxygenases (aapp),STIMULATES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),6.76e-13,222.43,7,28,0,8.75,4.0
Osteomalacia (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,223.04,12,10,0,18.33,9.0
Calcium (bacs),STIMULATES,Alkaline Phosphatase (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.19e-12,156.61,8,12,0,13.33,8.0
Calcium (bacs),STIMULATES,Alkaline Phosphatase (aapp),PREDISPOSES,Secondary malignant neoplasm of bone (neop),1.09e-10,103.3,8,8,0,16.0,12.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Prostate (bpoc),3.26e-17,64.86,35,12,0,16.11,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,"Preservation, Biological (lbpr)",1.1e-35,42.26,35,63,0,54.44,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Malignant neoplasm of prostate (neop),2.68e-09,93.55,35,6,0,7.03,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Bladder stenosis (anab),8.3e-19,34.2,35,17,0,25.26,2.0
DMD|BEST1 (gngm),PART_OF,Neck (blor),LOCATION_OF,Surgical margins (bpoc),2.15e-17,67.25,35,12,0,16.11,2.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),9.15e-07,5.38,21,30,0,35.7,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),9.15e-07,85.14,21,45,0,30.8,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),9.15e-07,82.82,21,14,0,23.33,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),9.15e-07,94.33,21,8,0,11.05,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),2.51e-06,14.89,21,7,0,9.33,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),9.87e-07,16.7,21,8,0,11.05,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),9.15e-07,57.5,21,12,0,18.86,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),9.15e-07,88.2,21,14,0,23.33,1.0
Glucocorticoids (horm),CAUSES,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,89.11,13,5,0,6.92,1.0
"PTH protein, human|PTH (aapp)",TREATS,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),5.04e-09,154.68,6,6,0,12.0,4.0
Column (bpoc),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,272.63,4,35,0,4.46,2.0
Column (bpoc),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.32e-07,263.65,4,28,0,4.57,2.0
Caucasoid Race (popg),ISA,Ethnic group (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),6.51e-08,94.57,30,5,0,5.83,2.0
Vitamin D (phsu),INTERACTS_WITH,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,194.74,13,9,0,15.23,5.0
Calcium-Binding Proteins (aapp),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.85e-12,112.26,9,15,0,14.4,8.0
Calcium-Binding Proteins (aapp),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,35.76,9,41,0,10.98,3.0
Calcium-Binding Proteins (aapp),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,35.55,9,1,0,1.11,3.0
Calcium-Binding Proteins (aapp),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.85e-12,123.78,9,23,0,12.52,10.0
Lithocholic Acid (bacs),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.34e-19,266.1,10,14,0,17.14,8.0
Lithocholic Acid (bacs),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),3.48e-19,265.33,10,13,0,17.69,10.0
Lithocholic Acid (bacs),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,277.6,10,6,0,9.6,8.0
Osteoporosis (dsyn),CAUSES,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.92e-07,71.01,7,5,0,8.57,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),3.58e-07,81.63,11,19,0,17.37,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),5.07e-06,79.22,11,4,0,5.45,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",3.12e-06,97.64,11,4,0,5.45,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),3.58e-07,87.41,11,8,0,13.82,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),3.61e-07,84.48,11,6,0,9.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),3.58e-07,82.29,11,10,0,19.09,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),3.58e-07,88.43,11,9,0,16.36,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),3.6e-07,97.64,11,6,0,9.27,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),3.61e-07,84.48,11,6,0,9.27,3.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),3.58e-07,91.07,11,13,0,20.31,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),3.58e-07,91.07,11,13,0,20.31,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),3.58e-07,132.19,11,33,0,14.67,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),3.58e-07,87.8,11,50,0,13.42,3.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),3.58e-07,86.69,11,37,0,14.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),3.61e-07,84.48,11,6,0,9.27,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),3.58e-07,90.39,11,35,0,14.46,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),3.58e-07,79.24,11,32,0,14.78,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),5.07e-06,79.22,11,4,0,5.45,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),3.58e-07,97.64,11,10,0,19.09,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),3.58e-07,86.13,11,7,0,11.45,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),3.58e-07,97.64,11,7,0,11.45,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),3.61e-07,84.48,11,6,0,9.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),3.58e-07,83.48,11,11,0,22.0,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),3.12e-06,97.64,11,4,0,5.45,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),3.58e-07,75.07,11,40,0,14.03,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",3.58e-07,80.6,11,22,0,16.5,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),3.58e-07,85.37,11,13,0,20.31,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),3.58e-07,89.97,11,11,0,22.0,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),5.07e-06,79.22,11,4,0,5.45,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),3.58e-07,91.23,11,40,0,14.03,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),3.58e-07,97.64,11,14,0,19.64,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),3.12e-06,97.64,11,4,0,5.45,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),3.61e-07,84.48,11,6,0,9.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),4.72e-07,82.29,11,5,0,7.27,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),3.61e-07,84.48,11,6,0,9.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),3.58e-07,90.39,11,35,0,14.46,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",3.6e-07,97.64,11,6,0,9.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),3.58e-07,82.91,11,21,0,16.76,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),3.58e-07,79.94,11,21,0,16.76,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),3.66e-07,66.95,11,6,0,9.27,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),3.58e-07,89.97,11,11,0,22.0,3.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),3.58e-07,84.06,11,138,0,11.88,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),3.58e-07,92.06,11,77,0,12.57,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),3.58e-07,93.64,11,22,0,16.5,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),3.58e-07,97.64,11,8,0,13.82,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),3.58e-07,80.8,11,58,0,13.09,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",3.58e-07,81.4,11,28,0,15.32,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),3.58e-07,97.64,11,10,0,19.09,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),3.58e-07,118.58,11,27,0,15.48,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),3.58e-07,87.41,11,8,0,13.82,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),3.58e-07,89.28,11,20,0,17.05,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),4.72e-07,82.29,11,5,0,7.27,3.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),3.58e-07,88.4,11,351,0,11.34,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),3.58e-07,97.64,11,7,0,11.45,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),3.6e-07,97.64,11,6,0,9.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),3.58e-07,87.97,11,51,0,13.37,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),5.49e-07,71.33,11,5,0,7.27,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),4.23e-07,97.64,11,5,0,7.27,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),3.58e-07,83.48,11,11,0,22.0,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),3.58e-07,97.64,11,7,0,11.45,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),3.58e-07,84.49,11,18,0,17.72,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.92e-07,120.66,11,5,0,7.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),3.58e-07,83.82,11,124,0,11.98,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),3.58e-07,92.07,11,31,0,14.9,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),3.58e-07,93.97,11,24,0,16.04,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",3.58e-07,80.62,11,66,0,12.83,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),3.58e-07,91.51,11,28,0,15.32,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),3.58e-07,90.24,11,57,0,13.12,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),3.58e-07,75.72,11,16,0,18.56,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),3.58e-07,92.8,11,18,0,17.72,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),3.58e-07,84.3,11,170,0,11.71,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),3.58e-07,77.91,11,11,0,22.0,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),3.58e-07,93.26,11,20,0,17.05,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),3.58e-07,86.14,11,28,0,15.32,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),3.58e-07,97.64,11,8,0,13.82,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),3.58e-07,85.12,11,76,0,12.59,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),3.58e-07,90.54,11,95,0,12.27,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),3.58e-07,68.06,11,38,0,14.18,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),3.58e-07,88.12,11,26,0,15.65,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),3.12e-06,97.64,11,4,0,5.45,3.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),3.58e-07,91.5,11,14,0,19.64,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),3.58e-07,97.65,11,20,0,17.05,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),4.23e-07,97.64,11,5,0,7.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),3.58e-07,59.73,11,10,0,19.09,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),4.23e-07,97.64,11,5,0,7.27,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),3.58e-07,89.28,11,20,0,17.05,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),3.58e-07,90.56,11,12,0,21.08,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),3.12e-06,97.64,11,4,0,5.45,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),3.58e-07,97.64,11,14,0,19.64,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),5.07e-06,79.22,11,4,0,5.45,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),3.58e-07,91.89,11,15,0,19.07,4.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),3.58e-07,61.09,11,430,0,11.28,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),3.58e-07,56.72,11,20,0,17.05,1.0
docetaxel (orch),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",3.61e-07,84.48,11,6,0,9.27,1.0
Vitamin D (phsu),DISRUPTS,Cell Proliferation (celf),PROCESS_OF,"Mice, Nude (mamm)",3.11e-11,160.61,17,13,0,22.94,1.0
Vitamin D (phsu),AFFECTS,Cell Growth (celf),PROCESS_OF,Cancer Model (emod),4.71e-06,259.22,22,4,0,4.73,1.0
Entire lumbar spine (blor),LOCATION_OF,Diagnostic radiologic examination (diap),DIAGNOSES,Secondary malignant neoplasm of bone (neop),3.15e-07,28.76,12,7,0,11.08,2.0
Osteoporosis (dsyn),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),5.28e-08,74.18,5,23,0,6.09,1.0
Osteoporosis (dsyn),PROCESS_OF,African American (popg),ISA,Racial group (popg),4.6e-08,75.4,5,78,0,5.32,1.0
Vitamin supplementation (phsu),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,231.24,21,10,0,14.76,4.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.23e-12,70.12,13,30,0,18.63,2.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),9.33e-21,149.89,13,45,0,16.76,2.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,FLVCR1 (gngm),9.66e-21,147.57,13,14,0,25.07,2.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),7.62e-13,159.08,13,8,0,12.92,2.0
Supplementation (topp),TREATS,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,79.64,13,7,0,10.77,4.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.16e-08,81.44,13,8,0,12.92,2.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.4e-17,122.25,13,12,0,23.08,2.0
Supplementation (topp),TREATS,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),9.51e-21,152.94,13,14,0,25.07,4.0
calcipotriene (orch),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.34e-19,272.64,10,35,0,12.86,5.0
calcipotriene (orch),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.34e-19,263.66,10,28,0,13.57,4.0
Calcitriol (horm),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,232.38,18,14,0,24.89,8.0
Calcitriol (horm),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,231.61,18,13,0,22.39,10.0
Calcitriol (horm),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,243.89,18,6,0,8.0,8.0
Rickets (dsyn),ISA,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,212.43,305,10,0,10.33,5.0
Vitamin D3 Receptor (gngm),ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.14e-14,256.13,56,9,0,10.45,5.0
Vitamin D3 Receptor (gngm),ISA,TRANSCRIPTION FACTOR (aapp),COEXISTS_WITH,FLVCR1 (gngm),2.76e-06,265.34,56,4,0,4.29,5.0
Vitamin D3 Receptor (gngm),ISA,TRANSCRIPTION FACTOR (aapp),INTERACTS_WITH,Androgens (horm),4.6e-07,224.42,56,5,0,5.45,5.0
Vitamin D3 Receptor (gngm),ISA,TRANSCRIPTION FACTOR (aapp),AFFECTS,Cell Proliferation (celf),4.18e-08,177.23,56,16,0,20.57,5.0
Vitamin D3 Receptor (gngm),ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.16e-68,261.17,56,42,0,73.5,5.0
Vitamin D3 Receptor (gngm),ISA,TRANSCRIPTION FACTOR (aapp),INTERACTS_WITH,Androgen Receptor|AR (aapp),4.56e-09,242.32,56,6,0,6.64,5.0
Vitamin D3 Receptor (gngm),ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Prostatic Neoplasms (neop),2.76e-06,265.34,56,4,0,4.29,5.0
Vitamin D3 Receptor (gngm),ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.71e-14,265.34,56,9,0,10.45,5.0
Vitamin D3 Receptor (gngm),ISA,TRANSCRIPTION FACTOR (aapp),PART_OF,Malignant neoplasm of prostate (neop),1.4e-12,255.11,56,8,0,9.14,3.0
Calcium supplementation (topp),USES,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,219.43,11,4,0,5.45,4.0
"Kidney Failure, Chronic (dsyn)",CAUSES,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,133.59,8,6,0,10.5,9.0
B-Lymphocytes (cell),PRODUCES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,266.08,4,14,0,5.14,8.0
B-Lymphocytes (cell),PRODUCES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.32e-07,265.32,4,13,0,5.23,20.0
B-Lymphocytes (cell),PRODUCES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.34e-07,277.59,4,6,0,6.67,8.0
"Hyperparathyroidism, Secondary (dsyn)",COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.9e-13,254.41,7,10,0,11.9,9.0
Osteopenia (dsyn),ISA,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.59e-09,277.59,5,10,0,7.5,5.0
Glucocorticoids (horm),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.25e-07,235.53,4,35,0,4.46,8.0
Glucocorticoids (horm),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.25e-07,226.55,4,28,0,4.57,4.0
Vitamin D3 Receptor|VDR (aapp),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.59e-09,272.63,5,35,0,5.71,8.0
Vitamin D3 Receptor|VDR (aapp),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.59e-09,263.65,5,28,0,5.89,4.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),TREATS,Osteoporosis (dsyn),1.03e-06,11.23,23,25,0,44.16,4.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),DISRUPTS,Osteoclasts (cell),2.87e-19,21.22,23,23,0,46.0,5.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),TREATS,Bone pain (sosy),8.34e-16,35.86,23,13,0,20.35,4.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),TREATS,Malignant neoplasm of prostate (neop),2.84e-19,90.69,21,59,2,28.47,4.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),PREVENTS,Neoplasm Metastasis (neop),4.05e-06,38.03,23,5,0,6.09,5.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),PREVENTS,loss; bone (patf),2.84e-19,27.04,22,27,1,39.93,5.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),TREATS,loss; bone (patf),4.18e-09,21.06,23,10,0,14.35,4.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),INHIBITS,Bone Resorption (ortf),2.84e-19,16.2,22,36,1,35.44,5.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),TREATS,Multiple Myeloma (neop),1.26e-14,19.49,23,17,0,29.57,4.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),TREATS,Bone Diseases (dsyn),1.82e-13,16.86,23,18,0,32.09,4.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),2.84e-19,35.09,23,104,0,28.09,4.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),PREVENTS,Secondary malignant neoplasm of bone (neop),1.14e-11,32.87,23,10,0,14.35,5.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),TREATS,Hypercalcemia (dsyn),3.25e-06,13.9,23,11,0,16.26,4.0
zoledronic acid (phsu),ISA,Diphosphonates (phsu),TREATS,Neoplasm Metastasis (neop),2.84e-19,32.61,23,36,0,37.69,4.0
"betamethasone-17,21-dipropionate (phsu)",ISA,Adrenal Cortex Hormones (phsu),TREATS,Malignant neoplasm of prostate (neop),3.7e-07,192.73,4,6,0,6.67,4.0
Vitamins (orch),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.77e-09,241.71,5,35,0,5.71,8.0
Vitamins (orch),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.77e-09,232.73,5,28,0,5.89,4.0
"Kidney Failure, Chronic (dsyn)",COEXISTS_WITH,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),2.21e-06,136.52,4,6,0,6.67,9.0
Tuberculosis (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),2.15e-13,277.6,7,10,0,11.9,9.0
Vitamin D (phsu),AFFECTS,Gene Expression (genf),AFFECTS,Malignant neoplasm of prostate (neop),1.07e-10,237.99,26,7,0,8.88,7.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),TREATS,Osteoporosis (dsyn),1.05e-06,24.75,7,25,0,8.96,4.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),DISRUPTS,Osteoclasts (cell),2.23e-08,34.75,7,23,0,9.13,6.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),TREATS,Bone pain (sosy),2.23e-08,49.38,7,13,0,10.77,4.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),TREATS,Malignant neoplasm of prostate (neop),2.23e-08,104.21,7,61,0,7.8,4.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),PREVENTS,Neoplasm Metastasis (neop),4.07e-06,51.56,7,5,0,8.57,6.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),PREVENTS,loss; bone (patf),2.23e-08,40.57,7,28,0,8.75,6.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),TREATS,loss; bone (patf),2.65e-08,34.59,7,10,0,11.9,4.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),INHIBITS,Bone Resorption (ortf),2.23e-08,29.72,7,37,0,8.32,6.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),TREATS,Multiple Myeloma (neop),2.23e-08,33.01,7,17,0,9.88,4.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),TREATS,Bone Diseases (dsyn),2.23e-08,30.39,7,18,0,9.72,4.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),2.23e-08,48.61,7,104,0,7.47,4.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),PREVENTS,Secondary malignant neoplasm of bone (neop),2.23e-08,46.39,7,10,0,11.9,6.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),TREATS,Hypercalcemia (dsyn),3.27e-06,27.43,7,11,0,11.45,4.0
Treatment Protocols (topp),USES,Diphosphonates (phsu),TREATS,Neoplasm Metastasis (neop),2.23e-08,46.13,7,36,0,8.36,4.0
FAVOR (phsu),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.77e-09,241.71,5,35,0,5.71,8.0
FAVOR (phsu),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.77e-09,232.73,5,28,0,5.89,4.0
Vitamin D3 Receptor (gngm),INTERACTS_WITH,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,174.13,16,9,0,14.06,5.0
Osteoblasts (cell),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.7e-12,114.68,9,15,0,14.4,2.0
Osteoblasts (cell),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,38.18,9,41,0,10.98,2.0
Osteoblasts (cell),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,37.97,9,1,0,1.11,2.0
Osteoblasts (cell),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.7e-12,126.2,9,23,0,12.52,2.0
Fracture (inpo),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),2.77e-09,246.68,5,10,0,7.5,9.0
Metabolic syndrome (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,237.29,18,10,0,15.56,9.0
Calcium (bacs),INTERACTS_WITH,FAVOR (phsu),TREATS,Malignant neoplasm of prostate (neop),1.19e-06,163.02,4,14,0,5.14,4.0
Triglycerides (bacs),ASSOCIATED_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.32e-07,277.59,4,10,0,5.6,8.0
Management procedure (hlca),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.91e-07,149.1,5,5,0,10.0,1.0
Vitamin D (phsu),INTERACTS_WITH,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,242.32,10,4,0,5.6,4.0
[M]Unspecified tumor cell NOS (cell),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.77e-09,241.71,5,35,0,5.71,2.0
[M]Unspecified tumor cell NOS (cell),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.77e-09,232.73,5,28,0,5.89,2.0
Vitamin D (phsu),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,244.05,59,14,0,17.32,8.0
Vitamin D (phsu),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,243.28,59,13,0,15.86,10.0
Vitamin D (phsu),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,255.56,59,6,0,6.61,8.0
Ibandronate (orch),ISA,Diphosphonates (phsu),TREATS,Osteoporosis (dsyn),1.03e-06,22.41,26,25,0,49.04,4.0
Ibandronate (orch),ISA,Diphosphonates (phsu),DISRUPTS,Osteoclasts (cell),3.23e-21,32.41,26,23,0,43.35,5.0
Ibandronate (orch),ISA,Diphosphonates (phsu),TREATS,Bone pain (sosy),8.34e-16,47.04,26,13,0,19.5,4.0
Ibandronate (orch),ISA,Diphosphonates (phsu),TREATS,Malignant neoplasm of prostate (neop),6.16e-30,101.87,26,61,0,37.08,4.0
Ibandronate (orch),ISA,Diphosphonates (phsu),PREVENTS,Neoplasm Metastasis (neop),4.05e-06,49.22,26,5,0,5.96,5.0
Ibandronate (orch),ISA,Diphosphonates (phsu),PREVENTS,loss; bone (patf),1.01e-29,38.23,26,28,0,50.14,5.0
Ibandronate (orch),ISA,Diphosphonates (phsu),TREATS,loss; bone (patf),4.18e-09,32.25,26,10,0,13.85,4.0
Ibandronate (orch),ISA,Diphosphonates (phsu),INHIBITS,Bone Resorption (ortf),1.62e-26,27.38,26,37,0,44.27,5.0
Ibandronate (orch),ISA,Diphosphonates (phsu),TREATS,Multiple Myeloma (neop),1.26e-14,30.68,26,17,0,28.12,4.0
Ibandronate (orch),ISA,Diphosphonates (phsu),TREATS,Bone Diseases (dsyn),1.82e-13,28.05,26,18,0,30.46,4.0
Ibandronate (orch),ISA,Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),6.16e-30,46.27,26,104,0,32.5,4.0
Ibandronate (orch),ISA,Diphosphonates (phsu),PREVENTS,Secondary malignant neoplasm of bone (neop),1.14e-11,44.05,26,10,0,13.85,5.0
Ibandronate (orch),ISA,Diphosphonates (phsu),TREATS,Hypercalcemia (dsyn),3.25e-06,25.09,26,11,0,15.65,4.0
Ibandronate (orch),ISA,Diphosphonates (phsu),TREATS,Neoplasm Metastasis (neop),6.16e-30,43.79,26,36,0,44.78,4.0
Fibroblasts (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,235.19,15,14,0,27.07,2.0
Fibroblasts (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,234.42,15,13,0,24.27,2.0
Fibroblasts (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,246.69,15,6,0,8.4,2.0
Endothelial Cells (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.25e-18,213.09,10,14,0,17.14,2.0
Endothelial Cells (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),3.26e-18,212.32,10,13,0,17.69,2.0
Endothelial Cells (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,224.6,10,6,0,9.6,2.0
Neck (blor),NEG_LOCATION_OF,Entire lumbar spine (blor),LOCATION_OF,Neoplasm Metastasis (neop),4.4e-06,81.26,6,6,0,12.0,2.0
Diphosphonates (phsu),COEXISTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.41e-08,161.06,5,15,0,6.67,8.0
Diphosphonates (phsu),COEXISTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.47e-06,84.56,5,41,0,5.61,3.0
Diphosphonates (phsu),COEXISTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),6.15e-07,84.35,5,1,0,1.2,3.0
Diphosphonates (phsu),COEXISTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.41e-08,172.58,5,23,0,6.09,9.0
Calcium (bacs),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),2.58e-09,122.43,287,12,0,12.5,2.0
Calcium (bacs),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),9.35e-45,122.16,287,58,0,69.72,2.0
chemokine (aapp),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.77e-09,241.71,5,35,0,5.71,8.0
chemokine (aapp),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.77e-09,232.73,5,28,0,5.89,4.0
"PTH protein, human|PTH (aapp)",COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.85e-25,210.81,14,35,0,19.6,8.0
"PTH protein, human|PTH (aapp)",COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.85e-25,201.83,14,28,0,21.0,4.0
25-hydroxyvitamin D (strd),INTERACTS_WITH,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.94e-06,222.07,4,4,0,8.0,4.0
monocyte (cell),LOCATION_OF,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),3.67e-07,194.72,4,9,0,5.78,2.0
Calcium Carbonate (orch),ISA,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.38e-22,141.67,14,15,0,27.07,5.0
Calcium Carbonate (orch),ISA,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,65.17,14,41,0,18.78,3.0
Calcium Carbonate (orch),ISA,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,64.96,14,1,0,1.07,3.0
Calcium Carbonate (orch),ISA,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),3.24e-22,153.19,14,23,0,22.52,5.0
calcipotriene (orch),compared_with,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),4.6e-07,157.62,4,9,0,5.78,5.0
Inflammatory Bowel Diseases (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.05e-06,8.94,10,30,0,13.33,1.0
Inflammatory Bowel Diseases (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),1.05e-06,88.71,10,45,0,12.22,1.0
Inflammatory Bowel Diseases (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),1.05e-06,86.39,10,14,0,17.14,1.0
Inflammatory Bowel Diseases (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),1.05e-06,97.9,10,8,0,14.4,1.0
Inflammatory Bowel Diseases (dsyn),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),2.65e-06,18.45,10,7,0,11.9,1.0
Inflammatory Bowel Diseases (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),1.13e-06,20.26,10,8,0,14.4,1.0
Inflammatory Bowel Diseases (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.05e-06,61.06,10,12,0,18.33,1.0
Inflammatory Bowel Diseases (dsyn),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),1.05e-06,91.76,10,14,0,17.14,1.0
Etidronate (opco),ISA,Diphosphonates (phsu),TREATS,Osteoporosis (dsyn),1.03e-06,23.18,40,25,0,40.62,4.0
Etidronate (opco),ISA,Diphosphonates (phsu),DISRUPTS,Osteoclasts (cell),3.23e-21,33.18,40,23,0,36.22,5.0
Etidronate (opco),ISA,Diphosphonates (phsu),TREATS,Bone pain (sosy),8.34e-16,47.81,40,13,0,17.23,4.0
Etidronate (opco),ISA,Diphosphonates (phsu),TREATS,Malignant neoplasm of prostate (neop),1.15e-46,102.64,40,61,0,66.23,4.0
Etidronate (opco),ISA,Diphosphonates (phsu),PREVENTS,Neoplasm Metastasis (neop),4.05e-06,49.99,40,5,0,5.62,5.0
Etidronate (opco),ISA,Diphosphonates (phsu),PREVENTS,loss; bone (patf),3.95e-30,38.99,40,28,0,47.6,5.0
Etidronate (opco),ISA,Diphosphonates (phsu),TREATS,loss; bone (patf),4.18e-09,33.02,40,10,0,12.5,4.0
Etidronate (opco),ISA,Diphosphonates (phsu),INHIBITS,Bone Resorption (ortf),1.62e-26,28.15,40,37,0,71.23,5.0
Etidronate (opco),ISA,Diphosphonates (phsu),TREATS,Multiple Myeloma (neop),1.26e-14,31.44,40,17,0,24.22,4.0
Etidronate (opco),ISA,Diphosphonates (phsu),TREATS,Bone Diseases (dsyn),1.82e-13,28.81,40,18,0,26.1,4.0
Etidronate (opco),ISA,Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),1.15e-46,47.04,40,104,0,55.38,4.0
Etidronate (opco),ISA,Diphosphonates (phsu),PREVENTS,Secondary malignant neoplasm of bone (neop),1.14e-11,44.82,40,10,0,12.5,5.0
Etidronate (opco),ISA,Diphosphonates (phsu),TREATS,Hypercalcemia (dsyn),3.25e-06,25.86,40,11,0,14.03,4.0
Etidronate (opco),ISA,Diphosphonates (phsu),TREATS,Neoplasm Metastasis (neop),1.7e-42,44.56,40,36,0,68.4,4.0
Cholecalciferol (phsu),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,231.56,7,5,0,8.57,1.0
Phosphorus (elii),COEXISTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.7e-06,103.24,5,15,0,6.67,8.0
Phosphorus (elii),COEXISTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),5.14e-06,26.74,5,41,0,5.61,3.0
Phosphorus (elii),COEXISTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),3.29e-06,26.52,5,1,0,1.2,3.0
Phosphorus (elii),COEXISTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.7e-06,114.75,5,23,0,6.09,9.0
Vitamin D (phsu),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),1.27e-09,181.15,26,12,0,17.54,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),2.26e-16,176.01,26,34,0,45.88,1.0
Stimulation procedure (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.48e-40,256.53,21,35,0,33.6,6.0
Stimulation procedure (topp),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),4.48e-40,247.56,21,28,0,36.75,4.0
Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,254.9,31,14,0,20.32,8.0
Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,254.13,31,13,0,18.45,9.0
Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,266.41,31,6,0,7.16,8.0
dihydroxy-vitamin D3 (orch),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),5.56e-57,266.71,30,35,0,55.71,5.0
dihydroxy-vitamin D3 (orch),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,257.73,30,28,0,54.13,4.0
Hypercalcemia (dsyn),COEXISTS_WITH,Lymphoma (neop),ISA,leukemia (neop),2.06e-07,54.1,5,20,0,6.25,5.0
Hypercalcemia (dsyn),COEXISTS_WITH,Lymphoma (neop),PART_OF,Prostate (bpoc),2.06e-07,93.2,5,40,0,5.62,3.0
Risedronate (orch),ISA,Diphosphonates (phsu),TREATS,Osteoporosis (dsyn),1.03e-06,27.51,30,25,0,45.83,4.0
Risedronate (orch),ISA,Diphosphonates (phsu),DISRUPTS,Osteoclasts (cell),3.23e-21,37.5,30,23,0,40.63,5.0
Risedronate (orch),ISA,Diphosphonates (phsu),TREATS,Bone pain (sosy),8.34e-16,52.14,30,13,0,18.63,4.0
Risedronate (orch),ISA,Diphosphonates (phsu),TREATS,Malignant neoplasm of prostate (neop),3.56e-37,106.97,30,61,0,44.75,4.0
Risedronate (orch),ISA,Diphosphonates (phsu),PREVENTS,Neoplasm Metastasis (neop),4.05e-06,54.31,30,5,0,5.83,5.0
Risedronate (orch),ISA,Diphosphonates (phsu),PREVENTS,loss; bone (patf),3.95e-30,43.32,30,28,0,54.13,5.0
Risedronate (orch),ISA,Diphosphonates (phsu),TREATS,loss; bone (patf),4.18e-09,37.34,30,10,0,13.33,4.0
Risedronate (orch),ISA,Diphosphonates (phsu),INHIBITS,Bone Resorption (ortf),1.62e-26,32.48,30,37,0,54.32,5.0
Risedronate (orch),ISA,Diphosphonates (phsu),TREATS,Multiple Myeloma (neop),1.26e-14,35.77,30,17,0,26.63,4.0
Risedronate (orch),ISA,Diphosphonates (phsu),TREATS,Bone Diseases (dsyn),1.82e-13,33.14,30,18,0,28.8,4.0
Risedronate (orch),ISA,Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),3.56e-37,51.37,30,104,0,38.65,4.0
Risedronate (orch),ISA,Diphosphonates (phsu),PREVENTS,Secondary malignant neoplasm of bone (neop),1.14e-11,49.15,30,10,0,13.33,5.0
Risedronate (orch),ISA,Diphosphonates (phsu),TREATS,Hypercalcemia (dsyn),3.25e-06,30.18,30,11,0,15.03,4.0
Risedronate (orch),ISA,Diphosphonates (phsu),TREATS,Neoplasm Metastasis (neop),3.56e-37,48.89,30,36,0,55.0,4.0
Combined Modality Therapy (topp),USES,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,230.65,11,4,0,5.45,4.0
Calcitriol (horm),INHIBITS,cyclooxygenase 2 (aapp),ASSOCIATED_WITH,Carcinogenesis (neop),4.11e-08,159.48,5,14,0,6.79,8.0
B-Lymphocytes (cell),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.59e-09,272.63,5,35,0,5.71,2.0
B-Lymphocytes (cell),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.59e-09,263.65,5,28,0,5.89,2.0
Osteoclasts (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.86e-17,266.1,9,14,0,14.79,2.0
Osteoclasts (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),2.87e-17,265.33,9,13,0,15.23,2.0
Osteoclasts (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,277.6,9,6,0,10.0,2.0
Calvaria (bpoc),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.02e-07,120.91,5,15,0,6.67,2.0
Calvaria (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.75e-06,44.4,5,41,0,5.61,2.0
Calvaria (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),8.94e-07,44.19,5,1,0,1.2,2.0
Calvaria (bpoc),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),3.02e-07,132.42,5,23,0,6.09,2.0
"Diabetes Mellitus, Insulin-Dependent (dsyn)",ASSOCIATED_WITH,gene polymorphism (genf),AFFECTS,Malignant neoplasm of prostate (neop),8.71e-12,139.96,8,15,0,12.27,7.0
Supplementation (topp),METHOD_OF,Prophylactic treatment (topp),USES,zoledronic acid (phsu),9.72e-12,44.55,11,18,0,17.72,6.0
Supplementation (topp),METHOD_OF,Prophylactic treatment (topp),TREATS,Malignant neoplasm of prostate (neop),9.72e-12,100.72,11,43,0,13.81,4.0
Supplementation (topp),METHOD_OF,Prophylactic treatment (topp),AFFECTS,Malignant neoplasm of prostate (neop),9.72e-12,108.54,11,10,0,19.09,7.0
Supplementation (topp),METHOD_OF,Prophylactic treatment (topp),USES,Diphosphonates (phsu),9.72e-12,29.91,11,26,0,15.65,6.0
Supplementation (topp),METHOD_OF,Prophylactic treatment (topp),TREATS,Secondary malignant neoplasm of bone (neop),9.72e-12,52.16,11,19,0,17.37,4.0
Oestrogen deficiency (dsyn),CAUSES,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,57.82,12,5,0,7.08,1.0
Vitamin D3 Receptor (gngm),AFFECTS,Cell Growth (celf),PROCESS_OF,Cancer Model (emod),4.71e-06,235.99,7,4,0,6.29,1.0
25-hydroxyvitamin D (strd),compared_with,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.15e-13,272.64,7,35,0,8.4,8.0
25-hydroxyvitamin D (strd),compared_with,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.15e-13,263.66,7,28,0,8.75,4.0
Vitamin D (phsu),TREATS,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.23e-12,164.49,73,30,0,42.33,2.0
Vitamin D (phsu),TREATS,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),8.21e-73,244.25,73,45,0,72.74,2.0
Vitamin D (phsu),TREATS,cohort (popg),LOCATION_OF,FLVCR1 (gngm),3.27e-22,241.94,73,14,0,16.68,2.0
Vitamin D (phsu),TREATS,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),7.62e-13,253.44,73,8,0,8.88,2.0
Vitamin D (phsu),TREATS,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,174.0,73,7,0,7.67,4.0
Vitamin D (phsu),TREATS,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.16e-08,175.81,73,8,0,8.88,2.0
Vitamin D (phsu),TREATS,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.4e-17,216.61,73,12,0,13.97,2.0
Vitamin D (phsu),TREATS,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),1.79e-22,247.31,73,14,0,16.68,4.0
Vitamin supplementation (phsu),TREATS,"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),2.26e-07,148.45,4,3,0,5.25,4.0
Gut (bpoc),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.73e-23,172.94,14,15,0,27.07,2.0
Gut (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,96.44,14,41,0,18.78,2.0
Gut (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,96.23,14,1,0,1.07,2.0
Gut (bpoc),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),3.96e-24,184.45,14,23,0,22.52,2.0
Bone Resorption (ortf),AFFECTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),7.03e-07,84.42,6,5,0,9.17,1.0
Vitamin D (phsu),ASSOCIATED_WITH,melanoma (neop),PART_OF,Prostate (bpoc),5.62e-34,217.48,18,33,0,27.82,3.0
Vitamin D (phsu),ASSOCIATED_WITH,melanoma (neop),PART_OF,Breast (bpoc),7.3e-31,182.98,18,26,0,30.46,3.0
Vitamin D (phsu),ASSOCIATED_WITH,melanoma (neop),PART_OF,Ovary (bpoc),2.27e-08,176.17,18,8,0,11.56,3.0
Vitamin D (phsu),ASSOCIATED_WITH,melanoma (neop),PART_OF,Colon (bpoc),8.81e-10,173.21,18,10,0,15.56,3.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Prostate (bpoc),3.71e-12,74.32,10,12,0,18.33,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"Preservation, Biological (lbpr)",3.71e-12,51.73,10,63,0,11.59,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Malignant neoplasm of prostate (neop),2.68e-09,103.02,10,6,0,9.6,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Bladder stenosis (anab),3.71e-12,43.66,10,17,0,15.88,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Surgical margins (bpoc),3.71e-12,76.71,10,12,0,18.33,2.0
jejunum (bpoc),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.68e-08,169.49,5,15,0,6.67,2.0
jejunum (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.46e-06,92.99,5,41,0,5.61,2.0
jejunum (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),6.08e-07,92.78,5,1,0,1.2,2.0
jejunum (bpoc),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.68e-08,181.01,5,23,0,6.09,2.0
Exercise (dora),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),1.29e-06,66.28,6,5,0,9.17,1.0
Vitamin D (phsu),ASSOCIATED_WITH,"Hepatitis C, Chronic (dsyn)",ISA,Virus Diseases (dsyn),7.89e-10,185.56,7,3,0,4.29,5.0
Treatment Protocols (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.44e-32,262.35,17,35,0,25.26,6.0
Treatment Protocols (topp),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.44e-32,253.37,17,28,0,27.32,4.0
Calcitriol (horm),STIMULATES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,272.63,4,35,0,4.46,8.0
Calcitriol (horm),STIMULATES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.32e-07,263.65,3,27,1,3.33,4.0
Fracture (inpo),COEXISTS_WITH,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),5.49e-06,99.04,4,5,0,7.2,1.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.68e-08,95.88,5,30,0,5.83,2.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),1.68e-08,175.65,5,45,0,5.56,2.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,FLVCR1 (gngm),1.68e-08,173.33,5,14,0,6.79,2.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),1.68e-08,184.84,5,8,0,8.12,2.0
Supplementation (topp),TREATS,cohort (popg),USES,Tissue Microarray (resd),1.61e-06,105.4,5,7,0,8.57,4.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),8.84e-08,107.2,5,8,0,8.12,2.0
Supplementation (topp),TREATS,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.68e-08,148.01,5,12,0,7.08,2.0
Supplementation (topp),TREATS,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),1.68e-08,178.7,5,14,0,6.79,4.0
CYP24A1 (gngm),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.34e-19,272.64,10,35,0,12.86,8.0
CYP24A1 (gngm),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.34e-19,263.66,10,28,0,13.57,4.0
Osteoblasts (cell),LOCATION_OF,Toxic effect (inpo),PROCESS_OF,cohort (popg),2.09e-06,35.58,5,30,0,5.83,1.0
Osteoblasts (cell),LOCATION_OF,Toxic effect (inpo),COEXISTS_WITH,Hormone-refractory prostate cancer (neop),2.09e-06,120.19,5,8,0,8.12,2.0
Osteoblasts (cell),LOCATION_OF,Toxic effect (inpo),COEXISTS_WITH,Prostate cancer metastatic (neop),2.09e-06,99.72,5,7,0,8.57,2.0
Osteoblasts (cell),LOCATION_OF,Toxic effect (inpo),COEXISTS_WITH,Malignant neoplasm of prostate (neop),2.09e-06,116.67,5,50,0,5.5,2.0
Alkaline Phosphatase (aapp),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),5.64e-07,193.12,4,35,0,4.46,8.0
Alkaline Phosphatase (aapp),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),5.64e-07,184.14,4,28,0,4.57,4.0
Metabolites (bacs),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.59e-09,272.63,5,35,0,5.71,8.0
Metabolites (bacs),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.59e-09,263.65,5,28,0,5.89,4.0
salvin (orch),ISA,Antioxidants (phsu),TREATS,Malignant neoplasm of prostate (neop),9.45e-14,137.51,9,16,0,14.06,4.0
Aging (orgf),AFFECTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),7.5e-07,76.96,6,5,0,9.17,1.0
Prophylactic treatment (topp),TREATS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,118.18,7,5,0,8.57,1.0
Chondrocytes (cell),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,272.63,4,35,0,4.46,2.0
Chondrocytes (cell),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.32e-07,263.65,4,28,0,4.57,2.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),4.16e-08,96.68,7,19,0,9.58,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.75e-06,94.27,7,4,0,6.29,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.81e-06,112.69,7,4,0,6.29,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),4.16e-08,102.46,7,8,0,13.12,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),4.43e-08,99.54,7,6,0,11.14,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),4.16e-08,97.35,7,10,0,11.9,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),4.16e-08,103.49,7,9,0,12.44,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),4.31e-08,112.69,7,6,0,11.14,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),4.43e-08,99.54,7,6,0,11.14,3.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),4.16e-08,106.12,7,13,0,10.77,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),4.16e-08,106.12,7,13,0,10.77,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),4.16e-08,147.24,7,33,0,8.48,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),4.16e-08,102.85,7,50,0,7.98,3.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),4.16e-08,101.75,7,37,0,8.32,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),4.43e-08,99.54,7,6,0,11.14,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),4.16e-08,105.44,7,35,0,8.4,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),4.16e-08,94.29,7,32,0,8.53,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.75e-06,94.27,7,4,0,6.29,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),4.16e-08,112.69,7,10,0,11.9,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),4.16e-08,101.18,7,7,0,14.0,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),4.16e-08,112.69,7,7,0,14.0,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),4.43e-08,99.54,7,6,0,11.14,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),4.16e-08,98.53,7,11,0,11.45,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.81e-06,112.69,7,4,0,6.29,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),4.16e-08,90.12,7,40,0,8.22,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",4.16e-08,95.65,7,22,0,9.23,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),4.16e-08,100.42,7,13,0,10.77,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),4.16e-08,105.02,7,11,0,11.45,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.75e-06,94.27,7,4,0,6.29,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),4.16e-08,106.29,7,40,0,8.22,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),4.16e-08,112.7,7,14,0,10.5,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.81e-06,112.69,7,4,0,6.29,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),4.43e-08,99.54,7,6,0,11.14,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.56e-07,97.34,7,5,0,8.57,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),4.43e-08,99.54,7,6,0,11.14,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),4.16e-08,105.44,7,35,0,8.4,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",4.31e-08,112.69,7,6,0,11.14,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),4.16e-08,97.97,7,21,0,9.33,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),4.16e-08,94.99,7,21,0,9.33,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),4.9e-08,82.0,7,6,0,11.14,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),4.16e-08,105.02,7,11,0,11.45,3.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),4.16e-08,99.12,7,138,0,7.36,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),4.16e-08,107.12,7,77,0,7.64,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),4.16e-08,108.7,7,22,0,9.23,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),4.16e-08,112.69,7,8,0,13.12,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),4.16e-08,95.86,7,58,0,7.84,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",4.16e-08,96.45,7,28,0,8.75,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),4.16e-08,112.69,7,10,0,11.9,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),4.16e-08,133.63,7,27,0,8.81,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),4.16e-08,102.46,7,8,0,13.12,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),4.16e-08,104.33,7,20,0,9.45,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.56e-07,97.34,7,5,0,8.57,3.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),4.16e-08,103.46,7,351,0,7.14,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),4.16e-08,112.69,7,7,0,14.0,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),4.31e-08,112.69,7,6,0,11.14,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),4.16e-08,103.02,7,51,0,7.96,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),2.32e-07,86.38,7,5,0,8.57,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),1.06e-07,112.69,7,5,0,8.57,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),4.16e-08,98.53,7,11,0,11.45,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),4.16e-08,112.69,7,7,0,14.0,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),4.16e-08,99.54,7,18,0,9.72,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),7.56e-08,135.71,7,5,0,8.57,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),4.16e-08,98.88,7,124,0,7.4,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),4.16e-08,107.12,7,31,0,8.58,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),4.16e-08,109.02,7,24,0,9.04,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",4.16e-08,95.67,7,66,0,7.74,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),4.16e-08,106.56,7,28,0,8.75,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),4.16e-08,105.29,7,57,0,7.86,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),4.16e-08,90.77,7,16,0,10.06,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),4.16e-08,107.85,7,18,0,9.72,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),4.16e-08,99.36,7,170,0,7.29,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),4.16e-08,92.96,7,11,0,11.45,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),4.16e-08,108.31,7,20,0,9.45,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),4.16e-08,101.19,7,28,0,8.75,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),4.16e-08,112.69,7,8,0,13.12,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),4.16e-08,100.17,7,76,0,7.64,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),4.16e-08,105.59,7,95,0,7.52,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),4.16e-08,83.11,7,38,0,8.29,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),4.16e-08,103.18,7,26,0,8.88,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.81e-06,112.69,7,4,0,6.29,3.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),4.16e-08,106.56,7,14,0,10.5,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),4.16e-08,112.7,7,20,0,9.45,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),1.06e-07,112.69,7,5,0,8.57,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),4.16e-08,74.78,7,10,0,11.9,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),1.06e-07,112.69,7,5,0,8.57,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),4.16e-08,104.33,7,20,0,9.45,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),4.16e-08,105.61,7,12,0,11.08,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.81e-06,112.69,7,4,0,6.29,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),4.16e-08,112.7,7,14,0,10.5,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.75e-06,94.27,7,4,0,6.29,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),4.16e-08,106.94,7,15,0,10.27,4.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),4.16e-08,76.14,7,430,0,7.11,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),4.16e-08,71.77,7,20,0,9.45,1.0
Therapeutic agent (substance) (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",4.43e-08,99.54,7,6,0,11.14,1.0
Agaricales (fngs),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.47e-10,198.43,6,35,0,7.03,2.0
Agaricales (fngs),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.47e-10,189.45,6,28,0,7.29,2.0
Anemia (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),9.34e-11,215.76,6,10,0,9.6,9.0
brush border membrane (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),2.58e-09,14.33,24,12,0,18.0,2.0
brush border membrane (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),3.14e-16,14.06,24,58,0,33.93,2.0
loss; bone (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.98e-11,43.24,8,30,0,10.13,1.0
loss; bone (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),2.86e-11,123.0,8,45,0,9.42,1.0
loss; bone (patf),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),2.86e-11,120.69,8,14,0,12.57,1.0
loss; bone (patf),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),2.94e-11,132.19,8,8,0,16.0,1.0
loss; bone (patf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,52.75,8,7,0,13.12,1.0
loss; bone (patf),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.16e-08,54.56,8,8,0,16.0,1.0
loss; bone (patf),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),2.86e-11,95.36,8,12,0,13.33,1.0
loss; bone (patf),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),2.86e-11,126.06,8,14,0,12.57,1.0
Entire fetus (anst),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.25e-07,235.53,4,35,0,4.46,2.0
Entire fetus (anst),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.25e-07,226.55,4,28,0,4.57,2.0
CA2 (gngm),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),2.58e-09,116.48,14,12,0,22.29,2.0
CA2 (gngm),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),1.12e-24,116.2,14,58,0,17.38,2.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),1.68e-20,168.84,12,19,0,19.58,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,166.43,12,4,0,5.33,21.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.76e-06,184.84,12,4,0,5.33,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),1.4e-12,174.61,12,8,0,13.33,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.68e-09,171.69,12,6,0,9.0,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),1.27e-15,169.5,12,10,0,18.33,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),3.14e-14,175.64,12,9,0,15.75,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),1.5e-09,184.84,12,6,0,9.0,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.68e-09,171.69,12,6,0,9.0,3.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.49e-20,178.27,12,13,0,23.08,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),2.49e-20,178.27,12,13,0,23.08,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),1.68e-20,219.39,12,33,0,16.36,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),1.68e-20,175.0,12,50,0,14.88,3.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),1.68e-20,173.9,12,37,0,15.89,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.68e-09,171.69,12,6,0,9.0,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),1.68e-20,177.59,12,35,0,16.11,5.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),1.68e-20,166.44,12,32,0,16.5,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,166.43,12,4,0,5.33,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),3.77e-16,184.85,12,10,0,18.33,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),6.2e-11,173.33,12,7,0,11.08,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),3.45e-11,184.84,12,7,0,11.08,20.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.68e-09,171.69,12,6,0,9.0,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.88e-17,170.68,12,11,0,21.08,20.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.76e-06,184.84,12,4,0,5.33,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),1.68e-20,162.27,12,40,0,15.6,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",1.68e-20,167.8,12,22,0,18.55,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),3.16e-20,172.57,12,13,0,23.08,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),1.59e-17,177.17,12,11,0,21.08,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,166.43,12,4,0,5.33,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),1.68e-20,178.44,12,40,0,15.6,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),1.69e-20,184.85,12,14,0,22.29,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.76e-06,184.84,12,4,0,5.33,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.68e-09,171.69,12,6,0,9.0,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.14e-07,169.5,12,5,0,7.08,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.68e-09,171.69,12,6,0,9.0,20.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),1.68e-20,177.59,12,35,0,16.11,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",1.5e-09,184.84,12,6,0,9.0,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),1.68e-20,170.12,12,21,0,18.86,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),1.68e-20,167.14,12,21,0,18.86,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),7.43e-09,154.15,12,6,0,9.0,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),1.59e-17,177.17,12,11,0,21.08,3.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),1.68e-20,171.27,12,138,0,13.04,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),1.68e-20,179.27,12,77,0,13.87,5.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),1.68e-20,180.85,12,22,0,18.55,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),7.62e-13,184.84,12,8,0,13.33,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),1.68e-20,168.01,12,58,0,14.48,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",1.68e-20,168.61,12,28,0,17.14,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),3.77e-16,184.85,12,10,0,18.33,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),1.68e-20,205.79,12,27,0,17.33,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),1.4e-12,174.61,12,8,0,13.33,5.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),1.68e-20,176.48,12,20,0,19.2,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.14e-07,169.5,12,5,0,7.08,3.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),1.68e-20,175.61,11,350,1,11.35,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),3.45e-11,184.84,12,7,0,11.08,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),1.5e-09,184.84,12,6,0,9.0,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),1.68e-20,175.18,12,51,0,14.82,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.91e-07,158.54,12,5,0,7.08,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.49e-08,184.84,12,5,0,7.08,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.88e-17,170.68,12,11,0,21.08,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),3.45e-11,184.84,12,7,0,11.08,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),1.68e-20,171.7,12,18,0,20.0,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.4e-08,207.86,12,5,0,7.08,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),1.68e-20,171.03,12,124,0,13.16,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),1.68e-20,179.28,12,31,0,16.65,5.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),1.68e-20,181.17,12,24,0,18.0,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",1.68e-20,167.82,12,66,0,14.18,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),1.68e-20,178.72,12,28,0,17.14,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),1.68e-20,177.45,12,57,0,14.53,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),1.68e-20,162.92,12,16,0,21.0,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),1.68e-20,180.0,12,18,0,20.0,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),1.68e-20,171.51,12,170,0,12.85,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),5.08e-17,165.11,12,11,0,21.08,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),1.68e-20,180.47,12,20,0,19.2,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),1.68e-20,173.35,12,28,0,17.14,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),7.62e-13,184.84,12,8,0,13.33,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),1.68e-20,172.32,12,76,0,13.89,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),1.68e-20,177.74,12,95,0,13.52,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),1.68e-20,155.26,12,38,0,15.79,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),1.68e-20,175.33,12,26,0,17.54,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.76e-06,184.84,12,4,0,5.33,3.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),1.7e-20,178.71,12,14,0,22.29,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),1.68e-20,184.85,11,19,1,17.37,21.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.49e-08,184.84,12,5,0,7.08,20.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),1.56e-14,146.93,12,10,0,18.33,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.49e-08,184.84,12,5,0,7.08,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),1.68e-20,176.48,12,20,0,19.2,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),3.73e-19,177.76,12,12,0,24.0,5.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.76e-06,184.84,12,4,0,5.33,9.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),1.69e-20,184.85,12,14,0,22.29,5.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,166.43,12,4,0,5.33,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),1.69e-20,179.09,12,15,0,21.6,7.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),1.68e-20,148.29,12,430,0,12.33,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),1.68e-20,143.92,12,20,0,19.2,1.0
Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.68e-09,171.69,12,6,0,9.0,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.24e-12,4.54,87,30,0,40.34,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),6.54e-15,84.31,87,45,0,68.28,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),6.54e-15,81.99,87,14,0,16.25,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),7.69e-13,93.5,87,8,0,8.74,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,14.06,87,7,0,7.56,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.16e-08,15.86,87,8,0,8.74,1.0
Birth (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),6.55e-15,56.67,87,12,0,13.66,1.0
Birth (orgf),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),6.54e-15,87.36,87,14,0,16.25,1.0
Bile Acids (bacs),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.85e-11,266.09,6,14,0,8.57,8.0
Bile Acids (bacs),STIMULATES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.85e-11,265.32,6,13,0,8.77,12.0
Bile Acids (bacs),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.52e-09,277.59,6,6,0,12.0,8.0
Calcitriol (horm),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.1e-18,235.18,10,14,0,17.14,8.0
Calcitriol (horm),STIMULATES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.11e-18,234.41,10,13,0,17.69,12.0
Calcitriol (horm),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,246.68,10,6,0,9.6,8.0
Epithelial Cells (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.28e-22,252.85,12,13,1,23.08,2.0
Epithelial Cells (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,252.09,13,13,0,26.0,2.0
Epithelial Cells (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,264.36,13,6,0,8.77,2.0
Vitamin D (phsu),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),1.27e-09,146.51,23,12,0,18.26,1.0
Vitamin D (phsu),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),2.26e-16,141.37,23,34,0,38.56,1.0
Bone structure of spine (bpoc),LOCATION_OF,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.81e-07,62.41,9,5,0,7.78,1.0
Calcitriol (horm),TREATS,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),2.77e-09,237.47,5,9,0,7.78,2.0
TRANCE protein|TNFSF11 (aapp),PART_OF,Osteoblasts (cell),LOCATION_OF,Secondary malignant neoplasm of bone (neop),4.65e-09,66.06,8,98,0,8.65,2.0
TRANCE protein|TNFSF11 (aapp),PART_OF,Osteoblasts (cell),LOCATION_OF,Bone lesion (dsyn),4.65e-09,66.9,8,15,0,12.27,2.0
TRANCE protein|TNFSF11 (aapp),PART_OF,Osteoblasts (cell),LOCATION_OF,Neoplasm Metastasis (neop),4.65e-09,54.52,8,114,0,8.56,2.0
TRANCE protein|TNFSF11 (aapp),PART_OF,Osteoblasts (cell),PRODUCES,Glycoproteins (aapp),1.57e-07,32.2,8,8,0,16.0,3.0
Cholecalciferol (phsu),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,258.27,184,34,1,40.28,5.0
Cholecalciferol (phsu),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,249.29,185,28,0,32.24,4.0
Immunoassay (lbpr),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.15e-13,272.64,7,35,0,8.4,6.0
Immunoassay (lbpr),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.15e-13,263.66,7,28,0,8.75,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,zoledronic acid (phsu),4.67e-10,31.46,22,18,0,32.73,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Malignant neoplasm of prostate (neop),4.67e-10,87.62,22,43,0,33.26,4.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),AFFECTS,Malignant neoplasm of prostate (neop),4.67e-10,95.44,22,10,0,14.55,7.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),USES,Diphosphonates (phsu),4.67e-10,16.81,22,26,0,40.62,6.0
Intervention regimes (hlca),METHOD_OF,Prophylactic treatment (topp),TREATS,Secondary malignant neoplasm of bone (neop),4.67e-10,39.07,22,19,0,35.41,4.0
Vitamin D (phsu),PREDISPOSES,Toxic effect (inpo),PROCESS_OF,cohort (popg),1.32e-07,192.98,4,30,0,4.53,1.0
Vitamin D (phsu),PREDISPOSES,Toxic effect (inpo),COEXISTS_WITH,Hormone-refractory prostate cancer (neop),1.32e-07,277.59,4,8,0,6.0,9.0
Vitamin D (phsu),PREDISPOSES,Toxic effect (inpo),COEXISTS_WITH,Prostate cancer metastatic (neop),1.32e-07,257.13,4,7,0,6.29,9.0
Vitamin D (phsu),PREDISPOSES,Toxic effect (inpo),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.32e-07,274.07,4,50,0,4.32,9.0
Gut (bpoc),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.5e-15,252.02,8,35,0,9.83,2.0
Gut (bpoc),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),4.5e-15,243.05,8,28,0,10.29,2.0
Dyslipidemias (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.59e-09,277.59,5,10,0,7.5,9.0
Intravenous therapy (topp),USES,amidronate (phsu),ISA,Diphosphonates (phsu),1.43e-08,28.42,7,21,0,9.33,5.0
Intravenous therapy (topp),USES,amidronate (phsu),TREATS,Secondary malignant neoplasm of bone (neop),1.41e-08,40.99,7,12,0,11.08,4.0
dihydroxy-vitamin D3 (orch),STIMULATES,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,236.43,37,15,0,21.08,8.0
dihydroxy-vitamin D3 (orch),STIMULATES,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,159.93,37,41,0,70.39,3.0
dihydroxy-vitamin D3 (orch),STIMULATES,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,159.72,37,1,0,1.03,3.0
dihydroxy-vitamin D3 (orch),STIMULATES,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,247.95,37,23,0,37.3,12.0
Vitamin D-Binding Protein (aapp),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),7.56e-33,272.66,17,35,0,25.26,8.0
Vitamin D-Binding Protein (aapp),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),7.56e-33,263.68,17,28,0,27.32,4.0
Vitamin D (phsu),STIMULATES,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,251.85,50,15,0,19.5,8.0
Vitamin D (phsu),STIMULATES,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,175.35,50,41,0,74.62,3.0
Vitamin D (phsu),STIMULATES,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,175.14,50,1,0,1.02,3.0
Vitamin D (phsu),STIMULATES,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,263.37,50,23,0,33.58,12.0
Lipopolysaccharides (lipd),INHIBITS,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.9e-13,242.9,7,14,0,10.5,8.0
Lipopolysaccharides (lipd),INHIBITS,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),3.9e-13,242.13,7,13,0,10.77,13.0
Lipopolysaccharides (lipd),INHIBITS,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,254.41,7,6,0,11.14,8.0
Bone structure of ischium (bpoc),LOCATION_OF,Entire lumbar spine (blor),LOCATION_OF,Neoplasm Metastasis (neop),4.4e-06,41.87,9,6,0,10.0,2.0
Prophylactic treatment (topp),TREATS,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,147.17,8,6,0,10.5,4.0
Epithelial Cells (cell),LOCATION_OF,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,259.18,7,4,0,6.29,2.0
Calcitriol (horm),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),5.62e-34,246.16,18,35,0,27.26,5.0
Calcitriol (horm),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),5.62e-34,237.18,18,28,0,29.57,4.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",LOCATION_OF,Down-Regulation (celf),4.27e-08,178.48,9,9,0,18.0,2.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",PART_OF,Prostate (bpoc),5.28e-17,248.92,8,402,1,8.16,3.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",PRODUCES,Glutamate Carboxypeptidase II (aapp),4.71e-06,240.63,9,4,0,5.78,7.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",LOCATION_OF,PTEN gene|PTEN (aapp),1.04e-09,194.25,9,8,0,15.11,2.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",LOCATION_OF,Malignant neoplasm of prostate (neop),4.29e-16,259.05,9,10,0,17.1,2.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",LOCATION_OF,Zinc (bacs),1.85e-06,202.39,9,5,0,7.78,2.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",LOCATION_OF,Cell Growth (celf),1.88e-06,175.95,9,8,0,15.11,2.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",LOCATION_OF,Gonadotropin-Releasing Hormone Receptor (aapp),3.01e-07,224.52,9,5,0,7.78,2.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",LOCATION_OF,Signal Transduction (celf),7.71e-07,173.41,9,10,0,17.1,2.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",LOCATION_OF,Silence (mobd),1.8e-10,180.13,9,11,0,16.36,2.0
Vitamin D (phsu),AFFECTS,"Tumor cells, malignant (cell)",LOCATION_OF,Cell Cycle Arrest (celf),1.18e-14,176.03,9,18,0,13.5,2.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),1.63e-24,236.87,13,19,0,21.89,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,234.46,13,4,0,5.23,21.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.76e-06,252.87,13,4,0,5.23,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),1.4e-12,242.64,13,8,0,12.92,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.68e-09,239.72,13,6,0,8.77,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),1.27e-15,237.53,13,10,0,17.69,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),3.14e-14,243.67,13,9,0,15.23,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),1.5e-09,252.87,13,6,0,8.77,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.68e-09,239.72,13,6,0,8.77,3.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),8.05e-21,246.3,13,13,0,26.0,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),8.05e-21,246.3,13,13,0,26.0,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),1.63e-24,287.43,13,33,0,18.12,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),1.63e-24,243.03,13,50,0,16.38,3.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),1.63e-24,241.93,12,36,1,16.0,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.68e-09,239.72,13,6,0,8.77,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),1.63e-24,245.62,13,35,0,17.83,5.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),1.63e-24,234.47,13,32,0,18.28,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,234.46,13,4,0,5.23,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),3.77e-16,252.88,13,10,0,17.69,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),6.2e-11,241.36,13,7,0,10.77,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),3.45e-11,252.87,13,7,0,10.77,20.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.68e-09,239.72,13,6,0,8.77,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.88e-17,238.71,13,11,0,20.31,20.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.76e-06,252.87,13,4,0,5.23,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),1.63e-24,230.3,13,40,0,17.23,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",1.63e-24,235.83,13,22,0,20.68,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),1.47e-20,240.6,13,13,0,26.0,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),1.59e-17,245.2,13,11,0,20.31,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,234.46,13,4,0,5.23,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),1.63e-24,246.47,13,40,0,17.23,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),9.64e-23,252.88,13,14,0,25.07,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.76e-06,252.87,13,4,0,5.23,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.68e-09,239.72,13,6,0,8.77,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.14e-07,237.53,13,5,0,6.92,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.68e-09,239.72,13,6,0,8.77,20.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),1.63e-24,245.62,13,35,0,17.83,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",1.5e-09,252.87,13,6,0,8.77,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),1.63e-24,238.15,13,21,0,21.05,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),1.63e-24,235.17,13,21,0,21.05,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),7.43e-09,222.18,13,6,0,8.77,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),1.59e-17,245.2,13,11,0,20.31,3.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),1.63e-24,239.3,13,138,0,14.22,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),1.63e-24,247.3,13,77,0,15.19,5.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),1.63e-24,248.88,13,22,0,20.68,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),7.62e-13,252.87,13,8,0,12.92,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),1.63e-24,236.04,13,58,0,15.91,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",1.63e-24,236.64,13,28,0,19.04,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),3.77e-16,252.88,13,10,0,17.69,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),1.63e-24,273.82,13,27,0,19.26,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),1.4e-12,242.64,13,8,0,12.92,5.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),1.63e-24,244.51,13,20,0,21.45,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.14e-07,237.53,13,5,0,6.92,3.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),1.63e-24,243.64,13,351,0,13.48,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),3.45e-11,252.87,13,7,0,10.77,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),1.5e-09,252.87,13,6,0,8.77,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),1.63e-24,243.21,13,51,0,16.31,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.91e-07,226.57,13,5,0,6.92,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.49e-08,252.87,13,5,0,6.92,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.88e-17,238.71,13,11,0,20.31,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),3.45e-11,252.87,13,7,0,10.77,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),1.63e-24,239.73,13,18,0,22.39,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.4e-08,275.89,13,5,0,6.92,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),1.63e-24,239.06,13,124,0,14.36,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),1.63e-24,247.31,13,31,0,18.45,5.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),1.63e-24,249.2,13,24,0,20.04,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",1.63e-24,235.85,13,66,0,15.56,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),1.63e-24,246.75,13,28,0,19.04,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),1.63e-24,245.48,13,57,0,15.96,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),2.54e-24,230.95,13,16,0,23.56,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),1.63e-24,248.03,13,18,0,22.39,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),1.63e-24,239.54,13,170,0,13.99,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),5.07e-17,233.14,13,11,0,20.31,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),1.63e-24,248.5,13,20,0,21.45,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),1.63e-24,241.38,13,28,0,19.04,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),7.62e-13,252.87,13,8,0,12.92,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),1.63e-24,240.35,13,76,0,15.22,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),1.63e-24,245.77,13,95,0,14.78,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),1.63e-24,223.29,13,38,0,17.45,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),1.63e-24,243.36,13,26,0,19.5,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.76e-06,252.87,13,4,0,5.23,3.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),1.81e-22,246.74,13,14,0,25.07,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),1.63e-24,252.88,13,20,0,21.45,21.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.49e-08,252.87,13,5,0,6.92,20.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),1.56e-14,214.96,13,10,0,17.69,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.49e-08,252.87,13,5,0,6.92,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),1.63e-24,244.51,12,19,1,19.58,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),3.56e-19,245.79,13,12,0,23.08,5.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.76e-06,252.87,13,4,0,5.23,9.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),9.64e-23,252.88,13,14,0,25.07,5.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,234.46,13,4,0,5.23,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),5.6e-24,247.12,13,15,0,24.27,7.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),1.63e-24,216.32,13,430,0,13.39,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),1.63e-24,211.95,13,20,0,21.45,1.0
Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.68e-09,239.72,13,6,0,8.77,1.0
Cholecalciferol (phsu),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,242.92,14,14,0,28.0,8.0
Cholecalciferol (phsu),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,242.15,14,13,0,25.07,10.0
Cholecalciferol (phsu),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,254.42,14,6,0,8.57,8.0
Vitamin supplementation (phsu),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.45e-47,247.08,25,35,0,42.86,8.0
Vitamin supplementation (phsu),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,238.11,25,28,0,47.32,4.0
KL gene|KL (gngm),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.82e-12,194.79,7,15,0,10.27,8.0
KL gene|KL (gngm),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,118.29,7,41,0,8.2,3.0
KL gene|KL (gngm),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,118.08,7,1,0,1.14,3.0
KL gene|KL (gngm),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.82e-12,206.31,7,23,0,9.13,10.0
Vitamin supplementation (phsu),INTERACTS_WITH,"NOS3 protein, human|NOS3 (aapp)",ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.3e-08,153.92,5,6,0,9.17,8.0
Rickets (dsyn),ISA,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,212.88,31,6,0,7.16,5.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),5.69e-30,81.89,49,19,0,26.37,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,79.48,49,4,0,4.33,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.76e-06,97.9,49,4,0,4.33,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),1.4e-12,87.67,49,8,0,9.31,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.68e-09,84.75,49,6,0,6.73,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),1.27e-15,82.56,49,10,0,12.04,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),3.14e-14,88.69,49,9,0,10.65,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),1.5e-09,97.9,49,6,0,6.73,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.68e-09,84.75,49,6,0,6.73,3.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),8.05e-21,91.33,49,13,0,16.45,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),8.05e-21,91.33,49,13,0,16.45,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),3.23e-32,132.45,49,33,0,55.22,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),3.23e-32,88.06,49,50,0,97.02,3.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),3.23e-32,86.96,49,37,0,64.94,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.68e-09,84.75,49,6,0,6.73,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),3.23e-32,90.65,49,35,0,60.0,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),3.23e-32,79.5,48,31,1,51.02,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,79.48,49,4,0,4.33,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),3.77e-16,97.9,49,10,0,12.04,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),6.2e-11,86.39,49,7,0,8.0,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),3.45e-11,97.9,49,7,0,8.0,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.68e-09,84.75,49,6,0,6.73,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.88e-17,83.74,49,11,0,13.47,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.76e-06,97.9,49,4,0,4.33,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),3.23e-32,75.33,49,40,0,72.65,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",3.24e-32,80.86,49,22,0,31.88,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),1.47e-20,85.63,49,13,0,16.45,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),1.59e-17,90.23,49,11,0,13.47,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,79.48,49,4,0,4.33,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),3.23e-32,91.5,49,40,0,72.65,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),9.48e-23,97.91,49,14,0,18.0,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.76e-06,97.9,49,4,0,4.33,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.68e-09,84.75,49,6,0,6.73,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.14e-07,82.55,49,5,0,5.51,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.68e-09,84.75,49,6,0,6.73,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),3.23e-32,90.65,49,35,0,60.0,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",1.5e-09,97.9,49,6,0,6.73,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),3.51e-32,83.18,49,21,0,30.0,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),3.73e-32,80.2,49,21,0,30.0,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),7.43e-09,67.21,49,6,0,6.73,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),1.59e-17,90.23,49,11,0,13.47,3.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),3.23e-32,84.33,49,138,0,66.4,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),3.23e-32,92.33,49,77,0,80.18,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),3.23e-32,93.91,49,22,0,31.88,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),7.62e-13,97.9,49,8,0,9.31,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),3.23e-32,81.07,49,58,0,90.4,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",3.23e-32,81.66,49,28,0,44.0,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),3.77e-16,97.9,49,10,0,12.04,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),3.23e-32,118.84,49,27,0,41.88,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),1.4e-12,87.67,49,8,0,9.31,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),6.99e-32,89.54,49,20,0,28.16,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.14e-07,82.55,49,5,0,5.51,3.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),3.23e-32,88.67,49,351,0,55.84,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),3.45e-11,97.9,49,7,0,8.0,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),1.5e-09,97.9,49,6,0,6.73,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),3.23e-32,88.23,49,51,0,96.08,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.91e-07,71.59,49,5,0,5.51,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.49e-08,97.9,49,5,0,5.51,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.88e-17,83.74,49,11,0,13.47,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),3.45e-11,97.9,49,7,0,8.0,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),1.41e-28,84.75,49,18,0,24.61,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.4e-08,120.92,49,5,0,5.51,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),3.23e-32,84.09,49,124,0,68.36,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),3.23e-32,92.33,49,31,0,50.61,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),3.23e-32,94.23,49,24,0,35.76,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",3.23e-32,80.88,49,66,0,85.38,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),3.23e-32,91.77,49,28,0,44.0,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),3.23e-32,90.5,49,57,0,91.12,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),9.16e-25,75.98,49,16,0,21.22,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),4.13e-29,93.06,49,18,0,24.61,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),3.23e-32,84.57,49,170,0,63.12,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),5.07e-17,78.17,49,11,0,13.47,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),5.23e-32,93.52,49,20,0,28.16,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),3.23e-32,86.4,49,28,0,44.0,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),7.62e-13,97.9,49,8,0,9.31,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),3.23e-32,85.38,49,76,0,80.59,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),3.23e-32,90.8,49,95,0,74.27,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),3.23e-32,68.32,49,38,0,67.47,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),3.23e-32,88.39,49,26,0,39.8,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.76e-06,97.9,49,4,0,4.33,3.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),1.79e-22,91.77,49,14,0,18.0,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),4.28e-32,97.91,49,20,0,28.16,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.49e-08,97.9,49,5,0,5.51,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),1.56e-14,59.99,49,10,0,12.04,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.49e-08,97.9,49,5,0,5.51,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),6.99e-32,89.54,49,20,0,28.16,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),3.56e-19,90.82,49,12,0,14.94,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.76e-06,97.9,49,4,0,4.33,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),9.48e-23,97.91,49,14,0,18.0,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,79.48,49,4,0,4.33,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),3.97e-24,92.15,49,15,0,19.59,4.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),3.23e-32,61.35,48,429,1,53.37,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),4.89e-29,56.98,49,20,0,28.16,1.0
Androgen therapy (topp),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.68e-09,84.75,49,6,0,6.73,1.0
Ionized calcium (bacs),ISA,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,148.75,26,15,0,23.65,5.0
Ionized calcium (bacs),ISA,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,72.24,26,41,0,42.49,3.0
Ionized calcium (bacs),ISA,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,72.03,26,1,0,1.04,3.0
Ionized calcium (bacs),ISA,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,160.26,26,23,0,43.35,5.0
Entire lumbar spine (blor),LOCATION_OF,Scanning (diap),DIAGNOSES,Neoplasm Metastasis (neop),5.84e-09,25.97,9,28,0,11.89,2.0
Entire lumbar spine (blor),LOCATION_OF,Scanning (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),5.84e-09,99.53,9,28,0,11.89,2.0
Entire lumbar spine (blor),LOCATION_OF,Scanning (diap),DIAGNOSES,Prostate cancer metastatic (neop),5.87e-09,105.65,9,7,0,12.44,2.0
Entire lumbar spine (blor),LOCATION_OF,Scanning (diap),DIAGNOSES,Secondary malignant neoplasm of bone (neop),5.84e-09,38.53,9,29,0,11.79,2.0
Calcium ion (elii),PART_OF,Extracellular (celc),LOCATION_OF,Vesicle (acab),1.41e-07,6.56,12,68,0,14.12,2.0
Prostate (bpoc),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),9.34e-17,238.91,8,34,1,9.88,2.0
Prostate (bpoc),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),9.34e-17,229.93,8,27,1,10.37,2.0
Vitamin D (phsu),TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),1.27e-09,181.12,13,12,0,23.08,1.0
Vitamin D (phsu),TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),2.26e-16,175.98,13,34,0,17.97,1.0
C-reactive protein (aapp),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.46e-15,272.64,8,35,0,9.83,8.0
C-reactive protein (aapp),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.46e-15,263.66,8,28,0,10.29,4.0
Insulin Resistance (patf),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,233.44,16,10,0,16.25,9.0
Prophylactic treatment (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,248.08,91,35,0,48.46,6.0
Prophylactic treatment (topp),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,239.1,91,28,0,36.62,4.0
"PTH protein, human|PTH (aapp)",STIMULATES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.5e-15,252.02,8,35,0,9.83,8.0
"PTH protein, human|PTH (aapp)",STIMULATES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),4.5e-15,243.05,8,28,0,10.29,4.0
"Receptors, Nuclear (aapp)",ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.04e-12,91.82,15,9,0,14.4,5.0
"Receptors, Nuclear (aapp)",ISA,TRANSCRIPTION FACTOR (aapp),COEXISTS_WITH,FLVCR1 (gngm),2.76e-06,101.03,15,4,0,5.07,5.0
"Receptors, Nuclear (aapp)",ISA,TRANSCRIPTION FACTOR (aapp),INTERACTS_WITH,Androgens (horm),4.6e-07,60.1,15,5,0,6.67,5.0
"Receptors, Nuclear (aapp)",ISA,TRANSCRIPTION FACTOR (aapp),AFFECTS,Cell Proliferation (celf),4.18e-08,12.92,15,16,0,29.06,5.0
"Receptors, Nuclear (aapp)",ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.01e-12,96.86,15,42,0,20.36,5.0
"Receptors, Nuclear (aapp)",ISA,TRANSCRIPTION FACTOR (aapp),INTERACTS_WITH,Androgen Receptor|AR (aapp),4.57e-09,78.01,15,6,0,8.4,5.0
"Receptors, Nuclear (aapp)",ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Prostatic Neoplasms (neop),2.76e-06,101.03,15,4,0,5.07,5.0
"Receptors, Nuclear (aapp)",ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.02e-12,101.03,15,9,0,14.4,5.0
"Receptors, Nuclear (aapp)",ISA,TRANSCRIPTION FACTOR (aapp),PART_OF,Malignant neoplasm of prostate (neop),3.41e-12,90.8,15,8,0,12.27,3.0
Control Groups (humn),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.35e-15,99.93,13,15,0,24.27,2.0
Control Groups (humn),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,23.43,13,41,0,17.12,2.0
Control Groups (humn),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,23.21,13,1,0,1.08,2.0
Control Groups (humn),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.35e-15,111.44,13,23,0,20.35,2.0
Sun Exposure (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.64e-06,77.33,4,30,0,4.53,1.0
Sun Exposure (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),1.64e-06,157.1,4,45,0,4.36,1.0
Sun Exposure (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),1.64e-06,154.78,4,14,0,5.14,1.0
Sun Exposure (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),1.64e-06,166.28,4,8,0,6.0,1.0
Sun Exposure (fndg),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),3.24e-06,86.84,4,7,0,6.29,1.0
Sun Exposure (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),1.72e-06,88.65,4,8,0,6.0,1.0
Sun Exposure (fndg),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.64e-06,129.45,4,12,0,5.33,1.0
Sun Exposure (fndg),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),1.64e-06,160.15,4,14,0,5.14,1.0
Skin Pigmentation (ortf),PRODUCES,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.94e-06,222.07,4,4,0,8.0,4.0
amidronate (phsu),ISA,Diphosphonates (phsu),TREATS,Osteoporosis (dsyn),1.03e-06,16.65,39,25,0,41.03,4.0
amidronate (phsu),ISA,Diphosphonates (phsu),DISRUPTS,Osteoclasts (cell),3.23e-21,26.65,39,23,0,36.56,5.0
amidronate (phsu),ISA,Diphosphonates (phsu),TREATS,Bone pain (sosy),8.34e-16,41.28,39,13,0,17.33,4.0
amidronate (phsu),ISA,Diphosphonates (phsu),TREATS,Malignant neoplasm of prostate (neop),8.24e-40,96.11,38,60,1,62.07,4.0
amidronate (phsu),ISA,Diphosphonates (phsu),PREVENTS,Neoplasm Metastasis (neop),4.05e-06,43.46,39,5,0,5.64,5.0
amidronate (phsu),ISA,Diphosphonates (phsu),PREVENTS,loss; bone (patf),3.95e-30,32.46,38,27,1,46.18,5.0
amidronate (phsu),ISA,Diphosphonates (phsu),TREATS,loss; bone (patf),4.18e-09,26.49,39,10,0,12.56,4.0
amidronate (phsu),ISA,Diphosphonates (phsu),INHIBITS,Bone Resorption (ortf),1.62e-26,21.62,39,37,0,72.1,5.0
amidronate (phsu),ISA,Diphosphonates (phsu),TREATS,Multiple Myeloma (neop),1.26e-14,24.91,38,16,1,22.74,4.0
amidronate (phsu),ISA,Diphosphonates (phsu),TREATS,Bone Diseases (dsyn),1.82e-13,22.29,39,18,0,26.31,4.0
amidronate (phsu),ISA,Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),8.24e-40,40.51,38,103,1,52.02,4.0
amidronate (phsu),ISA,Diphosphonates (phsu),PREVENTS,Secondary malignant neoplasm of bone (neop),1.14e-11,38.29,39,10,0,12.56,5.0
amidronate (phsu),ISA,Diphosphonates (phsu),TREATS,Hypercalcemia (dsyn),3.25e-06,19.33,39,11,0,14.1,4.0
amidronate (phsu),ISA,Diphosphonates (phsu),TREATS,Neoplasm Metastasis (neop),8.25e-40,38.03,39,36,0,69.23,4.0
Management procedure (hlca),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),9.34e-17,238.91,9,35,0,11.31,6.0
Management procedure (hlca),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),9.34e-17,229.93,9,28,0,11.89,4.0
Calcium (bacs),PART_OF,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),5.3e-07,121.52,5,9,0,7.78,2.0
Cartilage (tisu),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.25e-07,235.53,4,35,0,4.46,2.0
Cartilage (tisu),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.25e-07,226.55,4,28,0,4.57,2.0
Immunomodulators (imft),INTERACTS_WITH,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.84e-06,259.17,4,4,0,8.0,4.0
Extracellular Matrix (tisu),LOCATION_OF,Vesicle (acab),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,87.01,15,6,0,8.4,2.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),6.12e-19,242.33,10,16,0,16.25,21.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Metabolic syndrome (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),6.2e-11,249.23,10,7,0,11.9,9.0
Chemoprevention (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),5.28e-17,254.09,9,35,0,11.31,6.0
Chemoprevention (topp),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),5.28e-17,245.11,9,28,0,11.89,4.0
Cytosol (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),2.58e-09,54.64,27,12,0,17.33,2.0
Cytosol (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),1.22e-39,54.37,27,58,0,39.57,2.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),1.9e-26,238.41,14,19,0,24.32,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,236.01,14,4,0,5.14,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.76e-06,254.42,14,4,0,5.14,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),1.4e-12,244.19,14,8,0,12.57,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.68e-09,241.27,14,6,0,8.57,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),1.27e-15,239.08,14,10,0,17.14,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),3.14e-14,245.22,14,9,0,14.79,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),1.5e-09,254.42,14,6,0,8.57,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.68e-09,241.27,14,6,0,8.57,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),8.05e-21,247.85,14,13,0,25.07,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),8.05e-21,247.85,14,13,0,25.07,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),1.9e-26,288.97,14,33,0,19.94,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),1.9e-26,244.58,14,50,0,17.92,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),1.9e-26,243.48,14,37,0,19.3,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.68e-09,241.27,14,6,0,8.57,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),1.9e-26,247.17,14,35,0,19.6,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),1.9e-26,236.02,14,32,0,20.12,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,236.01,14,4,0,5.14,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),3.77e-16,254.42,14,10,0,17.14,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),6.2e-11,242.91,14,7,0,10.5,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),3.45e-11,254.42,14,7,0,10.5,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.68e-09,241.27,14,6,0,8.57,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.88e-17,240.26,14,11,0,19.64,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.76e-06,254.42,14,4,0,5.14,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),1.9e-26,231.85,14,40,0,18.9,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",1.9e-26,237.38,14,22,0,22.91,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),1.47e-20,242.15,14,13,0,25.07,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),1.59e-17,246.75,14,11,0,19.64,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,236.01,14,4,0,5.14,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),1.9e-26,248.02,14,40,0,18.9,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),9.48e-23,254.43,14,14,0,28.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.76e-06,254.42,14,4,0,5.14,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.68e-09,241.27,14,6,0,8.57,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.14e-07,239.07,14,5,0,6.79,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.68e-09,241.27,14,6,0,8.57,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),1.9e-26,247.17,14,35,0,19.6,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",1.5e-09,254.42,14,6,0,8.57,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),1.9e-26,239.7,14,21,0,23.33,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),1.9e-26,236.72,14,21,0,23.33,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),7.43e-09,223.73,14,6,0,8.57,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),1.59e-17,246.75,14,11,0,19.64,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),1.9e-26,240.85,14,138,0,15.42,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),1.9e-26,248.85,14,77,0,16.55,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),1.9e-26,250.43,14,22,0,22.91,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),7.62e-13,254.42,14,8,0,12.57,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),1.9e-26,237.59,13,57,1,15.96,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",1.9e-26,238.18,14,28,0,21.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),3.77e-16,254.42,14,10,0,17.14,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),1.9e-26,275.36,14,27,0,21.26,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),1.4e-12,244.19,14,8,0,12.57,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),1.9e-26,246.06,14,20,0,23.8,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.14e-07,239.07,14,5,0,6.79,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),1.9e-26,245.19,14,351,0,14.56,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),3.45e-11,254.42,14,7,0,10.5,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),1.5e-09,254.42,14,6,0,8.57,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),1.9e-26,244.75,14,51,0,17.84,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.91e-07,228.11,14,5,0,6.79,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.49e-08,254.42,14,5,0,6.79,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.88e-17,240.26,14,11,0,19.64,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),3.45e-11,254.42,14,7,0,10.5,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),1.92e-26,241.27,14,18,0,24.89,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.4e-08,277.44,14,5,0,6.79,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),1.9e-26,240.61,14,124,0,15.58,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),1.9e-26,248.86,14,31,0,20.32,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),1.9e-26,250.75,12,22,2,18.55,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",1.9e-26,237.4,14,66,0,16.97,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),1.9e-26,248.3,14,28,0,21.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),1.9e-26,247.02,14,57,0,17.44,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),9.35e-25,232.5,14,16,0,26.25,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),1.91e-26,249.58,14,18,0,24.89,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),1.9e-26,241.09,14,170,0,15.15,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),5.07e-17,234.69,14,11,0,19.64,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),1.9e-26,250.05,14,20,0,23.8,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),1.9e-26,242.92,14,28,0,21.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),7.62e-13,254.42,14,8,0,12.57,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),1.9e-26,241.9,14,76,0,16.58,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),1.9e-26,247.32,14,95,0,16.06,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),1.9e-26,224.84,14,38,0,19.16,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),1.9e-26,244.91,14,26,0,21.54,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.76e-06,254.42,14,4,0,5.14,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),1.79e-22,248.29,14,14,0,28.0,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),1.9e-26,254.43,14,20,0,23.8,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.49e-08,254.42,14,5,0,6.79,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),1.56e-14,216.51,14,10,0,17.14,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.49e-08,254.42,14,5,0,6.79,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),1.9e-26,246.06,14,20,0,23.8,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),3.56e-19,247.34,14,12,0,22.29,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.76e-06,254.42,14,4,0,5.14,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),9.48e-23,254.43,14,14,0,28.0,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,236.01,14,4,0,5.14,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),3.99e-24,248.67,14,15,0,27.07,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),1.9e-26,217.87,14,430,0,14.46,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),1.91e-26,213.5,14,20,0,23.8,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.68e-09,241.27,14,6,0,8.57,1.0
Adipocytes (cell),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.77e-09,241.71,5,35,0,5.71,2.0
Adipocytes (cell),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.77e-09,232.73,5,28,0,5.89,2.0
differentiation therapy (topp),TREATS,leukemia (neop),PART_OF,Prostate (bpoc),1.38e-06,96.69,5,15,0,6.67,3.0
differentiation therapy (topp),TREATS,leukemia (neop),PART_OF,Pancreas (bpoc),1.46e-06,67.75,5,6,0,9.17,3.0
differentiation therapy (topp),TREATS,leukemia (neop),PART_OF,Colon (bpoc),1.38e-06,84.23,5,11,0,7.27,3.0
differentiation therapy (topp),TREATS,leukemia (neop),PART_OF,Ovary (bpoc),1.38e-06,66.0,5,8,0,8.12,3.0
differentiation therapy (topp),TREATS,leukemia (neop),PART_OF,Breast (bpoc),1.38e-06,52.17,5,9,0,7.78,3.0
keratinocyte (cell),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.39e-06,94.13,6,15,0,8.4,2.0
keratinocyte (cell),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),3.83e-06,17.63,6,41,0,6.88,2.0
keratinocyte (cell),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),1.98e-06,17.41,6,1,0,1.17,2.0
keratinocyte (cell),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.39e-06,105.64,6,23,0,7.57,2.0
"PTH protein, human|PTH (aapp)",STIMULATES,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,122.67,25,15,0,24.0,8.0
"PTH protein, human|PTH (aapp)",STIMULATES,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,46.17,25,41,0,40.24,3.0
"PTH protein, human|PTH (aapp)",STIMULATES,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,45.95,25,1,0,1.04,3.0
"PTH protein, human|PTH (aapp)",STIMULATES,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.54e-36,134.18,25,23,0,44.16,12.0
Neck (blor),LOCATION_OF,Entire lumbar spine (blor),LOCATION_OF,Neoplasm Metastasis (neop),4.4e-06,48.01,29,6,0,7.24,2.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,257.47,206,15,0,16.09,8.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,180.97,206,41,0,49.16,3.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,180.76,206,1,0,1.0,3.0
Vitamin D (phsu),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,268.99,206,23,0,25.57,10.0
Periodontitis (dsyn),ASSOCIATED_WITH,gene polymorphism (genf),AFFECTS,Malignant neoplasm of prostate (neop),1.18e-09,129.19,7,15,0,10.27,7.0
"Hyperparathyroidism, Secondary (dsyn)",CAUSES,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.96e-07,138.8,5,5,0,10.0,1.0
Vitamin D3 Receptor (gngm),STIMULATES,NF-kappa B (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.59e-09,268.4,5,27,0,5.93,8.0
Vitamin D3 Receptor (gngm),STIMULATES,NF-kappa B (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.59e-09,277.59,5,9,0,7.78,8.0
Vitamin D3 Receptor (gngm),STIMULATES,NF-kappa B (gngm),ASSOCIATED_WITH,Neoplasm progression (neop),8.38e-09,205.98,5,8,0,8.12,8.0
25-hydroxyvitamin D (strd),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.59e-09,259.18,5,16,0,6.56,8.0
25-hydroxyvitamin D (strd),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.65e-09,266.08,5,7,0,8.57,8.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.49e-11,44.35,8,30,0,10.13,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),2.37e-11,124.12,8,45,0,9.42,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),2.37e-11,121.8,8,14,0,12.57,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),2.45e-11,133.31,8,8,0,16.0,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,53.87,8,7,0,13.12,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.16e-08,55.67,8,8,0,16.0,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),2.37e-11,96.48,8,12,0,13.33,1.0
BONE MASS (dsyn),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),2.37e-11,127.17,8,14,0,12.57,1.0
DIO3 (gngm),INTERACTS_WITH,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,237.81,23,4,0,4.7,4.0
Fracture (inpo),ISA,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.78e-08,111.87,6,6,0,12.0,5.0
Osteoporosis (dsyn),PROCESS_OF,Research Personnel (prog),DIAGNOSES,Malignant neoplasm of prostate (neop),2.24e-10,193.28,6,21,0,7.71,1.0
General Population (popg),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,272.63,4,35,0,4.46,2.0
General Population (popg),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.32e-07,263.65,4,28,0,4.57,2.0
Stromal Cells (cell),PART_OF,Bone Marrow (bpoc),LOCATION_OF,Micrometastasis (fndg),8.45e-06,4.28,32,16,0,24.0,2.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,142.87,57,15,0,18.95,8.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,66.37,57,41,0,70.49,3.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,66.16,57,1,0,1.02,3.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,154.39,57,23,0,32.28,10.0
Calcifediol (phsu),COEXISTS_WITH,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.94e-06,222.07,4,4,0,8.0,4.0
7-dehydrocholesterol (strd),ISA,Cholesterol (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.08e-07,104.37,6,14,0,8.57,5.0
Osteoporosis (dsyn),ISA,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,83.83,41,6,0,6.88,5.0
Vitamin D (phsu),NEG_COEXISTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.25e-07,225.15,4,15,0,5.07,8.0
Vitamin D (phsu),NEG_COEXISTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.67e-06,148.64,4,41,0,4.39,3.0
Vitamin D (phsu),NEG_COEXISTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),8.17e-07,148.43,4,1,0,1.25,3.0
Vitamin D (phsu),NEG_COEXISTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.25e-07,236.66,4,23,0,4.7,21.0
agonists (phsu),TREATS,Benign prostatic hypertrophy (neop),ISA,Prostatic Diseases (dsyn),2.91e-06,127.62,4,35,0,4.46,4.0
agonists (phsu),TREATS,Benign prostatic hypertrophy (neop),COEXISTS_WITH,Malignant neoplasm of prostate (neop),2.91e-06,144.4,4,26,0,4.62,4.0
agonists (phsu),TREATS,Benign prostatic hypertrophy (neop),PROCESS_OF,Participant (humn),2.91e-06,95.76,4,7,0,6.29,1.0
agonists (phsu),TREATS,Benign prostatic hypertrophy (neop),CAUSES,Bladder outlet obstruction (dsyn),2.91e-06,69.73,4,15,0,5.07,4.0
agonists (phsu),TREATS,Benign prostatic hypertrophy (neop),ISA,Urologic Diseases (dsyn),2.91e-06,87.24,4,8,0,6.0,4.0
agonists (phsu),TREATS,Benign prostatic hypertrophy (neop),COEXISTS_WITH,Chronic inflammation (patf),3.37e-06,112.99,4,5,0,7.2,4.0
agonists (phsu),TREATS,Benign prostatic hypertrophy (neop),PROCESS_OF,Control Groups (humn),2.91e-06,118.11,4,11,0,5.45,1.0
agonists (phsu),TREATS,Benign prostatic hypertrophy (neop),PROCESS_OF,cohort (popg),2.91e-06,101.3,4,12,0,5.33,1.0
Intervention regimes (hlca),USES,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,228.27,10,4,0,5.6,4.0
Vitamin D3 Receptor (gngm),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,264.02,100,35,0,47.25,8.0
Vitamin D3 Receptor (gngm),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,255.04,100,28,0,35.84,4.0
Vitamin D (phsu),ASSOCIATED_WITH,Oxidative Stress (comd),COEXISTS_WITH,Benign prostatic hypertrophy (neop),2.62e-08,231.56,7,6,0,11.14,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Oxidative Stress (comd),COEXISTS_WITH,Malignant neoplasm of prostate (neop),2.15e-13,270.79,7,25,0,8.96,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Oxidative Stress (comd),AFFECTS,Malignant neoplasm of prostate (neop),2.15e-13,277.6,7,11,0,11.45,7.0
"Receptors, Calcium-Sensing (aapp)",INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.39e-08,98.03,7,15,0,10.27,8.0
"Receptors, Calcium-Sensing (aapp)",INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.48e-06,21.52,7,41,0,8.2,3.0
"Receptors, Calcium-Sensing (aapp)",INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),6.25e-07,21.31,7,1,0,1.14,3.0
"Receptors, Calcium-Sensing (aapp)",INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),3.39e-08,109.54,7,23,0,9.13,10.0
Screening procedure (hlca),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,230.13,47,35,0,61.06,6.0
Screening procedure (hlca),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,221.15,47,28,0,44.68,4.0
Muscle - Striated (Skeletal) (MMHCC) (tisu),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.34e-19,272.64,10,35,0,12.86,2.0
Muscle - Striated (Skeletal) (MMHCC) (tisu),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.34e-19,263.66,10,28,0,13.57,2.0
Vitamin D (phsu),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,263.66,73,10,0,11.37,4.0
Vitamin D (phsu),TREATS,Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),5.24e-25,215.03,16,16,0,32.0,4.0
Vitamin D (phsu),TREATS,Metabolic syndrome (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),6.2e-11,221.93,16,7,0,10.06,4.0
T-Lymphocyte (cell),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),6.79e-31,272.66,16,35,0,23.31,2.0
T-Lymphocyte (cell),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),6.79e-31,263.68,16,28,0,25.14,2.0
Vitamin D (phsu),TREATS,African American (popg),ISA,Ethnic group (popg),6.81e-09,162.79,25,23,0,44.16,4.0
Vitamin D (phsu),TREATS,African American (popg),ISA,Racial group (popg),2.94e-40,164.02,25,78,0,33.01,4.0
Dihydroxycholecalciferols (phsu),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,239.61,18,14,0,24.89,8.0
Dihydroxycholecalciferols (phsu),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,238.84,18,13,0,22.39,10.0
Dihydroxycholecalciferols (phsu),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,251.12,18,6,0,8.0,8.0
Vitamin D (phsu),compared_with,Supplementation (topp),USES,alpha Tocopherol (phsu),2.99e-06,154.45,9,17,0,13.76,6.0
Vitamin D (phsu),compared_with,Supplementation (topp),AFFECTS,Malignant neoplasm of prostate (neop),1.14e-07,228.52,9,5,0,7.78,7.0
Vitamin D (phsu),compared_with,Supplementation (topp),USES,Soy Proteins (phsu),5.55e-08,160.56,9,10,0,17.1,6.0
Vitamin D (phsu),compared_with,Supplementation (topp),METHOD_OF,cancer prevention (topp),4.6e-07,202.95,9,5,0,7.78,16.0
Vitamin D (phsu),compared_with,Supplementation (topp),USES,lycopene (phsu),9.42e-17,161.87,9,22,0,12.68,6.0
Vitamin D (phsu),compared_with,Supplementation (topp),USES,Androgens (horm),9.34e-17,167.81,9,28,0,11.89,6.0
Vitamin D (phsu),compared_with,Supplementation (topp),USES,Testosterone (strd),9.34e-17,157.57,9,46,0,10.76,6.0
Vitamin D (phsu),compared_with,Supplementation (topp),PREVENTS,Malignant neoplasm of prostate (neop),5.58e-14,227.13,9,9,0,18.0,17.0
Vitamin D (phsu),compared_with,Supplementation (topp),TREATS,Malignant neoplasm of prostate (neop),9.34e-17,225.46,9,20,0,13.05,4.0
Vitamin D (phsu),compared_with,Supplementation (topp),USES,Iron (phsu),3.17e-07,151.85,9,3,0,4.0,6.0
Autoimmune Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,240.51,12,10,0,18.33,9.0
Vitamin D Deficiency (dsyn),PROCESS_OF,Ethnic group (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),6.49e-08,240.49,8,5,0,8.12,1.0
Vitamin D Analog (vita),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.06e-22,251.83,12,14,0,22.29,8.0
Vitamin D Analog (vita),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.48e-20,251.06,12,13,0,23.08,10.0
Vitamin D Analog (vita),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,263.34,12,6,0,9.0,8.0
Hormones (horm),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,163.83,23,15,0,24.78,8.0
Hormones (horm),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,87.33,23,41,0,35.9,3.0
Hormones (horm),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,87.12,23,1,0,1.04,3.0
Hormones (horm),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.24e-37,175.35,23,23,0,46.0,10.0
Vitamin D (phsu),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,218.99,41,5,0,5.61,1.0
Fracture (inpo),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.38e-12,14.0,15,30,0,22.5,1.0
Fracture (inpo),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),1.51e-13,93.76,15,45,0,20.0,1.0
Fracture (inpo),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),1.51e-13,91.44,15,14,0,27.07,1.0
Fracture (inpo),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),9.13e-13,102.95,15,8,0,12.27,1.0
Fracture (inpo),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,23.51,15,7,0,10.27,1.0
Fracture (inpo),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.16e-08,25.32,15,8,0,12.27,1.0
Fracture (inpo),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.51e-13,66.12,15,12,0,21.6,1.0
Fracture (inpo),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),1.51e-13,96.82,15,14,0,27.07,1.0
Vertebral column (bpoc),LOCATION_OF,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,68.49,19,5,0,6.32,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),3.34e-19,261.6,10,19,0,15.26,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,259.19,10,4,0,5.6,21.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.76e-06,277.6,10,4,0,5.6,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),1.4e-12,267.37,10,8,0,14.4,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.68e-09,264.45,10,6,0,9.6,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),1.27e-15,262.26,10,10,0,20.0,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),3.14e-14,268.4,10,9,0,17.1,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),1.5e-09,277.6,10,6,0,9.6,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.68e-09,264.45,10,6,0,9.6,3.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),3.42e-19,271.03,10,13,0,17.69,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),3.42e-19,271.03,10,13,0,17.69,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),3.34e-19,312.16,10,33,0,13.03,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),3.34e-19,267.76,10,50,0,12.0,3.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),3.34e-19,266.66,10,37,0,12.7,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.68e-09,264.45,10,6,0,9.6,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),3.34e-19,270.35,10,35,0,12.86,5.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),3.34e-19,259.2,10,32,0,13.12,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,259.19,10,4,0,5.6,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),3.77e-16,277.61,10,10,0,20.0,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),6.2e-11,266.09,10,7,0,11.9,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),3.45e-11,277.6,10,7,0,11.9,20.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.68e-09,264.45,10,6,0,9.6,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.92e-17,263.44,10,11,0,19.09,20.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.76e-06,277.6,10,4,0,5.6,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),3.34e-19,255.03,10,40,0,12.5,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",3.34e-19,260.56,10,22,0,14.55,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),3.48e-19,265.33,10,13,0,17.69,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),1.63e-17,269.93,10,11,0,19.09,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,259.19,10,4,0,5.6,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),3.34e-19,271.2,10,40,0,12.5,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),3.34e-19,277.61,10,14,0,17.14,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.76e-06,277.6,10,4,0,5.6,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.68e-09,264.45,10,6,0,9.6,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.14e-07,262.26,10,5,0,7.5,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.68e-09,264.45,10,6,0,9.6,20.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),3.34e-19,270.35,10,35,0,12.86,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",1.5e-09,277.6,10,6,0,9.6,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),3.34e-19,262.88,10,21,0,14.76,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),3.34e-19,259.9,10,21,0,14.76,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),7.43e-09,246.91,10,6,0,9.6,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),1.63e-17,269.93,10,11,0,19.09,3.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),3.34e-19,264.03,10,138,0,10.72,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),3.34e-19,272.03,10,77,0,11.3,5.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),3.34e-19,273.61,10,22,0,14.55,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),7.62e-13,277.61,10,8,0,14.4,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),3.34e-19,260.77,10,58,0,11.72,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",3.34e-19,261.37,10,28,0,13.57,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),3.77e-16,277.61,10,10,0,20.0,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),3.34e-19,298.55,10,27,0,13.7,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),1.4e-12,267.37,10,8,0,14.4,5.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),3.34e-19,269.24,10,20,0,15.0,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.14e-07,262.26,10,5,0,7.5,3.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),3.34e-19,268.37,10,351,0,10.28,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),3.45e-11,277.6,10,7,0,11.9,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),1.5e-09,277.6,10,6,0,9.6,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),3.34e-19,267.94,10,51,0,11.96,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.91e-07,251.3,10,5,0,7.5,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.49e-08,277.6,10,5,0,7.5,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.92e-17,263.44,10,11,0,19.09,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),3.45e-11,277.6,10,7,0,11.9,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),3.34e-19,264.46,10,18,0,15.56,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.4e-08,300.62,10,5,0,7.5,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),3.34e-19,263.79,10,124,0,10.81,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),3.34e-19,272.04,10,31,0,13.23,5.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),3.34e-19,273.93,10,24,0,14.17,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",3.34e-19,260.58,10,66,0,11.52,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),3.34e-19,271.48,10,28,0,13.57,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),3.34e-19,270.21,10,57,0,11.75,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),3.34e-19,255.69,10,16,0,16.25,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),3.34e-19,272.76,10,18,0,15.56,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),3.34e-19,264.27,10,170,0,10.59,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),5.11e-17,257.88,10,11,0,19.09,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),3.34e-19,273.23,10,20,0,15.0,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),3.34e-19,266.11,10,28,0,13.57,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),7.62e-13,277.61,10,8,0,14.4,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),3.34e-19,265.08,10,76,0,11.32,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),3.34e-19,270.5,10,95,0,11.05,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),3.34e-19,248.02,10,38,0,12.63,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),3.34e-19,268.09,10,26,0,13.85,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.76e-06,277.6,10,4,0,5.6,3.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),3.34e-19,271.47,10,14,0,17.14,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),3.34e-19,277.61,10,20,0,15.0,21.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.49e-08,277.6,10,5,0,7.5,20.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),1.56e-14,239.69,10,10,0,20.0,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.49e-08,277.6,10,5,0,7.5,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),3.34e-19,269.24,10,20,0,15.0,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),6.89e-19,270.52,10,12,0,18.33,5.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.76e-06,277.6,10,4,0,5.6,9.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),3.34e-19,277.61,10,14,0,17.14,5.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,259.19,10,4,0,5.6,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),3.34e-19,271.85,10,15,0,16.67,7.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),3.34e-19,241.05,10,430,0,10.23,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),3.34e-19,236.69,10,20,0,15.0,1.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.68e-09,264.45,10,6,0,9.6,1.0
Dietary Supplementation (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.06e-52,235.57,28,35,0,50.4,6.0
Dietary Supplementation (topp),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,226.59,28,28,0,56.0,4.0
Vitamin D (phsu),TREATS,Oxidative Stress (comd),COEXISTS_WITH,Benign prostatic hypertrophy (neop),1.59e-07,231.55,4,6,0,6.67,4.0
Vitamin D (phsu),TREATS,Oxidative Stress (comd),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.32e-07,270.78,4,25,0,4.64,4.0
Vitamin D (phsu),TREATS,Oxidative Stress (comd),AFFECTS,Malignant neoplasm of prostate (neop),1.32e-07,277.59,4,11,0,5.45,4.0
"Antigens, Differentiation (imft)",PART_OF,Osteoblasts (cell),LOCATION_OF,Secondary malignant neoplasm of bone (neop),6.73e-07,54.24,9,98,0,9.83,2.0
"Antigens, Differentiation (imft)",PART_OF,Osteoblasts (cell),LOCATION_OF,Bone lesion (dsyn),6.73e-07,55.08,9,15,0,14.4,2.0
"Antigens, Differentiation (imft)",PART_OF,Osteoblasts (cell),LOCATION_OF,Neoplasm Metastasis (neop),6.73e-07,42.7,9,114,0,9.71,2.0
"Antigens, Differentiation (imft)",PART_OF,Osteoblasts (cell),PRODUCES,Glycoproteins (aapp),8.25e-07,20.38,9,8,0,15.11,3.0
Supplementation (topp),ADMINISTERED_TO,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),7.08e-08,113.79,6,9,0,10.0,2.0
Fatty fish (food),ISA,Food (food),PREDISPOSES,Malignant neoplasm of prostate (neop),2.91e-06,130.9,4,6,0,6.67,5.0
Entire tibia (bpoc),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.21e-06,144.19,4,15,0,5.07,2.0
Entire tibia (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),4.65e-06,67.69,4,41,0,4.39,2.0
Entire tibia (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),2.8e-06,67.48,4,1,0,1.25,2.0
Entire tibia (bpoc),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.21e-06,155.71,4,23,0,4.7,2.0
Osteocytes (cell),PRODUCES,Fibroblast Growth Factor (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),7.41e-09,193.86,5,11,0,7.27,8.0
Nuclear Hormone Receptors (aapp),AFFECTS,Gene Expression (genf),AFFECTS,Malignant neoplasm of prostate (neop),4.41e-07,111.95,5,7,0,8.57,7.0
Calcium (bacs),compared_with,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.66e-52,266.06,27,35,0,47.83,8.0
Calcium (bacs),compared_with,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,257.08,27,28,0,53.04,4.0
DIO3 (gngm),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,242.93,21,14,0,23.33,8.0
DIO3 (gngm),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,242.16,21,13,0,21.05,10.0
DIO3 (gngm),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,254.44,21,6,0,7.71,8.0
amidronate (phsu),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,94.86,10,5,0,7.5,1.0
Tumor necrosis factor receptor 11b (aapp),STIMULATES,NF-kappa B (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.2e-09,97.03,9,27,0,12.0,8.0
Tumor necrosis factor receptor 11b (aapp),STIMULATES,NF-kappa B (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.2e-09,106.23,9,9,0,18.0,8.0
Tumor necrosis factor receptor 11b (aapp),STIMULATES,NF-kappa B (gngm),ASSOCIATED_WITH,Neoplasm progression (neop),1.1e-08,34.61,9,8,0,15.11,8.0
Metaphysis (bpoc),PART_OF,Bone structure of tibia (bpoc),PART_OF,"Mice, Nude (mamm)",7.52e-14,56.79,30,10,0,13.33,3.0
Calcifediol (phsu),compared_with,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,203.54,14,4,0,5.14,4.0
Entire spine (bpoc),LOCATION_OF,Diagnostic radiologic examination (diap),DIAGNOSES,Secondary malignant neoplasm of bone (neop),1.51e-06,28.44,7,7,0,14.0,2.0
Vitamin D3 Receptor (gngm),CAUSES,Up-Regulation (Physiology) (celf),AFFECTS,Malignant neoplasm of prostate (neop),9.49e-07,169.49,4,5,0,7.2,7.0
Vitamin D3 Receptor (gngm),CAUSES,Up-Regulation (Physiology) (celf),AFFECTS,Neoplasm progression (neop),8.36e-07,118.16,4,8,0,6.0,7.0
Breast (bpoc),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.13e-12,216.98,7,35,0,8.4,2.0
Breast (bpoc),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.13e-12,208.0,7,28,0,8.75,2.0
Vitamin D (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),5.24e-25,227.43,29,16,0,24.83,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),6.2e-11,234.33,29,7,0,8.69,8.0
Bone structure of ischium (bpoc),LOCATION_OF,Scanning (diap),DIAGNOSES,Neoplasm Metastasis (neop),1.85e-11,32.56,10,28,0,13.57,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Scanning (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),1.85e-11,106.12,10,28,0,13.57,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Scanning (diap),DIAGNOSES,Prostate cancer metastatic (neop),5.29e-11,112.24,10,7,0,11.9,2.0
Bone structure of ischium (bpoc),LOCATION_OF,Scanning (diap),DIAGNOSES,Secondary malignant neoplasm of bone (neop),1.85e-11,45.13,10,29,0,13.45,2.0
Diphosphonates (phsu),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,85.71,31,5,0,5.81,1.0
DIO3 (gngm),DISRUPTS,Cell Proliferation (celf),PROCESS_OF,"Mice, Nude (mamm)",3.11e-11,169.44,12,13,0,23.08,1.0
Calcium (bacs),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,269.24,52,35,0,58.56,8.0
Calcium (bacs),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,260.26,52,28,0,43.08,4.0
Diphosphonates (phsu),TREATS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,86.48,17,5,0,6.47,1.0
Vitamin D3 Receptor (gngm),AFFECTS,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),1.35e-07,193.76,4,12,0,5.33,2.0
Vitamin D3 Receptor (gngm),AFFECTS,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),1.32e-07,193.48,4,58,0,4.28,2.0
Alendronate (opco),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,88.45,16,5,0,6.56,1.0
Vitamin D (phsu),AFFECTS,Signal Transduction Pathways (celf),AFFECTS,Malignant neoplasm of prostate (neop),1.32e-07,277.59,4,11,0,5.45,7.0
Biological Response Modifiers (phsu),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.12e-13,303.56,7,35,0,8.4,8.0
Biological Response Modifiers (phsu),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.12e-13,294.58,7,28,0,8.75,4.0
Vitamin D (phsu),TREATS,Asians (popg),ISA,Population Group (popg),3.12e-06,221.89,7,10,0,11.9,4.0
Mitochondria (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),4.85e-08,28.54,7,12,0,11.08,2.0
Mitochondria (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),4.6e-08,28.26,7,58,0,7.84,2.0
Supplementation (topp),PREVENTS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,277.61,13,10,0,17.69,21.0
dihydroxy-vitamin D3 (orch),STIMULATES,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,232.68,6,4,0,6.67,4.0
Cell membrane (celc),PART_OF,Osteoblasts (cell),LOCATION_OF,Secondary malignant neoplasm of bone (neop),4.29e-06,60.87,6,98,0,6.37,2.0
Cell membrane (celc),PART_OF,Osteoblasts (cell),LOCATION_OF,Bone lesion (dsyn),4.29e-06,61.72,6,15,0,8.4,2.0
Cell membrane (celc),PART_OF,Osteoblasts (cell),LOCATION_OF,Neoplasm Metastasis (neop),4.29e-06,49.34,6,114,0,6.32,2.0
Cell membrane (celc),PART_OF,Osteoblasts (cell),PRODUCES,Glycoproteins (aapp),4.44e-06,27.01,6,8,0,10.5,3.0
Chemoprevention (topp),TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),1.92e-06,25.21,6,12,0,9.0,1.0
Chemoprevention (topp),TREATS,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),1.91e-06,20.07,6,34,0,7.06,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),1.27e-09,173.75,8,12,0,13.33,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),4.72e-15,168.61,8,34,0,9.88,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Tumorigenesis (neop),PROCESS_OF,"Mice, Nude (mamm)",2.57e-07,190.79,9,12,0,15.75,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Tumorigenesis (neop),COEXISTS_WITH,Malignant neoplasm of prostate (neop),2.86e-17,263.8,9,17,0,13.76,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Tumorigenesis (neop),AFFECTS,Malignant neoplasm of prostate (neop),2.76e-06,277.6,9,4,0,5.78,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Tumorigenesis (neop),PART_OF,Prostate (bpoc),2.86e-17,255.4,9,500,0,9.16,3.0
Magnesium (bacs),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.65e-07,210.79,4,35,0,4.46,8.0
Magnesium (bacs),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.65e-07,201.81,4,28,0,4.57,4.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,SUBCUTANEOUS TUMOR (fndg),2.19e-07,76.06,10,6,0,9.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Benign Neoplasm (neop),1.69e-06,129.77,10,4,0,5.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Diffusion Magnetic Resonance Imaging (diap),2.15e-07,83.07,10,19,0,15.26,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,Participant (humn),5.16e-07,64.55,10,5,0,7.5,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Ovarian Carcinoma (neop),4.92e-06,80.66,10,4,0,5.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Glandular proliferation (patf),2.33e-07,57.23,10,6,0,9.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,melanoma (neop),1.69e-06,129.77,10,4,0,5.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,cohort (popg),4.92e-06,80.66,10,4,0,5.6,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Anatomical location (blor),2.15e-07,80.66,10,8,0,14.4,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Morphologically altered structure (anab),2.15e-07,38.39,10,15,0,16.67,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Malignant neoplasm of prostate (neop),2.15e-07,92.03,10,60,0,11.67,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Burden (diap),2.15e-07,78.62,10,7,0,11.9,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Toxic effect (inpo),1.19e-06,48.85,10,5,0,7.5,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,ABNORMAL GROWTH (fndg),2.15e-07,69.11,10,29,0,13.45,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Hemorrhage (fndg),2.15e-07,38.5,10,13,0,17.69,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Chronic inflammation (patf),2.15e-07,46.47,10,24,0,14.17,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Aggressive behavior (mobd),2.15e-07,89.87,10,9,0,17.1,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic resonance imaging guided biopsy (diap),2.15e-07,69.11,10,29,0,13.45,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Testosterone (strd),2.15e-07,31.52,10,41,0,12.44,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Neoplasm Metastasis (neop),2.15e-07,82.98,10,33,0,13.03,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Palpation (diap),2.15e-07,59.05,10,13,0,17.69,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,SCID Mice (mamm),2.18e-07,85.93,10,6,0,9.6,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Imaging (diap),2.15e-07,72.89,10,505,0,10.2,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,tomography (diap),2.15e-07,72.78,10,30,0,13.33,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,"Rats, Wistar (mamm)",2.15e-07,31.71,10,11,0,19.09,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tumorigenesis (neop),2.15e-07,104.2,10,19,0,15.26,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tuberculosis (dsyn),2.74e-07,18.05,10,9,0,17.1,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,"Tomography, Emission-Computed (diap)",4.92e-06,80.66,10,4,0,5.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Suppressor Genes (aapp),2.19e-07,76.06,10,6,0,9.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Digital Rectal Examination (diap),2.15e-07,67.44,10,42,0,12.38,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Driving While Intoxicated (mobd),2.15e-07,73.97,10,8,0,14.4,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Primary Carcinoma (neop),2.98e-06,99.08,10,4,0,5.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Atrophic (patf),2.15e-07,33.96,10,36,0,12.78,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,"Mice, Nude (mamm)",2.15e-07,84.72,10,54,0,11.85,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,Bladder (bpoc),2.15e-07,65.6,10,14,0,17.14,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Prolactin|PRL (aapp),2.15e-07,61.17,10,10,0,20.0,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Cell Invasion (fndg),2.15e-07,74.97,10,31,0,13.23,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PRODUCES,Prostate-Specific Antigen (aapp),2.15e-07,78.16,10,17,0,15.88,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Positron-Emission Tomography (diap),2.15e-07,92.0,10,12,0,18.33,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Medical Imaging (diap),2.15e-07,64.27,10,169,0,10.59,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Vitamin D (phsu),2.15e-07,82.34,10,9,0,17.1,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Acute inflammation (fndg),2.15e-07,78.62,10,7,0,11.9,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,Wild Type Mouse (mamm),2.8e-07,99.08,10,5,0,7.5,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Digital palpation (diap),2.15e-07,60.72,10,14,0,17.14,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,Gerbils (mamm),5.15e-06,22.35,10,6,0,9.6,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,Carcinoma (neop),2.15e-07,82.34,10,9,0,17.1,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,AR gene|AR (aapp),2.18e-07,85.93,10,6,0,9.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Serum specimen (bdsu),2.16e-07,99.08,10,6,0,9.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Stanolone (strd),2.15e-07,36.75,10,52,0,11.92,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Secondary malignant neoplasm of bone (neop),2.15e-07,83.74,10,25,0,14.0,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Carcinogenesis (neop),2.15e-07,122.11,10,20,0,15.0,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Functional assessment (diap),2.15e-07,80.67,10,20,0,15.0,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,"Phantoms, Imaging (medd)",2.15e-07,63.82,10,66,0,11.52,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Malacoplakia (patf),2.15e-07,25.42,10,15,0,16.67,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Lymphoma (neop),4.92e-06,80.66,10,4,0,5.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Nodule (acab),2.15e-07,74.53,10,22,0,14.55,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Prostate-Specific Antigen (aapp),2.15e-07,65.32,10,19,0,15.26,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Malignant disease (dsyn),2.15e-07,97.18,10,47,0,12.13,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Adenocarcinoma (neop),2.15e-07,110.04,10,123,0,10.81,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Needle biopsy procedure (diap),2.15e-07,62.09,10,682,0,10.15,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Transgenic Model (emod),2.15e-07,73.97,10,8,0,14.4,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Carcinogens (hops),2.15e-07,83.74,10,15,0,16.67,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Probes (medd),2.15e-07,59.62,10,12,0,18.33,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Transrectal Ultrasound (diap),2.15e-07,58.37,10,92,0,11.09,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Prostatic Intraepithelial Neoplasias (neop),2.15e-07,92.0,10,12,0,18.33,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Benign prostatic hypertrophy (neop),2.15e-07,57.23,10,18,0,15.56,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Cystadenoma (neop),4.92e-06,80.66,10,4,0,5.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Anatomical zone (blor),2.27e-07,62.25,10,6,0,9.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Primary Neoplasm (neop),2.15e-07,112.24,10,16,0,16.25,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Core needle biopsy (diap),2.15e-07,70.21,10,322,0,10.31,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,FLVCR1 (gngm),2.19e-07,76.06,10,6,0,9.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Biopsy (diap),2.15e-07,56.14,10,4533,0,10.02,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Bacteria (bact),1.45e-06,27.46,10,6,0,9.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,protrusion (anab),2.15e-07,30.02,10,9,0,17.1,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Fine needle aspiration biopsy (diap),2.15e-07,71.03,10,57,0,11.75,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,Rodent (mamm),2.15e-07,37.7,10,15,0,16.67,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,"[M]Adenocarcinoma, metastatic, NOS (neop)",2.22e-07,68.39,10,6,0,9.6,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Stiffness (sosy),2.15e-07,59.62,10,12,0,18.33,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Elastography (diap),5.16e-07,64.55,10,5,0,7.5,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Differential Diagnosis (diap),2.15e-07,82.34,10,9,0,17.1,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Model (emod),2.15e-07,86.95,10,420,0,10.24,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Small cell carcinoma of lung (neop),2.15e-07,125.39,10,9,0,17.1,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,Malignant neoplasm of prostate (neop),2.15e-07,85.45,10,23,0,14.35,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Abnormal shape (anab),2.16e-07,56.58,10,7,0,11.9,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Biopsy of rectum (diap),2.15e-07,34.63,10,18,0,15.56,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Estrogens (strd),2.15e-07,41.99,10,19,0,15.26,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),PART_OF,"Mice, Transgenic (mamm)",2.15e-07,70.02,10,52,0,11.92,3.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Ultrasonography (diap),2.15e-07,55.42,10,145,0,10.69,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Spectroscopy (diap),2.15e-07,64.02,10,52,0,11.92,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Localized Malignant Neoplasm (neop),2.15e-07,141.95,10,240,0,10.42,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Androgen Receptor|AR (aapp),4.87e-07,23.96,10,7,0,11.9,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Diagnosis (diap),2.15e-07,79.88,10,1087,0,10.09,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Infiltration (patf),2.15e-07,43.11,10,20,0,15.0,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Implants (medd),2.15e-07,73.02,10,154,0,10.65,2.0
Normal cell (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Carcinoma (neop),2.15e-07,95.27,10,46,0,12.17,2.0
Calcium intake (fndg),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),9.9e-08,95.0,6,25,0,7.44,1.0
High pressure liquid chromatography procedure (lbpr),METHOD_OF,Chromatography (lbpr),USES,Ions (elii),1.79e-06,7.31,11,1,0,1.09,6.0
Malignant neoplasm of skin (neop),PRODUCES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.91e-25,259.4,13,35,0,17.83,8.0
Malignant neoplasm of skin (neop),PRODUCES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),8.91e-25,250.42,13,28,0,19.04,4.0
Female (orga),ASSOCIATED_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,267.32,17,10,0,15.88,8.0
T-Lymphocyte (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.3e-22,231.32,13,14,0,25.07,2.0
T-Lymphocyte (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,230.55,13,13,0,26.0,2.0
T-Lymphocyte (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,242.82,13,6,0,8.77,2.0
Vitamin D (phsu),PART_OF,Ethnic group (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),1.97e-07,277.59,4,5,0,7.2,2.0
Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,242.85,90,14,0,16.18,8.0
Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,242.08,89,12,1,13.62,9.0
Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,254.36,90,6,0,6.4,8.0
Treatment Protocols (topp),USES,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,106.85,10,9,0,17.1,5.0
Muscle Cells (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),9.34e-17,232.36,9,14,0,14.79,2.0
Muscle Cells (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),9.34e-17,231.6,9,13,0,15.23,2.0
Muscle Cells (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,243.87,9,6,0,10.0,2.0
Sunscreening Agents (phsu),INHIBITS,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.5e-15,252.02,8,35,0,9.83,8.0
Sunscreening Agents (phsu),INHIBITS,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),4.5e-15,243.05,8,28,0,10.29,4.0
25-hydroxyvitamin D (strd),ASSOCIATED_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),4.7e-16,243.87,9,10,0,17.1,8.0
Cancer Cell Growth (neop),PART_OF,Breast (bpoc),LOCATION_OF,Malignant neoplasm of lung (neop),2.78e-07,32.85,23,6,0,7.57,2.0
Cancer Cell Growth (neop),PART_OF,Breast (bpoc),LOCATION_OF,Carcinoma (neop),4.08e-13,17.86,23,14,0,22.52,2.0
Cancer Cell Growth (neop),PART_OF,Breast (bpoc),PART_OF,Cancer Patient (humn),1.49e-10,42.06,23,8,0,10.78,3.0
Cancer Cell Growth (neop),PART_OF,Breast (bpoc),PART_OF,Participant (humn),7.88e-13,28.78,23,11,0,16.26,3.0
Cancer Cell Growth (neop),PART_OF,Breast (bpoc),LOCATION_OF,docetaxel (orch),3.13e-06,35.92,23,5,0,6.09,2.0
Cancer Cell Growth (neop),PART_OF,Breast (bpoc),LOCATION_OF,Early Diagnosis (diap),3.2e-06,13.5,23,8,0,10.78,2.0
Cancer Cell Growth (neop),PART_OF,Breast (bpoc),LOCATION_OF,Neoplasm Metastasis (neop),3.15e-14,21.83,23,22,0,43.04,2.0
Cancer Cell Growth (neop),PART_OF,Breast (bpoc),LOCATION_OF,Malignant neoplasm of prostate (neop),3.15e-14,75.65,23,26,0,43.35,2.0
Cancer Cell Growth (neop),PART_OF,Breast (bpoc),LOCATION_OF,Secondary malignant neoplasm of bone (neop),3.15e-14,64.81,23,33,0,39.03,2.0
"PTH protein, human|PTH (aapp)",TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),4.29e-16,259.05,9,10,0,17.1,4.0
Calcitriol (horm),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,244.72,23,14,0,22.52,8.0
Calcitriol (horm),STIMULATES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,243.95,23,13,0,20.35,12.0
Calcitriol (horm),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,256.23,23,6,0,7.57,8.0
Alkaline Phosphatase (aapp),STIMULATES,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),9.87e-11,133.2,7,15,0,10.27,8.0
Alkaline Phosphatase (aapp),STIMULATES,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,56.7,7,41,0,8.2,3.0
Alkaline Phosphatase (aapp),STIMULATES,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,56.48,7,1,0,1.14,3.0
Alkaline Phosphatase (aapp),STIMULATES,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),9.87e-11,144.71,7,23,0,9.13,12.0
Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.66e-39,236.99,21,35,0,33.6,8.0
Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.66e-39,228.01,21,28,0,36.75,4.0
"Phosphorus, homeopathic preparation (inch)",INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.91e-06,138.57,4,15,0,5.07,8.0
"Phosphorus, homeopathic preparation (inch)",INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),5.35e-06,62.07,4,41,0,4.39,3.0
"Phosphorus, homeopathic preparation (inch)",INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),3.5e-06,61.86,4,1,0,1.25,3.0
"Phosphorus, homeopathic preparation (inch)",INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.91e-06,150.09,4,23,0,4.7,10.0
KL gene|KL (gngm),PART_OF,Membrane (celc),LOCATION_OF,Vesicle (acab),4.88e-08,77.42,5,12,0,7.08,2.0
"Rats, Inbred SHR (mamm)",LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.24e-12,95.81,11,15,0,19.07,2.0
"Rats, Inbred SHR (mamm)",LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,19.31,11,41,0,13.95,2.0
"Rats, Inbred SHR (mamm)",LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,19.1,11,1,0,1.09,2.0
"Rats, Inbred SHR (mamm)",LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.24e-12,107.32,11,23,0,16.26,2.0
Vitamin D (phsu),ASSOCIATED_WITH,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,243.68,16,6,0,8.25,8.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),ASSOCIATED_WITH,Prostate cancer metastatic (neop),1.32e-07,259.18,4,12,0,5.33,8.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),DISRUPTS,Malignant neoplasm of prostate (neop),3.23e-07,251.28,4,5,0,7.2,12.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),AFFECTS,Malignant neoplasm of prostate (neop),1.32e-07,268.39,4,18,0,4.89,7.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),ASSOCIATED_WITH,Prostatic Neoplasms (neop),1.97e-07,277.59,4,5,0,7.2,8.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),ISA,Small RNA (bacs),2.48e-07,187.19,4,35,0,4.46,5.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),ASSOCIATED_WITH,Carcinogenesis (neop),1.33e-07,189.39,4,21,0,4.76,8.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),ISA,Functional RNA (bacs),1.32e-07,187.59,4,84,0,4.19,5.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.32e-07,265.6,4,40,0,4.4,12.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),AFFECTS,Gene Expression (genf),1.32e-07,187.21,4,74,0,4.22,7.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),INTERACTS_WITH,AR gene|AR (aapp),4.33e-07,243.06,4,5,0,7.2,10.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),INTERACTS_WITH,Androgen Receptor|AR (aapp),1.4e-07,246.9,4,6,0,6.67,10.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,255.19,4,195,0,4.08,8.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),ASSOCIATED_WITH,Neoplasm progression (neop),1.32e-07,192.44,4,27,0,4.59,8.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),ASSOCIATED_WITH,Tumorigenesis (neop),1.32e-07,188.97,4,27,0,4.59,8.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),ISA,"RNA, Untranslated (nnon)",1.49e-06,187.52,4,24,0,4.67,5.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),INTERACTS_WITH,Androgens (horm),3.23e-07,251.28,4,5,0,7.2,10.0
Vitamin D (phsu),STIMULATES,MicroRNAs (bacs),AFFECTS,Neoplasm progression (neop),1.65e-07,193.13,4,11,0,5.45,7.0
Hydroxycholecalciferols (strd),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.9e-13,249.45,7,35,0,8.4,5.0
Hydroxycholecalciferols (strd),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.9e-13,240.47,7,28,0,8.75,4.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),2.25e-07,222.08,4,16,0,5.0,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),2.25e-07,228.98,4,7,0,6.29,8.0
Vitamin D (phsu),PREDISPOSES,Anemia (dsyn),COEXISTS_WITH,Iron deficiency anemia (dsyn),2.25e-07,194.45,4,9,0,5.78,9.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.42e-07,125.15,5,9,0,7.78,5.0
ileum (bpoc),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.27e-09,146.3,6,15,0,8.4,2.0
ileum (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.45e-06,69.8,6,41,0,6.88,2.0
ileum (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.93e-07,69.59,6,1,0,1.17,2.0
ileum (bpoc),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.27e-09,157.82,6,23,0,7.57,2.0
Intervention regimes (hlca),TREATS,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,133.59,8,6,0,10.5,4.0
Brush Border (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),1.65e-08,13.32,14,12,0,22.29,2.0
Brush Border (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),1.4e-08,13.05,14,58,0,17.38,2.0
macrophage (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),7.43e-21,250.64,11,14,0,19.64,2.0
macrophage (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),2.18e-20,249.87,11,13,0,20.31,2.0
macrophage (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,262.15,11,6,0,9.27,2.0
Dihydroxycholecalciferols (phsu),STIMULATES,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,240.45,15,15,0,30.0,8.0
Dihydroxycholecalciferols (phsu),STIMULATES,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,163.94,15,41,0,20.49,3.0
Dihydroxycholecalciferols (phsu),STIMULATES,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,163.73,15,1,0,1.07,3.0
Dihydroxycholecalciferols (phsu),STIMULATES,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.12e-28,251.96,15,23,0,24.78,12.0
Calcium (bacs),CAUSES,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,132.61,7,5,0,8.57,1.0
Vitamin D (phsu),PART_OF,African American (popg),ISA,Ethnic group (popg),9.58e-09,157.42,5,23,0,6.09,3.0
Vitamin D (phsu),PART_OF,African American (popg),ISA,Racial group (popg),2.77e-09,158.65,5,78,0,5.32,3.0
cinacalcet (orch),INHIBITS,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.11e-15,129.74,10,15,0,16.67,8.0
cinacalcet (orch),INHIBITS,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,53.24,10,41,0,12.44,3.0
cinacalcet (orch),INHIBITS,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,53.03,10,1,0,1.1,3.0
cinacalcet (orch),INHIBITS,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),4.11e-15,141.26,10,23,0,14.35,13.0
Vitamin D (phsu),ISA,Steroids (strd),STIMULATES,Androgen Receptor|AR (aapp),4.2e-12,240.17,28,8,0,10.29,5.0
Vitamin D (phsu),ISA,Steroids (strd),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.62e-25,255.05,28,16,0,25.14,5.0
"Diabetes, Gestational (dsyn)",COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.29e-11,251.09,6,10,0,9.6,9.0
Vitamin D3 Receptor (gngm),PART_OF,Membrane (celc),LOCATION_OF,Vesicle (acab),1.52e-08,83.29,13,12,0,23.08,2.0
Vitamin D2 (phsu),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,267.32,66,35,0,53.56,5.0
Vitamin D2 (phsu),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,258.34,66,28,0,39.88,4.0
Immunity (phsf),ASSOCIATED_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),7.07e-08,334.47,4,35,0,4.46,8.0
Immunity (phsf),ASSOCIATED_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),7.07e-08,325.49,4,28,0,4.57,4.0
Organism (orgm),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.74e-25,272.65,13,35,0,17.83,2.0
Organism (orgm),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),4.74e-25,263.67,13,28,0,19.04,2.0
Intervention regimes (hlca),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.9e-13,254.41,7,10,0,11.9,4.0
Combined Modality Therapy (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.17e-44,226.29,24,35,0,40.46,6.0
Combined Modality Therapy (topp),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.53e-44,217.31,24,28,0,44.57,4.0
dihydroxy-vitamin D3 (orch),compared_with,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,259.18,5,4,0,7.2,4.0
Peripheral blood mononuclear cell (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.22e-14,204.25,8,14,0,12.57,2.0
Peripheral blood mononuclear cell (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),2.22e-14,203.49,8,13,0,12.92,2.0
Peripheral blood mononuclear cell (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,215.76,8,6,0,10.5,2.0
Vitamin D (phsu),AFFECTS,Blood supply aspects (bpoc),PART_OF,Solid tumor (neop),1.35e-07,172.17,6,8,0,10.5,3.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.91e-25,259.4,13,35,0,17.83,8.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),8.91e-25,250.42,13,28,0,19.04,4.0
Mixed Function Oxygenases (aapp),INHIBITS,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,272.63,4,35,0,4.46,8.0
Mixed Function Oxygenases (aapp),INHIBITS,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.32e-07,263.65,4,28,0,4.57,4.0
Colon (bpoc),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.15e-13,272.64,7,35,0,8.4,2.0
Colon (bpoc),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.15e-13,263.66,6,27,1,7.33,2.0
Alkaline Phosphatase (aapp),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.65e-07,210.79,4,35,0,4.46,8.0
Alkaline Phosphatase (aapp),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.65e-07,201.81,4,28,0,4.57,4.0
Calcifediol (phsu),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,252.71,66,35,0,53.56,5.0
Calcifediol (phsu),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,243.73,66,28,0,39.88,4.0
cohort (popg),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,254.51,15,14,0,27.07,2.0
cohort (popg),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,253.75,15,13,0,24.27,2.0
cohort (popg),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,266.02,15,6,0,8.4,2.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),PREDISPOSES,Malignant neoplasm of prostate (neop),7.92e-15,234.86,8,61,0,9.05,9.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),7.92e-15,226.01,8,112,0,8.57,8.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,CYP17A1 gene|CYP17A1 (gngm),1.63e-09,173.82,8,8,0,16.0,9.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),PART_OF,8q24 (nusq),7.92e-15,191.39,8,14,0,12.57,3.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),ASSOCIATED_WITH,Aggressive behavior (mobd),1.07e-10,187.19,8,8,0,16.0,8.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),CAUSES,Malignant neoplasm of prostate (neop),2.76e-06,240.49,8,4,0,6.0,9.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),COEXISTS_WITH,PSCA gene|PSCA (gngm),2.68e-09,227.34,8,6,0,10.5,9.0
Vitamin D3 Receptor (gngm),COEXISTS_WITH,Single Nucleotide Polymorphism (nusq),LOCATION_OF,Malignant neoplasm of prostate (neop),1.5e-09,240.5,8,6,0,10.5,2.0
Calcium (bacs),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.47e-17,295.83,9,35,0,11.31,8.0
Calcium (bacs),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.47e-17,286.85,9,28,0,11.89,4.0
Calcium (bacs),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),2.58e-09,168.49,19,12,0,19.58,2.0
Calcium (bacs),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),6.32e-36,168.22,19,58,0,25.22,2.0
Calcium (bacs),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),2.91e-06,70.68,4,12,0,5.33,1.0
Calcium (bacs),ASSOCIATED_WITH,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),2.91e-06,65.54,4,34,0,4.47,1.0
25-hydroxyvitamin D (strd),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,262.39,34,35,0,67.03,8.0
25-hydroxyvitamin D (strd),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,253.41,34,28,0,51.06,4.0
calcium deposit substance (bdsu),PART_OF,Entire tibia (bpoc),PART_OF,SCID Mice (mamm),7.42e-07,97.88,5,5,0,10.0,3.0
calcium deposit substance (bdsu),PART_OF,Entire tibia (bpoc),PART_OF,"Mice, Nude (mamm)",4.78e-07,64.2,5,7,0,8.57,3.0
Supplementation (topp),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,124.53,11,5,0,7.27,1.0
Fibroblasts (cell),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.25e-07,235.53,4,35,0,4.46,2.0
Fibroblasts (cell),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.25e-07,226.55,4,28,0,4.57,2.0
Supplementation (topp),USES,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,204.28,370,4,0,4.04,4.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Tumorigenesis (neop),PROCESS_OF,"Mice, Nude (mamm)",3.89e-07,190.77,4,12,0,5.33,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Tumorigenesis (neop),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.32e-07,263.78,4,17,0,4.94,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Tumorigenesis (neop),AFFECTS,Malignant neoplasm of prostate (neop),2.9e-06,277.59,4,4,0,8.0,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Tumorigenesis (neop),PART_OF,Prostate (bpoc),1.32e-07,255.38,4,500,0,4.03,3.0
gene polymorphism (genf),PROCESS_OF,Caucasoid Race (popg),ISA,Racial group (popg),4.67e-07,24.5,6,25,0,7.44,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Disease Progression (patf),COEXISTS_WITH,Prostate cancer metastatic (neop),2.99e-06,240.49,4,4,0,8.0,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Disease Progression (patf),COEXISTS_WITH,Malignant neoplasm of prostate (neop),2.25e-07,233.69,4,50,0,4.32,8.0
Supplementation (topp),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,251.13,24,10,0,14.17,4.0
DMD|BEST1 (gngm),PART_OF,Entire lumbar spine (blor),LOCATION_OF,Neoplasm Metastasis (neop),4.4e-06,36.76,46,6,0,6.78,2.0
Epithelial Cells (cell),PART_OF,Colon (bpoc),LOCATION_OF,Malignant neoplasm of prostate (neop),2.79e-07,93.92,29,5,0,5.86,2.0
Vitamin D (phsu),TREATS,Ethnic group (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),6.49e-08,220.52,9,5,0,7.78,2.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of lymph node (neop),1.66e-06,19.18,10,11,0,19.09,2.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Secondary malignant neoplasm of bone (neop),4.53e-10,35.58,10,10,0,20.0,2.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),4.26e-10,102.06,10,21,0,14.76,2.0
Entire radius (bpoc),LOCATION_OF,tomography (diap),ISA,Medical Imaging (diap),4.26e-10,15.44,10,214,0,10.47,2.0
Vertebrates (vtbt),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.15e-13,272.64,7,35,0,8.4,2.0
Vertebrates (vtbt),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.15e-13,263.66,7,28,0,8.75,2.0
"PTH protein, human|PTH (aapp)",compared_with,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,272.63,4,35,0,4.46,8.0
"PTH protein, human|PTH (aapp)",compared_with,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.32e-07,263.65,4,28,0,4.57,4.0
"Receptors, Nuclear (aapp)",AFFECTS,Gene Expression (genf),AFFECTS,Malignant neoplasm of prostate (neop),1.8e-08,87.58,8,7,0,13.12,7.0
Energy Metabolism (phsf),ASSOCIATED_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.65e-07,210.79,4,35,0,4.46,8.0
Energy Metabolism (phsf),ASSOCIATED_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.65e-07,201.81,4,28,0,4.57,4.0
25-hydroxyvitamin D (strd),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.38e-30,252.04,16,35,0,23.31,8.0
25-hydroxyvitamin D (strd),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.38e-30,243.06,16,28,0,25.14,4.0
Duodenum (bpoc),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.65e-07,204.25,4,14,0,5.14,2.0
Duodenum (bpoc),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),3.65e-07,203.48,4,13,0,5.23,2.0
Duodenum (bpoc),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.67e-07,215.75,4,6,0,6.67,2.0
Cholecalciferol (phsu),PREVENTS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.32e-07,277.59,4,10,0,5.6,21.0
Estrogens (strd),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.81e-07,62.57,9,5,0,7.78,1.0
Vascular calcification (patf),COEXISTS_WITH,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.89e-09,161.82,6,6,0,12.0,9.0
Population Group (popg),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.43e-12,358.85,6,14,0,8.57,2.0
Population Group (popg),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),4.43e-12,358.08,6,13,0,8.77,2.0
Population Group (popg),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.51e-09,370.35,6,6,0,12.0,2.0
Vertebral column (bpoc),LOCATION_OF,Diagnostic radiologic examination (diap),DIAGNOSES,Secondary malignant neoplasm of bone (neop),3.92e-07,23.09,11,7,0,11.45,2.0
"Codon, Initiator (bacs)",COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.59e-09,266.09,5,14,0,6.79,8.0
"Codon, Initiator (bacs)",COEXISTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.59e-09,265.32,5,13,0,6.92,9.0
"Codon, Initiator (bacs)",COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.09e-09,277.59,5,6,0,9.17,8.0
Vitamin D (phsu),AFFECTS,Carcinogenesis (neop),PROCESS_OF,Animal Model (anim),1.09e-16,162.44,9,20,0,13.05,1.0
Vitamin D (phsu),AFFECTS,Carcinogenesis (neop),PART_OF,Prostate (bpoc),9.34e-17,222.92,9,1160,0,9.07,3.0
Vitamin D (phsu),AFFECTS,Carcinogenesis (neop),PROCESS_OF,Transgenic Model (emod),1.15e-16,204.41,9,12,0,15.75,1.0
Vitamin D (phsu),AFFECTS,Carcinogenesis (neop),COEXISTS_WITH,Malignant neoplasm of prostate (neop),7.98e-16,235.5,9,10,0,17.1,7.0
Organ (bpoc),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),6.18e-08,142.99,5,15,0,6.67,2.0
Organ (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.51e-06,66.49,5,41,0,5.61,2.0
Organ (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),6.53e-07,66.28,5,1,0,1.2,2.0
Organ (bpoc),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),6.18e-08,154.51,5,23,0,6.09,2.0
Vitamin D (phsu),INHIBITS,Interleukin-6 (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.29e-10,310.51,5,35,0,5.71,8.0
Vitamin D (phsu),INHIBITS,Interleukin-6 (aapp),ASSOCIATED_WITH,Prostatic Neoplasms (neop),6.57e-08,323.97,5,5,0,10.0,8.0
Vitamin D (phsu),INHIBITS,Interleukin-6 (aapp),ASSOCIATED_WITH,Neoplasm progression (neop),8.29e-10,263.39,5,13,0,6.92,8.0
Vitamin D (phsu),INHIBITS,Interleukin-6 (aapp),AUGMENTS,Malignant neoplasm of prostate (neop),2.33e-09,323.97,5,6,0,9.17,13.0
Genistein (bacs),ISA,Phytoestrogens (horm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.92e-07,77.59,13,8,0,12.92,5.0
Fracture (inpo),PROCESS_OF,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),5.11e-09,96.67,9,9,0,18.0,1.0
Phosphorus (elii),TREATS,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),6.18e-08,149.13,5,9,0,7.78,2.0
Vitamin D (phsu),TREATS,Adverse effects (patf),COEXISTS_WITH,Malignant neoplasm of prostate (neop),2.77e-09,243.51,5,28,0,5.89,4.0
Vitamin D (phsu),INTERACTS_WITH,Biological Response Modifiers (phsu),TREATS,Malignant neoplasm of prostate (neop),2.76e-06,277.64,25,4,0,4.64,4.0
Vitamin D Deficiency (dsyn),PROCESS_OF,African American (popg),ISA,Ethnic group (popg),6.81e-09,181.52,26,23,0,43.35,1.0
Vitamin D Deficiency (dsyn),PROCESS_OF,African American (popg),ISA,Racial group (popg),2.94e-40,182.74,26,78,0,34.67,1.0
Phosphorus (elii),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.49e-11,148.88,7,15,0,10.27,8.0
Phosphorus (elii),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,72.38,7,41,0,8.2,3.0
Phosphorus (elii),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,72.17,7,1,0,1.14,3.0
Phosphorus (elii),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.49e-11,160.4,7,23,0,9.13,10.0
Calcium (bacs),ASSOCIATED_WITH,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.89e-09,161.82,6,6,0,12.0,8.0
Intervention regimes (hlca),TREATS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),1.42e-06,81.71,5,5,0,10.0,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),5.65e-30,233.52,28,19,0,31.89,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,231.11,28,4,0,4.57,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.76e-06,249.53,28,4,0,4.57,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),1.4e-12,239.3,28,8,0,10.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.68e-09,236.38,28,6,0,7.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),1.27e-15,234.19,28,10,0,13.57,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),3.14e-14,240.32,28,9,0,11.89,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),1.5e-09,249.53,28,6,0,7.29,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.68e-09,236.38,28,6,0,7.29,3.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),8.05e-21,242.96,28,13,0,19.04,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),8.05e-21,242.96,28,13,0,19.04,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),6.36e-53,284.08,28,33,0,51.76,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),6.36e-53,239.69,28,50,0,43.68,3.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),6.36e-53,238.59,28,37,0,49.19,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.68e-09,236.38,28,6,0,7.29,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),6.36e-53,242.28,28,35,0,50.4,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),1.85e-50,231.13,27,31,1,50.52,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,231.11,28,4,0,4.57,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),3.77e-16,249.53,28,10,0,13.57,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),6.2e-11,238.02,28,7,0,8.75,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),3.45e-11,249.53,28,7,0,8.75,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.68e-09,236.38,28,6,0,7.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.88e-17,235.37,28,11,0,15.32,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.76e-06,249.53,28,4,0,4.57,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),6.36e-53,226.96,28,40,0,47.6,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",1.12e-34,232.49,28,22,0,39.29,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),1.47e-20,237.26,28,13,0,19.04,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),1.59e-17,241.86,28,11,0,15.32,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,231.11,28,4,0,4.57,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),6.36e-53,243.13,28,40,0,47.6,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),9.48e-23,249.54,28,14,0,21.0,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.76e-06,249.53,28,4,0,4.57,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.68e-09,236.38,28,6,0,7.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.14e-07,234.18,28,5,0,5.89,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.68e-09,236.38,28,6,0,7.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),6.36e-53,242.28,28,35,0,50.4,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",1.5e-09,249.53,28,6,0,7.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),2.82e-33,234.81,28,21,0,36.75,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),5.05e-33,231.83,28,21,0,36.75,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),7.43e-09,218.84,28,6,0,7.29,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),1.59e-17,241.86,28,11,0,15.32,3.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),6.36e-53,235.96,28,138,0,33.68,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),6.36e-53,243.96,28,77,0,38.18,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),9.77e-36,245.54,28,22,0,39.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),7.62e-13,249.53,28,8,0,10.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),6.36e-53,232.7,28,58,0,41.52,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",2.46e-44,233.29,28,28,0,56.0,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),3.77e-16,249.53,28,10,0,13.57,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),7.16e-46,270.47,28,27,0,53.04,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),1.4e-12,239.3,28,8,0,10.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),3.76e-32,241.17,28,20,0,34.29,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.14e-07,234.18,28,5,0,5.89,3.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),6.36e-53,240.3,28,351,0,30.23,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),3.45e-11,249.53,28,7,0,8.75,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),1.5e-09,249.53,28,6,0,7.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),6.36e-53,239.86,28,51,0,43.37,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.91e-07,223.22,28,5,0,5.89,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.49e-08,249.53,28,5,0,5.89,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.88e-17,235.37,28,11,0,15.32,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),3.45e-11,249.53,28,7,0,8.75,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),1.41e-28,236.38,28,18,0,29.57,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.4e-08,272.55,28,5,0,5.89,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),6.36e-53,235.72,28,124,0,34.32,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),2.21e-50,243.96,28,31,0,53.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),4.77e-39,245.86,28,24,0,44.57,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",6.36e-53,232.51,28,66,0,39.88,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),2.13e-45,243.4,28,28,0,56.0,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),6.36e-53,242.13,28,57,0,41.75,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),9.16e-25,227.61,28,16,0,25.14,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),4.13e-29,244.69,28,18,0,29.57,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),6.36e-53,236.2,27,169,1,31.31,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),5.07e-17,229.8,28,11,0,15.32,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),2.01e-32,245.15,28,20,0,34.29,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),7.46e-45,238.03,28,28,0,56.0,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),7.62e-13,249.53,28,8,0,10.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),6.36e-53,237.01,28,76,0,38.32,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),6.36e-53,242.43,27,94,1,34.76,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),6.36e-53,219.95,28,38,0,48.63,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),8.17e-42,240.02,28,26,0,50.14,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.76e-06,249.53,28,4,0,4.57,3.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),1.79e-22,243.4,28,14,0,21.0,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),1.05e-32,249.54,28,20,0,34.29,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.49e-08,249.53,28,5,0,5.89,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),1.56e-14,211.62,28,10,0,13.57,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.49e-08,249.53,28,5,0,5.89,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),3.76e-32,241.17,28,20,0,34.29,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),3.56e-19,242.45,28,12,0,17.14,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.76e-06,249.53,28,4,0,4.57,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),9.48e-23,249.54,28,14,0,21.0,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,231.11,28,4,0,4.57,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),3.97e-24,243.78,28,15,0,23.04,4.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),6.36e-53,212.98,28,430,0,29.82,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),4.89e-29,208.61,28,20,0,34.29,1.0
Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.68e-09,236.38,28,6,0,7.29,1.0
Calcitriol (horm),ISA,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,235.57,41,4,0,4.39,4.0
Vitamin supplementation (phsu),PREVENTS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,277.61,10,10,0,20.0,21.0
VITAMIN D AND METABOLITES (bacs),INTERACTS_WITH,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.84e-06,259.17,4,4,0,8.0,4.0
Biological Response Modifiers (phsu),INTERACTS_WITH,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,228.26,5,4,0,7.2,4.0
Calcifediol (phsu),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.6e-16,226.26,9,35,0,11.31,5.0
Calcifediol (phsu),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.6e-16,217.28,9,28,0,11.89,4.0
Vitamin D (phsu),ASSOCIATED_WITH,Carcinogenesis (neop),PROCESS_OF,Animal Model (anim),1.54e-17,173.0,21,20,0,39.05,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Carcinogenesis (neop),PART_OF,Prostate (bpoc),8.24e-40,233.48,19,1158,2,19.31,3.0
Vitamin D (phsu),ASSOCIATED_WITH,Carcinogenesis (neop),PROCESS_OF,Transgenic Model (emod),2.15e-17,214.98,21,12,0,18.86,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Carcinogenesis (neop),COEXISTS_WITH,Malignant neoplasm of prostate (neop),7.05e-16,246.07,21,10,0,14.76,8.0
Assessment procedure (hlca),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,246.81,37,35,0,68.11,6.0
Assessment procedure (hlca),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,237.83,37,28,0,49.19,4.0
Plants (plnt),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.9e-26,249.46,14,35,0,19.6,2.0
Plants (plnt),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.9e-26,240.48,14,28,0,21.0,2.0
Calcitriol (horm),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,257.79,113,35,0,45.84,5.0
Calcitriol (horm),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,248.81,113,28,0,34.94,4.0
Cholecalciferol (phsu),TREATS,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),2.77e-09,157.72,5,30,0,5.83,2.0
Cholecalciferol (phsu),TREATS,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),2.77e-09,237.49,5,45,0,5.56,2.0
Cholecalciferol (phsu),TREATS,cohort (popg),LOCATION_OF,FLVCR1 (gngm),2.77e-09,235.17,5,14,0,6.79,2.0
Cholecalciferol (phsu),TREATS,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),2.77e-09,246.67,5,8,0,8.12,2.0
Cholecalciferol (phsu),TREATS,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,167.23,5,7,0,8.57,4.0
Cholecalciferol (phsu),TREATS,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.44e-08,169.04,5,8,0,8.12,2.0
Cholecalciferol (phsu),TREATS,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),2.77e-09,209.84,5,12,0,7.08,2.0
Cholecalciferol (phsu),TREATS,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),2.77e-09,240.54,5,14,0,6.79,4.0
Hypocalcemia result (fndg),PROCESS_OF,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),1.65e-07,134.4,5,9,0,7.78,1.0
Calcifediol (phsu),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.32e-07,277.59,4,10,0,5.6,4.0
arterial stiffness (phsf),ASSOCIATED_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.29e-11,246.13,6,35,0,7.03,8.0
arterial stiffness (phsf),ASSOCIATED_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.29e-11,237.15,6,28,0,7.29,4.0
Atherosclerosis (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),1.32e-07,277.59,4,10,0,5.6,9.0
Vitamin D3 Receptor (gngm),PART_OF,Endothelial Cells (cell),PART_OF,Aorta (bpoc),1.61e-09,159.09,6,7,0,11.14,3.0
basolateral membrane (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),2.58e-09,42.7,13,12,0,23.08,2.0
basolateral membrane (celc),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),1.43e-17,42.43,13,58,0,15.91,2.0
"PTH protein, human|PTH (aapp)",STIMULATES,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.29e-11,235.75,6,15,0,8.4,8.0
"PTH protein, human|PTH (aapp)",STIMULATES,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,159.25,6,41,0,6.88,3.0
"PTH protein, human|PTH (aapp)",STIMULATES,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,159.04,6,1,0,1.17,3.0
"PTH protein, human|PTH (aapp)",STIMULATES,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),3.29e-11,247.27,6,23,0,7.57,12.0
tomography (diap),ISA,Medical Imaging (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),3.9e-09,89.21,7,30,0,8.63,5.0
tomography (diap),ISA,Medical Imaging (diap),USES,Imaging Device (medd),7.67e-07,10.32,7,8,0,13.12,5.0
tomography (diap),ISA,Medical Imaging (diap),USES,Tissue Microarray (resd),6.99e-09,23.1,7,8,0,13.12,5.0
tomography (diap),ISA,Medical Imaging (diap),METHOD_OF,Biopsy (diap),3.9e-09,20.04,7,13,0,10.77,5.0
Intestinal Mucosa (tisu),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.65e-07,204.25,4,14,0,5.14,2.0
Intestinal Mucosa (tisu),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),3.65e-07,203.48,4,13,0,5.23,2.0
Intestinal Mucosa (tisu),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.67e-07,215.75,4,6,0,6.67,2.0
"Intestines, Small (bpoc)",LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),9.7e-18,147.11,11,15,0,19.07,2.0
"Intestines, Small (bpoc)",LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,70.61,11,41,0,13.95,2.0
"Intestines, Small (bpoc)",LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,70.4,11,1,0,1.09,2.0
"Intestines, Small (bpoc)",LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),9.7e-18,158.62,11,23,0,16.26,2.0
Hormones (horm),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.59e-09,266.09,5,14,0,6.79,8.0
Hormones (horm),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.59e-09,265.32,5,13,0,6.92,10.0
Hormones (horm),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.09e-09,277.59,5,6,0,9.17,8.0
Osteoporosis (dsyn),ASSOCIATED_WITH,gene polymorphism (genf),AFFECTS,Malignant neoplasm of prostate (neop),8.74e-19,184.85,11,15,0,19.07,7.0
Hepatocyte (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.29e-11,239.59,6,14,0,8.57,2.0
Hepatocyte (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),3.29e-11,238.82,6,13,0,8.77,2.0
Hepatocyte (cell),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.53e-09,251.09,6,6,0,12.0,2.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),USES,alpha Tocopherol (phsu),3.04e-06,74.01,5,17,0,6.47,6.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),AFFECTS,Malignant neoplasm of prostate (neop),1.6e-07,148.08,5,5,0,10.0,7.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),USES,Soy Proteins (phsu),1.02e-07,80.12,5,10,0,7.5,6.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),METHOD_OF,cancer prevention (topp),5.06e-07,122.51,5,5,0,10.0,16.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),USES,lycopene (phsu),4.6e-08,81.43,5,22,0,6.14,6.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),USES,Androgens (horm),4.6e-08,87.37,5,28,0,5.89,6.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),USES,Testosterone (strd),4.6e-08,77.13,5,46,0,5.54,6.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),PREVENTS,Malignant neoplasm of prostate (neop),4.6e-08,146.69,5,9,0,7.78,22.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),TREATS,Malignant neoplasm of prostate (neop),4.6e-08,145.02,5,20,0,6.25,4.0
Bariatric Surgery (topp),PRECEDES,Supplementation (topp),USES,Iron (phsu),3.63e-07,71.4,5,3,0,4.8,6.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),3.27e-07,9.77,10,30,0,13.33,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),3.27e-07,89.54,10,45,0,12.22,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),3.27e-07,87.22,10,14,0,17.14,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),3.27e-07,98.73,10,8,0,14.4,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),1.92e-06,19.29,10,7,0,11.9,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),3.99e-07,21.09,10,8,0,14.4,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),3.27e-07,61.9,10,12,0,18.33,1.0
Pregnancy (orgf),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),3.27e-07,92.59,10,14,0,17.14,1.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,SUBCUTANEOUS TUMOR (fndg),4.56e-09,75.59,25,6,0,7.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Benign Neoplasm (neop),1.48e-06,129.3,25,4,0,4.64,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Diffusion Magnetic Resonance Imaging (diap),1.42e-17,82.6,25,19,0,33.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,Participant (humn),3.01e-07,64.08,25,5,0,6.0,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Ovarian Carcinoma (neop),4.71e-06,80.2,25,4,0,4.64,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Glandular proliferation (patf),1.77e-08,56.76,25,6,0,7.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,melanoma (neop),1.48e-06,129.3,25,4,0,4.64,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,cohort (popg),4.71e-06,80.2,25,4,0,4.64,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Anatomical location (blor),2.47e-12,80.2,25,8,0,10.56,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Morphologically altered structure (anab),1.46e-17,37.93,25,15,0,24.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Malignant neoplasm of prostate (neop),1.42e-17,91.56,25,60,0,35.42,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Burden (diap),1.07e-10,78.15,25,7,0,8.96,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Toxic effect (inpo),9.75e-07,48.39,25,5,0,6.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,ABNORMAL GROWTH (fndg),1.42e-17,68.64,25,29,0,46.55,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Hemorrhage (fndg),1.52e-16,38.04,25,13,0,19.76,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Chronic inflammation (patf),1.42e-17,46.0,25,24,0,47.04,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Aggressive behavior (mobd),3.15e-14,89.41,25,9,0,12.24,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic resonance imaging guided biopsy (diap),1.42e-17,68.64,25,29,0,46.55,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Testosterone (strd),1.42e-17,31.05,25,41,0,40.24,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Neoplasm Metastasis (neop),1.42e-17,82.51,25,33,0,43.94,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Palpation (diap),1.5e-17,58.58,25,13,0,19.76,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,SCID Mice (mamm),2.68e-09,85.46,25,6,0,7.44,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Imaging (diap),1.42e-17,72.42,25,505,0,26.24,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,tomography (diap),1.42e-17,72.31,25,30,0,45.83,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,"Rats, Wistar (mamm)",4.84e-13,31.24,25,11,0,15.84,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Tumorigenesis (neop),1.42e-17,103.74,25,19,0,33.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Tuberculosis (dsyn),5.88e-08,17.58,25,9,0,12.24,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,"Tomography, Emission-Computed (diap)",4.71e-06,80.2,25,4,0,4.64,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Suppressor Genes (aapp),4.56e-09,75.59,25,6,0,7.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Digital Rectal Examination (diap),1.42e-17,66.97,25,42,0,39.88,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Driving While Intoxicated (mobd),4.2e-12,73.5,25,8,0,10.56,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Primary Carcinoma (neop),2.76e-06,98.61,25,4,0,4.64,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Atrophic (patf),1.42e-17,33.49,25,36,0,42.36,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,"Mice, Nude (mamm)",1.42e-17,84.25,25,54,0,36.57,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,Bladder (bpoc),1.42e-17,65.13,25,14,0,21.84,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Prolactin|PRL (aapp),1.56e-14,60.7,25,10,0,14.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Cell Invasion (fndg),1.42e-17,74.51,25,31,0,45.16,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PRODUCES,Prostate-Specific Antigen (aapp),1.42e-17,77.69,25,17,0,28.56,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Positron-Emission Tomography (diap),1.46e-17,91.53,25,12,0,17.76,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Medical Imaging (diap),1.42e-17,63.8,25,169,0,28.7,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Vitamin D (phsu),5.57e-14,81.87,25,9,0,12.24,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Acute inflammation (fndg),1.07e-10,78.15,25,7,0,8.96,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,Wild Type Mouse (mamm),6.49e-08,98.61,25,5,0,6.0,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Digital palpation (diap),1.42e-17,60.25,25,14,0,21.84,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,Gerbils (mamm),4.94e-06,21.88,25,6,0,7.44,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,Carcinoma (neop),5.57e-14,81.87,25,9,0,12.24,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,AR gene|AR (aapp),2.68e-09,85.46,25,6,0,7.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Serum specimen (bdsu),1.5e-09,98.61,25,6,0,7.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Stanolone (strd),1.42e-17,36.28,25,52,0,37.02,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Secondary malignant neoplasm of bone (neop),1.42e-17,83.27,25,25,0,50.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Carcinogenesis (neop),1.42e-17,121.64,25,20,0,36.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Functional assessment (diap),1.42e-17,80.2,25,20,0,36.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,"Phantoms, Imaging (medd)",1.42e-17,63.35,25,66,0,34.47,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Malacoplakia (patf),3.27e-16,24.95,25,15,0,24.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Lymphoma (neop),4.71e-06,80.2,25,4,0,4.64,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Nodule (acab),1.42e-17,74.06,25,22,0,41.36,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Prostate-Specific Antigen (aapp),1.42e-17,64.85,25,19,0,33.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Malignant disease (dsyn),1.42e-17,96.72,25,47,0,38.3,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Adenocarcinoma (neop),1.42e-17,109.57,25,123,0,30.08,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Needle biopsy procedure (diap),1.42e-17,61.62,25,682,0,25.92,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Transgenic Model (emod),4.2e-12,73.5,25,8,0,10.56,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Carcinogens (hops),1.42e-17,83.27,25,15,0,24.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Probes (medd),3.57e-17,59.15,25,12,0,17.76,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Transrectal Ultrasound (diap),1.42e-17,57.9,25,92,0,31.79,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Prostatic Intraepithelial Neoplasias (neop),1.46e-17,91.53,25,12,0,17.76,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Benign prostatic hypertrophy (neop),1.42e-17,56.76,25,18,0,30.96,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Cystadenoma (neop),4.71e-06,80.2,25,4,0,4.64,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Anatomical zone (blor),1.17e-08,61.78,25,6,0,7.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Primary Neoplasm (neop),1.42e-17,111.77,25,16,0,26.24,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Core needle biopsy (diap),1.42e-17,69.75,25,322,0,26.94,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,FLVCR1 (gngm),4.56e-09,75.59,25,6,0,7.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Biopsy (diap),1.42e-17,55.68,25,4533,0,25.14,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Bacteria (bact),1.23e-06,27.0,25,6,0,7.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,protrusion (anab),2.09e-10,29.55,25,9,0,12.24,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Fine needle aspiration biopsy (diap),1.42e-17,70.56,25,57,0,35.96,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,Rodent (mamm),1.47e-17,37.23,25,15,0,24.0,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,"[M]Adenocarcinoma, metastatic, NOS (neop)",7.43e-09,67.92,25,6,0,7.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Stiffness (sosy),3.57e-17,59.15,25,12,0,17.76,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Elastography (diap),3.01e-07,64.08,25,5,0,6.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Differential Diagnosis (diap),5.57e-14,81.87,25,9,0,12.24,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Model (emod),1.42e-17,86.49,25,420,0,26.49,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Small cell carcinoma of lung (neop),4.22e-15,124.92,25,9,0,12.24,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,Malignant neoplasm of prostate (neop),1.42e-17,84.98,25,23,0,44.16,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Abnormal shape (anab),6.82e-10,56.11,25,7,0,8.96,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Biopsy of rectum (diap),1.42e-17,34.16,25,18,0,30.96,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Estrogens (strd),1.42e-17,41.53,25,19,0,33.44,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),PART_OF,"Mice, Transgenic (mamm)",1.42e-17,69.55,25,52,0,37.02,3.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Ultrasonography (diap),1.42e-17,54.95,25,145,0,29.31,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Spectroscopy (diap),1.42e-17,63.55,25,52,0,37.02,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Localized Malignant Neoplasm (neop),1.42e-17,141.49,25,240,0,27.6,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Androgen Receptor|AR (aapp),2.72e-07,23.5,25,7,0,8.96,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Diagnosis (diap),1.42e-17,79.41,25,1087,0,25.57,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Infiltration (patf),1.42e-17,42.65,25,20,0,36.0,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Implants (medd),1.42e-17,72.55,25,154,0,29.06,2.0
Cancer Cell Growth (neop),PART_OF,Prostate (bpoc),LOCATION_OF,Carcinoma (neop),1.42e-17,94.8,25,46,0,38.59,2.0
Alendronate (opco),TREATS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),7.87e-07,74.58,6,5,0,9.17,1.0
paricalcitol (orch),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.46e-15,266.09,8,14,0,12.57,8.0
paricalcitol (orch),STIMULATES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),2.46e-15,265.33,8,13,0,12.92,12.0
paricalcitol (orch),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,277.6,8,6,0,10.5,8.0
Vitamin measurement (lbpr),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,272.63,4,35,0,4.46,6.0
Vitamin measurement (lbpr),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.32e-07,263.65,4,28,0,4.57,4.0
Vitamin D (phsu),PREDISPOSES,Oxidative Stress (comd),COEXISTS_WITH,Benign prostatic hypertrophy (neop),2.62e-08,210.95,8,6,0,10.5,9.0
Vitamin D (phsu),PREDISPOSES,Oxidative Stress (comd),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.5e-15,250.18,8,25,0,10.56,9.0
Vitamin D (phsu),PREDISPOSES,Oxidative Stress (comd),AFFECTS,Malignant neoplasm of prostate (neop),4.5e-15,256.99,8,11,0,13.82,7.0
macrophage (cell),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.34e-30,243.36,16,35,0,23.31,2.0
macrophage (cell),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),4.34e-30,234.38,16,28,0,25.14,2.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),PROCESS_OF,Cancer Patient (humn),3.92e-06,24.25,10,56,0,11.79,1.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),PART_OF,Breast (bpoc),3.92e-06,34.7,10,10,0,20.0,3.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),COEXISTS_WITH,Advanced cancer (neop),3.92e-06,71.97,10,8,0,14.4,4.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),ISA,Neoplasm Metastasis (neop),3.92e-06,21.37,10,16,0,16.25,4.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),PROCESS_OF,Animal Model (anim),3.93e-06,35.69,10,7,0,11.9,1.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),PART_OF,Prostate (bpoc),3.92e-06,88.91,10,41,0,12.44,3.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),COEXISTS_WITH,Prostate carcinoma (neop),3.92e-06,78.67,10,20,0,15.0,4.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),COEXISTS_WITH,Malignant neoplasm of prostate (neop),3.92e-06,85.72,10,183,0,10.55,4.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),ISA,Solid tumor (neop),3.92e-06,62.0,10,13,0,17.69,4.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),AFFECTS,Malignant neoplasm of prostate (neop),3.92e-06,97.08,10,8,0,14.4,4.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),COEXISTS_WITH,Prostate cancer metastatic (neop),3.92e-06,107.31,10,10,0,20.0,4.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),COEXISTS_WITH,Multiple Myeloma (neop),3.92e-06,83.92,10,6,0,9.6,4.0
Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),COEXISTS_WITH,Solid tumor (neop),6.38e-06,37.89,10,5,0,7.5,4.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),PREDISPOSES,Malignant neoplasm of prostate (neop),3.65e-07,205.24,4,31,0,4.52,10.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),AUGMENTS,Malignant neoplasm of prostate (neop),5.08e-06,197.34,4,4,0,8.0,10.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),INTERACTS_WITH,Stanolone (strd),3.65e-07,141.67,4,83,0,4.19,10.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),CAUSES,Malignant neoplasm of prostate (neop),3.65e-07,207.75,4,21,0,4.76,10.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),CONVERTS_TO,Stanolone (strd),3.65e-07,142.92,4,14,0,5.14,10.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),INTERACTS_WITH,Androgen Receptor|AR (aapp),4.79e-07,133.78,4,9,0,5.78,10.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),TREATS,Hypogonadism (dsyn),3.65e-07,137.24,4,14,0,5.14,4.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),ISA,Androgens (horm),2.42e-06,132.55,4,8,0,6.0,5.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.65e-07,205.03,4,53,0,4.3,8.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),INTERACTS_WITH,Androgens (horm),3.65e-07,133.74,4,20,0,4.8,10.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),AFFECTS,Prostate (bpoc),3.66e-07,143.41,4,9,0,5.78,7.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),compared_with,Stanolone (strd),4.21e-07,138.71,4,8,0,6.0,10.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),ISA,Hormones (horm),2.19e-06,129.5,4,10,0,5.6,5.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),ISA,Androgens (horm),3.65e-07,131.97,4,73,0,4.22,5.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),ISA,Androgens (horm),4.6e-07,134.03,4,9,0,5.78,5.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),TREATS,Malignant neoplasm of prostate (neop),3.65e-07,207.31,4,69,0,4.23,4.0
Vitamin D (phsu),INTERACTS_WITH,Testosterone (strd),TREATS,Malignant neoplasm of prostate (neop),3.65e-07,205.54,4,32,0,4.5,4.0
brush border membrane (celc),LOCATION_OF,Vesicle (acab),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,71.9,77,6,0,6.47,2.0
Vitamin D (phsu),ISA,Lipids (lipd),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.71e-09,213.08,5,7,0,8.57,5.0
Calcium (bacs),compared_with,Alkaline Phosphatase (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.13e-08,195.14,5,12,0,7.08,8.0
Calcium (bacs),compared_with,Alkaline Phosphatase (aapp),PREDISPOSES,Secondary malignant neoplasm of bone (neop),1.15e-08,141.83,5,8,0,8.12,17.0
Muscle Weakness (fndg),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,260.74,10,10,0,20.0,9.0
dihydroxy-vitamin D3 (orch),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,266.14,29,14,0,20.76,8.0
dihydroxy-vitamin D3 (orch),STIMULATES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,265.38,29,13,0,18.83,12.0
dihydroxy-vitamin D3 (orch),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,277.65,29,6,0,7.24,8.0
Heel (blor),LOCATION_OF,Ultrasonography (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),4.35e-06,104.49,5,127,0,5.2,2.0
Heel (blor),LOCATION_OF,Ultrasonography (diap),METHOD_OF,Core needle biopsy (diap),5.71e-06,62.15,5,5,0,10.0,2.0
Heel (blor),LOCATION_OF,Ultrasonography (diap),METHOD_OF,Cancer Diagnosis (diap),5.32e-06,65.64,5,5,0,10.0,2.0
Heel (blor),LOCATION_OF,Ultrasonography (diap),AFFECTS,Malignant neoplasm of prostate (neop),4.38e-06,138.88,5,5,0,10.0,2.0
Heel (blor),LOCATION_OF,Ultrasonography (diap),METHOD_OF,Biopsy (diap),4.35e-06,40.07,5,26,0,5.96,2.0
Heel (blor),LOCATION_OF,Ultrasonography (diap),DIAGNOSES,Prostatic Diseases (dsyn),4.36e-06,79.03,5,6,0,9.17,2.0
Heel (blor),LOCATION_OF,Ultrasonography (diap),DIAGNOSES,Carcinoma (neop),4.35e-06,35.99,5,11,0,7.27,2.0
Heel (blor),LOCATION_OF,Ultrasonography (diap),DIAGNOSES,Prostatic Neoplasms (neop),7.11e-06,115.86,5,4,0,7.2,2.0
Black race (humn),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.15e-08,138.57,5,15,0,6.67,2.0
Black race (humn),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.53e-06,62.07,5,41,0,5.61,2.0
Black race (humn),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),6.73e-07,61.86,5,1,0,1.2,2.0
Black race (humn),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),8.15e-08,150.09,5,23,0,6.09,2.0
PTH gene|PTH (gngm),COEXISTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,162.09,23,15,0,24.78,8.0
PTH gene|PTH (gngm),COEXISTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,85.59,23,41,0,35.9,3.0
PTH gene|PTH (gngm),COEXISTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,85.38,23,1,0,1.04,3.0
PTH gene|PTH (gngm),COEXISTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.27e-37,173.61,23,23,0,46.0,9.0
Mixed Function Oxygenases (aapp),INTERACTS_WITH,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,171.54,7,9,0,12.44,5.0
Calcium (bacs),INHIBITS,Alkaline Phosphatase (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.65e-07,134.24,5,12,0,7.08,8.0
Calcium (bacs),INHIBITS,Alkaline Phosphatase (aapp),PREDISPOSES,Secondary malignant neoplasm of bone (neop),3.65e-07,80.93,5,8,0,8.12,13.0
Cholecalciferol (phsu),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.72e-22,239.6,12,14,0,22.29,8.0
Cholecalciferol (phsu),STIMULATES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.49e-20,238.83,12,13,0,23.08,12.0
Cholecalciferol (phsu),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,251.1,12,6,0,9.0,8.0
Vitamin D3 Receptor (gngm),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),2.58e-09,109.02,57,12,0,14.53,2.0
Vitamin D3 Receptor (gngm),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),9.35e-45,108.75,57,58,0,113.02,2.0
Calcitriol (horm),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,219.47,20,15,0,26.25,8.0
Calcitriol (horm),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,142.97,20,41,0,29.76,3.0
Calcitriol (horm),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,142.75,20,1,0,1.05,3.0
Calcitriol (horm),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),6.22e-37,230.98,20,23,0,37.39,10.0
"PTH protein, human|PTH (aapp)",INHIBITS,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.6e-16,226.26,9,35,0,11.31,8.0
"PTH protein, human|PTH (aapp)",INHIBITS,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.6e-16,217.28,9,28,0,11.89,4.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),TREATS,Osteoporosis (dsyn),1.03e-06,32.2,28,24,1,44.57,4.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),DISRUPTS,Osteoclasts (cell),3.23e-21,42.2,29,23,0,41.24,6.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),TREATS,Bone pain (sosy),8.34e-16,56.84,29,13,0,18.83,4.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),TREATS,Malignant neoplasm of prostate (neop),7.65e-38,111.66,29,61,0,42.79,4.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),PREVENTS,Neoplasm Metastasis (neop),4.05e-06,59.01,29,5,0,5.86,6.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),PREVENTS,loss; bone (patf),3.95e-30,48.02,29,28,0,55.03,6.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),TREATS,loss; bone (patf),4.18e-09,42.04,29,10,0,13.45,4.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),INHIBITS,Bone Resorption (ortf),1.62e-26,37.17,29,37,0,51.73,6.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),TREATS,Multiple Myeloma (neop),1.26e-14,40.47,29,17,0,26.97,4.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),TREATS,Bone Diseases (dsyn),1.82e-13,37.84,29,18,0,29.17,4.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),7.65e-38,56.06,29,104,0,37.09,4.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),PREVENTS,Secondary malignant neoplasm of bone (neop),1.14e-11,53.84,29,10,0,13.45,6.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),TREATS,Hypercalcemia (dsyn),3.25e-06,34.88,29,11,0,15.17,4.0
Prophylactic treatment (topp),USES,Diphosphonates (phsu),TREATS,Neoplasm Metastasis (neop),7.65e-38,53.58,29,36,0,52.36,4.0
Spinal Fractures (inpo),PROCESS_OF,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),1.61e-12,144.71,8,9,0,15.11,1.0
Intact parathyrin (aapp),COEXISTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.64e-06,150.94,4,15,0,5.07,8.0
Intact parathyrin (aapp),COEXISTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),4.09e-06,74.44,4,41,0,4.39,3.0
Intact parathyrin (aapp),COEXISTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),2.24e-06,74.23,4,1,0,1.25,3.0
Intact parathyrin (aapp),COEXISTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.64e-06,162.46,4,23,0,4.7,9.0
glucose homeostasis (phsf),ASSOCIATED_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.32e-07,272.63,4,35,0,4.46,8.0
glucose homeostasis (phsf),ASSOCIATED_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.32e-07,263.65,4,28,0,4.57,4.0
Vitamin D3 Receptor|VDR (aapp),ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.14e-14,228.64,11,9,0,16.36,5.0
Vitamin D3 Receptor|VDR (aapp),ISA,TRANSCRIPTION FACTOR (aapp),COEXISTS_WITH,FLVCR1 (gngm),2.76e-06,237.85,11,4,0,5.45,5.0
Vitamin D3 Receptor|VDR (aapp),ISA,TRANSCRIPTION FACTOR (aapp),INTERACTS_WITH,Androgens (horm),4.6e-07,196.93,11,5,0,7.27,5.0
Vitamin D3 Receptor|VDR (aapp),ISA,TRANSCRIPTION FACTOR (aapp),AFFECTS,Cell Proliferation (celf),4.18e-08,149.74,11,16,0,18.56,5.0
Vitamin D3 Receptor|VDR (aapp),ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.27e-20,233.69,11,42,0,13.88,5.0
Vitamin D3 Receptor|VDR (aapp),ISA,TRANSCRIPTION FACTOR (aapp),INTERACTS_WITH,Androgen Receptor|AR (aapp),4.56e-09,214.83,11,6,0,9.27,5.0
Vitamin D3 Receptor|VDR (aapp),ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Prostatic Neoplasms (neop),2.76e-06,237.85,11,4,0,5.45,5.0
Vitamin D3 Receptor|VDR (aapp),ISA,TRANSCRIPTION FACTOR (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.71e-14,237.85,11,9,0,16.36,5.0
Vitamin D3 Receptor|VDR (aapp),ISA,TRANSCRIPTION FACTOR (aapp),PART_OF,Malignant neoplasm of prostate (neop),1.4e-12,227.62,11,8,0,13.82,3.0
Vitamin D (phsu),CAUSES,Oxidative Stress (comd),COEXISTS_WITH,Benign prostatic hypertrophy (neop),2.78e-08,231.55,5,6,0,9.17,9.0
Vitamin D (phsu),CAUSES,Oxidative Stress (comd),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.59e-09,270.78,5,25,0,6.0,9.0
Vitamin D (phsu),CAUSES,Oxidative Stress (comd),AFFECTS,Malignant neoplasm of prostate (neop),1.59e-09,277.6,5,11,0,7.27,7.0
Vitamin supplementation (phsu),COEXISTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.9e-26,249.46,14,35,0,19.6,8.0
Vitamin supplementation (phsu),COEXISTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.9e-26,240.48,14,28,0,21.0,4.0
Calcifediol (phsu),ISA,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,232.73,30,4,0,4.53,4.0
FGF23 (gngm),INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.25e-07,225.15,4,15,0,5.07,8.0
FGF23 (gngm),INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.67e-06,148.64,4,41,0,4.39,3.0
FGF23 (gngm),INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),8.17e-07,148.43,4,1,0,1.25,3.0
FGF23 (gngm),INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.25e-07,236.66,4,23,0,4.7,10.0
Dihydroxycholecalciferols (phsu),STIMULATES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.25e-07,235.53,4,35,0,4.46,8.0
Dihydroxycholecalciferols (phsu),STIMULATES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.25e-07,226.55,4,28,0,4.57,4.0
"Risk factor, cardiovascular (dsyn)",COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),2.84e-15,277.6,8,10,0,14.4,9.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,cohort (popg),2.64e-07,4.96,47,23,0,34.26,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,Cancer Patient (humn),1.74e-06,6.17,47,14,0,18.17,1.0
Cardiovascular Diseases (dsyn),CAUSES,Cessation of life (orgf),PROCESS_OF,American (popg),4.17e-07,13.82,47,8,0,9.36,1.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,SUBCUTANEOUS TUMOR (fndg),3.87e-06,73.38,11,6,0,9.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Benign Neoplasm (neop),5.35e-06,127.09,11,4,0,5.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Diffusion Magnetic Resonance Imaging (diap),3.87e-06,80.39,11,19,0,17.37,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,Participant (humn),4.17e-06,61.87,11,5,0,7.27,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Ovarian Carcinoma (neop),8.58e-06,77.99,11,4,0,5.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Glandular proliferation (patf),3.88e-06,54.55,11,6,0,9.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,melanoma (neop),5.35e-06,127.09,11,4,0,5.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,cohort (popg),8.58e-06,77.99,11,4,0,5.45,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Anatomical location (blor),3.87e-06,77.99,11,8,0,13.82,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Morphologically altered structure (anab),3.87e-06,35.72,11,15,0,19.07,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Malignant neoplasm of prostate (neop),3.87e-06,89.35,11,60,0,13.02,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Burden (diap),3.87e-06,75.94,11,7,0,11.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Toxic effect (inpo),4.84e-06,46.18,11,5,0,7.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,ABNORMAL GROWTH (fndg),3.87e-06,66.43,11,29,0,15.17,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Hemorrhage (fndg),3.87e-06,35.83,11,13,0,20.31,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Chronic inflammation (patf),3.87e-06,43.79,11,24,0,16.04,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Aggressive behavior (mobd),3.87e-06,87.2,11,9,0,16.36,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic resonance imaging guided biopsy (diap),3.87e-06,66.43,11,29,0,15.17,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Testosterone (strd),3.87e-06,28.84,11,41,0,13.95,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Neoplasm Metastasis (neop),3.87e-06,80.3,11,33,0,14.67,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Palpation (diap),3.87e-06,56.37,11,13,0,20.31,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,SCID Mice (mamm),3.87e-06,83.25,11,6,0,9.27,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Imaging (diap),3.87e-06,70.21,11,505,0,11.24,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,tomography (diap),3.87e-06,70.1,11,30,0,15.03,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,"Rats, Wistar (mamm)",3.87e-06,29.03,11,11,0,22.0,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tumorigenesis (neop),3.87e-06,101.53,11,19,0,17.37,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tuberculosis (dsyn),3.93e-06,15.37,11,9,0,16.36,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,"Tomography, Emission-Computed (diap)",8.58e-06,77.99,11,4,0,5.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Suppressor Genes (aapp),3.87e-06,73.38,11,6,0,9.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Digital Rectal Examination (diap),3.87e-06,64.76,11,42,0,13.88,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Driving While Intoxicated (mobd),3.87e-06,71.29,11,8,0,13.82,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Primary Carcinoma (neop),6.63e-06,96.4,11,4,0,5.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Atrophic (patf),3.87e-06,31.28,11,36,0,14.36,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,"Mice, Nude (mamm)",3.87e-06,82.04,11,54,0,13.24,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,Bladder (bpoc),3.87e-06,62.92,11,14,0,19.64,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Prolactin|PRL (aapp),3.87e-06,58.49,11,10,0,19.09,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Tumor Cell Invasion (fndg),3.87e-06,72.3,11,31,0,14.9,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PRODUCES,Prostate-Specific Antigen (aapp),3.87e-06,75.48,11,17,0,18.12,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Positron-Emission Tomography (diap),3.87e-06,89.32,11,12,0,21.08,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Medical Imaging (diap),3.87e-06,61.59,11,169,0,11.72,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Vitamin D (phsu),3.87e-06,79.66,10,8,1,14.4,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Acute inflammation (fndg),3.87e-06,75.94,11,7,0,11.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,Wild Type Mouse (mamm),3.93e-06,96.4,11,5,0,7.27,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Digital palpation (diap),3.87e-06,58.04,11,14,0,19.64,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,Gerbils (mamm),8.81e-06,19.67,11,6,0,9.27,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,Carcinoma (neop),3.87e-06,79.66,11,9,0,16.36,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,AR gene|AR (aapp),3.87e-06,83.25,11,6,0,9.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Serum specimen (bdsu),3.87e-06,96.4,11,6,0,9.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Stanolone (strd),3.87e-06,34.07,11,52,0,13.33,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Secondary malignant neoplasm of bone (neop),3.87e-06,81.06,11,25,0,15.84,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Carcinogenesis (neop),3.87e-06,119.43,11,20,0,17.05,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Functional assessment (diap),3.87e-06,77.99,11,20,0,17.05,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,"Phantoms, Imaging (medd)",3.87e-06,61.14,11,66,0,12.83,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Malacoplakia (patf),3.87e-06,22.74,11,15,0,19.07,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Lymphoma (neop),8.58e-06,77.99,11,4,0,5.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Nodule (acab),3.87e-06,71.85,11,22,0,16.5,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Prostate-Specific Antigen (aapp),3.87e-06,62.64,11,19,0,17.37,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Malignant disease (dsyn),3.87e-06,94.51,11,47,0,13.57,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Adenocarcinoma (neop),3.87e-06,107.36,11,123,0,11.98,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Needle biopsy procedure (diap),3.87e-06,59.41,11,682,0,11.18,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Transgenic Model (emod),3.87e-06,71.29,11,8,0,13.82,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Carcinogens (hops),3.87e-06,81.06,11,15,0,19.07,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Probes (medd),3.87e-06,56.94,11,12,0,21.08,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Transrectal Ultrasound (diap),3.87e-06,55.69,11,92,0,12.32,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Prostatic Intraepithelial Neoplasias (neop),3.87e-06,89.32,11,12,0,21.08,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Benign prostatic hypertrophy (neop),3.87e-06,54.55,11,18,0,17.72,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Cystadenoma (neop),8.58e-06,77.99,11,4,0,5.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Anatomical zone (blor),3.88e-06,59.57,11,6,0,9.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Primary Neoplasm (neop),3.87e-06,109.56,11,16,0,18.56,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Core needle biopsy (diap),3.87e-06,67.54,11,322,0,11.38,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,FLVCR1 (gngm),3.87e-06,73.38,11,6,0,9.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Biopsy (diap),3.87e-06,53.47,11,4533,0,11.03,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Bacteria (bact),5.1e-06,24.79,11,6,0,9.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,protrusion (anab),3.87e-06,27.34,11,9,0,16.36,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Fine needle aspiration biopsy (diap),3.87e-06,68.35,11,57,0,13.12,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,Rodent (mamm),3.87e-06,35.02,11,15,0,19.07,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,"[M]Adenocarcinoma, metastatic, NOS (neop)",3.87e-06,65.71,11,6,0,9.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Stiffness (sosy),3.87e-06,56.94,11,12,0,21.08,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Elastography (diap),4.17e-06,61.87,11,5,0,7.27,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Differential Diagnosis (diap),3.87e-06,79.66,11,9,0,16.36,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Model (emod),3.87e-06,84.28,11,420,0,11.29,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Small cell carcinoma of lung (neop),3.87e-06,122.71,11,9,0,16.36,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,Malignant neoplasm of prostate (neop),3.87e-06,82.77,11,23,0,16.26,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Abnormal shape (anab),3.87e-06,53.9,11,7,0,11.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Biopsy of rectum (diap),3.87e-06,31.95,11,18,0,17.72,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Estrogens (strd),3.87e-06,39.32,11,19,0,17.37,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),PART_OF,"Mice, Transgenic (mamm)",3.87e-06,67.34,11,52,0,13.33,3.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Ultrasonography (diap),3.87e-06,52.74,11,145,0,11.83,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Magnetic Resonance Spectroscopy (diap),3.87e-06,61.34,11,52,0,13.33,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Localized Malignant Neoplasm (neop),3.87e-06,139.28,11,240,0,11.5,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Androgen Receptor|AR (aapp),4.14e-06,21.29,11,7,0,11.45,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Cancer Diagnosis (diap),3.87e-06,77.2,11,1087,0,11.11,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Infiltration (patf),3.87e-06,40.44,11,20,0,17.05,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Implants (medd),3.87e-06,70.34,11,154,0,11.79,2.0
Stromal Cells (cell),PART_OF,Prostate (bpoc),LOCATION_OF,Carcinoma (neop),3.87e-06,92.59,11,46,0,13.63,2.0
Liver diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),2.25e-07,240.49,4,10,0,5.6,9.0
Vitamin D (phsu),TREATS,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),3.14e-14,238.25,36,9,0,11.25,2.0
GRB2 (gngm),PART_OF,Entire tibia (bpoc),PART_OF,SCID Mice (mamm),3.01e-07,72.49,24,5,0,6.04,3.0
GRB2 (gngm),PART_OF,Entire tibia (bpoc),PART_OF,"Mice, Nude (mamm)",3.79e-08,38.82,24,7,0,9.04,3.0
Cardiovascular Diseases (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,253.87,34,10,0,12.94,9.0
Calcitriol (horm),AFFECTS,Gene Expression (genf),AFFECTS,Malignant neoplasm of prostate (neop),1.32e-07,257.13,4,7,0,6.29,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),5.65e-30,251.63,35,19,0,29.31,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,249.22,35,4,0,4.46,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.76e-06,267.63,35,4,0,4.46,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),1.4e-12,257.4,35,8,0,9.83,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.68e-09,254.48,35,6,0,7.03,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),1.27e-15,252.29,35,10,0,12.86,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),3.14e-14,258.43,35,9,0,11.31,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),1.5e-09,267.63,35,6,0,7.03,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.68e-09,254.48,35,6,0,7.03,3.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),8.05e-21,261.06,35,13,0,17.83,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),8.05e-21,261.06,35,13,0,17.83,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),3.16e-57,302.18,35,33,0,64.11,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),2.05e-67,257.79,35,50,0,59.5,3.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),1.59e-59,256.69,35,37,0,68.11,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.68e-09,254.48,35,6,0,7.03,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),9.32e-57,260.38,35,35,0,70.0,5.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),1.85e-50,249.23,35,32,0,61.26,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,249.22,35,4,0,4.46,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),3.77e-16,267.64,35,10,0,12.86,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),6.2e-11,256.12,35,7,0,8.4,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),3.45e-11,267.63,35,7,0,8.4,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.68e-09,254.48,35,6,0,7.03,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.88e-17,253.47,35,11,0,14.46,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.76e-06,267.63,35,4,0,4.46,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),1.77e-62,245.06,35,40,0,65.62,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",1.12e-34,250.59,34,21,1,33.97,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),1.47e-20,255.36,35,13,0,17.83,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),1.59e-17,259.96,35,11,0,14.46,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,249.22,35,4,0,4.46,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),4.66e-65,261.23,35,40,0,65.62,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),9.48e-23,267.64,35,14,0,19.6,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.76e-06,267.63,35,4,0,4.46,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.68e-09,254.48,35,6,0,7.03,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.14e-07,252.29,35,5,0,5.71,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.68e-09,254.48,35,6,0,7.03,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),9.32e-57,260.38,35,35,0,70.0,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",1.5e-09,267.63,35,6,0,7.03,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),2.82e-33,252.91,35,21,0,33.6,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),5.05e-33,249.93,35,21,0,33.6,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),7.43e-09,236.94,35,6,0,7.03,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),1.59e-17,259.96,35,11,0,14.46,3.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),2.05e-67,254.06,35,138,0,43.88,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),2.05e-67,262.06,35,77,0,50.91,5.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),9.77e-36,263.64,35,22,0,35.83,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),7.62e-13,267.63,35,8,0,9.83,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),2.05e-67,250.8,35,58,0,56.12,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",2.46e-44,251.39,35,28,0,50.4,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),3.77e-16,267.64,35,10,0,12.86,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),7.16e-46,288.58,35,27,0,47.83,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),1.4e-12,257.4,35,8,0,9.83,5.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),3.76e-32,259.27,35,20,0,31.43,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.14e-07,252.29,35,5,0,5.71,3.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),2.05e-67,258.4,35,351,0,38.49,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),3.45e-11,267.63,35,7,0,8.4,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),1.5e-09,267.63,35,6,0,7.03,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),2.05e-67,257.96,35,51,0,59.02,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.91e-07,241.32,35,5,0,5.71,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.49e-08,267.63,35,5,0,5.71,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.88e-17,253.47,35,11,0,14.46,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),3.45e-11,267.63,35,7,0,8.4,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),1.41e-28,254.49,35,18,0,27.26,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.4e-08,290.65,35,5,0,5.71,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),2.05e-67,253.82,35,124,0,44.88,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),2.2e-50,262.07,35,31,0,58.46,5.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),4.77e-39,263.96,35,24,0,40.46,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",2.05e-67,250.61,35,66,0,53.56,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),2.13e-45,261.51,34,27,1,48.44,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),2.05e-67,260.24,35,57,0,56.49,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),9.16e-25,245.71,35,16,0,23.31,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),4.13e-29,262.79,35,18,0,27.26,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),2.05e-67,254.3,34,169,1,40.84,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),5.07e-17,247.9,35,11,0,14.46,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),2.01e-32,263.26,35,20,0,31.43,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),7.46e-45,256.13,35,28,0,50.4,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),7.62e-13,267.63,35,8,0,9.83,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),2.05e-67,255.11,35,76,0,51.12,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),2.05e-67,260.53,35,95,0,47.89,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),4.91e-58,238.05,35,38,0,67.24,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),8.17e-42,258.12,35,26,0,45.31,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.76e-06,267.63,35,4,0,4.46,3.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),1.79e-22,261.5,35,14,0,19.6,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),1.05e-32,267.64,35,20,0,31.43,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.49e-08,267.63,35,5,0,5.71,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),1.56e-14,229.72,35,10,0,12.86,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.49e-08,267.63,35,5,0,5.71,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),3.76e-32,259.27,35,20,0,31.43,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),3.56e-19,260.55,35,12,0,16.11,5.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.76e-06,267.63,35,4,0,4.46,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),9.48e-23,267.64,35,14,0,19.6,5.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,249.22,35,4,0,4.46,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),3.97e-24,261.88,35,15,0,21.43,7.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),2.05e-67,231.08,35,430,0,37.85,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),4.89e-29,226.71,35,20,0,31.43,1.0
Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.68e-09,254.48,35,6,0,7.03,1.0
Calcitriol (horm),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),6.12e-19,255.78,9,34,1,11.38,8.0
Calcitriol (horm),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),6.12e-19,246.8,10,28,0,13.57,4.0
Osteoporosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.83e-06,32.11,5,30,0,5.83,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),1.83e-06,111.88,5,45,0,5.56,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,FLVCR1 (gngm),1.83e-06,109.56,5,14,0,6.79,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),1.83e-06,121.07,5,8,0,8.12,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (popg),USES,Tissue Microarray (resd),3.42e-06,41.62,5,7,0,8.57,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),1.9e-06,43.43,5,8,0,8.12,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.83e-06,84.24,5,12,0,7.08,1.0
Osteoporosis (dsyn),PROCESS_OF,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),1.83e-06,114.93,5,14,0,6.79,1.0
Treatment Protocols (topp),USES,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,235.99,7,4,0,6.29,4.0
Carcinogenesis (neop),PART_OF,Colon (bpoc),LOCATION_OF,Malignant neoplasm of prostate (neop),6.55e-08,94.07,36,5,0,5.69,2.0
Diabetic Retinopathy (dsyn),COEXISTS_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),2.25e-07,240.49,4,10,0,5.6,9.0
fibroblast growth factor 23 (aapp),CONVERTS_TO,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.77e-09,241.71,5,35,0,5.71,8.0
fibroblast growth factor 23 (aapp),CONVERTS_TO,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.77e-09,232.73,5,28,0,5.89,4.0
Immunomodulators (imft),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,272.7,32,35,0,61.26,8.0
Immunomodulators (imft),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,263.72,32,28,0,52.5,4.0
Osteomalacia (dsyn),ISA,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,178.22,30,6,0,7.2,5.0
Intestines (bpoc),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,162.6,31,15,0,22.26,2.0
Intestines (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,86.1,31,41,0,54.44,2.0
Intestines (bpoc),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,85.89,31,1,0,1.03,2.0
Intestines (bpoc),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,174.12,31,23,0,40.06,2.0
Aromatase Inhibitors (phsu),CAUSES,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.8e-07,131.66,6,5,0,9.17,1.0
Screening procedure (hlca),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,261.71,53,10,0,11.89,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),2.25e-07,224.48,4,19,0,4.84,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.94e-06,222.07,4,4,0,8.0,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.99e-06,240.49,4,4,0,8.0,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),2.25e-07,230.26,4,8,0,6.0,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.28e-07,227.33,4,6,0,6.67,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),2.25e-07,225.14,4,10,0,5.6,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),2.25e-07,231.28,4,9,0,5.78,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),2.27e-07,240.49,4,6,0,6.67,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.28e-07,227.33,4,6,0,6.67,3.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),2.25e-07,233.91,4,13,0,5.23,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),2.25e-07,233.91,4,13,0,5.23,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),2.25e-07,275.04,4,33,0,4.48,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),2.25e-07,230.65,4,50,0,4.32,3.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),2.25e-07,229.54,4,37,0,4.43,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.28e-07,227.33,4,6,0,6.67,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),2.25e-07,233.23,4,35,0,4.46,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),2.25e-07,222.08,4,32,0,4.5,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.94e-06,222.07,4,4,0,8.0,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),2.25e-07,240.49,4,10,0,5.6,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),2.25e-07,228.98,4,7,0,6.29,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),2.25e-07,240.49,4,7,0,6.29,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.28e-07,227.33,4,6,0,6.67,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),2.25e-07,226.32,4,11,0,5.45,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.99e-06,240.49,4,4,0,8.0,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),2.25e-07,217.92,4,40,0,4.4,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",2.25e-07,223.44,4,22,0,4.73,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),2.25e-07,228.21,4,13,0,5.23,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),2.25e-07,232.82,4,11,0,5.45,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.94e-06,222.07,4,4,0,8.0,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),2.25e-07,234.08,4,40,0,4.4,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),2.25e-07,240.49,4,14,0,5.14,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.99e-06,240.49,4,4,0,8.0,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.28e-07,227.33,4,6,0,6.67,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),3.39e-07,225.14,4,5,0,7.2,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.28e-07,227.33,4,6,0,6.67,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),2.25e-07,233.23,4,35,0,4.46,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",2.27e-07,240.49,4,6,0,6.67,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),2.25e-07,225.76,4,21,0,4.76,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),2.25e-07,222.79,4,21,0,4.76,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),2.33e-07,209.79,4,6,0,6.67,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),2.25e-07,232.82,4,11,0,5.45,3.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),2.25e-07,226.91,4,138,0,4.12,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),2.25e-07,234.91,4,77,0,4.21,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),2.25e-07,236.49,4,22,0,4.73,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),2.25e-07,240.49,4,8,0,6.0,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),2.25e-07,223.65,4,58,0,4.28,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",2.25e-07,224.25,4,28,0,4.57,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),2.25e-07,240.49,4,10,0,5.6,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),2.25e-07,261.43,4,27,0,4.59,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),2.25e-07,230.26,4,8,0,6.0,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),2.25e-07,232.12,4,20,0,4.8,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),3.39e-07,225.14,4,5,0,7.2,3.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),2.25e-07,231.25,4,351,0,4.05,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),2.25e-07,240.49,4,7,0,6.29,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),2.27e-07,240.49,4,6,0,6.67,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),2.25e-07,230.82,4,51,0,4.31,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),4.16e-07,214.18,4,5,0,7.2,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),2.9e-07,240.49,4,5,0,7.2,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),2.25e-07,226.32,4,11,0,5.45,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),2.25e-07,240.49,4,7,0,6.29,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),2.25e-07,227.34,4,18,0,4.89,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),2.59e-07,263.51,4,5,0,7.2,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),2.25e-07,226.67,4,124,0,4.13,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),2.25e-07,234.92,4,31,0,4.52,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),2.25e-07,236.81,4,24,0,4.67,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",2.25e-07,223.46,4,66,0,4.24,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),2.25e-07,234.36,4,28,0,4.57,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),2.25e-07,233.09,4,57,0,4.28,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),2.25e-07,218.57,4,16,0,5.0,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),2.25e-07,235.65,4,18,0,4.89,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),2.25e-07,227.15,4,170,0,4.09,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),2.25e-07,220.76,4,11,0,5.45,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),2.25e-07,236.11,4,20,0,4.8,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),2.25e-07,228.99,4,28,0,4.57,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),2.25e-07,240.49,4,8,0,6.0,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),2.25e-07,227.97,4,76,0,4.21,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),2.25e-07,233.38,4,95,0,4.17,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),2.25e-07,210.9,4,38,0,4.42,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),2.25e-07,230.97,4,26,0,4.62,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.99e-06,240.49,4,4,0,8.0,3.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),2.25e-07,234.35,4,14,0,5.14,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),2.25e-07,240.5,4,20,0,4.8,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),2.9e-07,240.49,4,5,0,7.2,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),2.25e-07,202.57,4,10,0,5.6,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),2.9e-07,240.49,4,5,0,7.2,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),2.25e-07,232.12,4,20,0,4.8,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),2.25e-07,233.41,4,12,0,5.33,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.99e-06,240.49,4,4,0,8.0,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),2.25e-07,240.49,4,14,0,5.14,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.94e-06,222.07,4,4,0,8.0,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),2.25e-07,234.74,4,15,0,5.07,4.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),2.25e-07,203.94,4,430,0,4.04,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),2.25e-07,199.57,4,20,0,4.8,1.0
Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.28e-07,227.33,4,6,0,6.67,1.0
Vitamin D (phsu),COEXISTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.33e-23,259.54,64,15,0,18.52,8.0
Vitamin D (phsu),COEXISTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,183.04,64,41,0,67.27,3.0
Vitamin D (phsu),COEXISTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,182.82,64,1,0,1.02,3.0
Vitamin D (phsu),COEXISTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),2.19e-37,271.05,64,23,0,31.27,9.0
Vitamin D (phsu),ADMINISTERED_TO,Control Groups (humn),LOCATION_OF,Prostate-Specific Antigen (aapp),5.68e-11,222.01,6,9,0,10.0,2.0
Organ (bpoc),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),6.41e-46,258.4,24,35,0,40.46,2.0
Organ (bpoc),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.43e-44,249.42,24,28,0,44.57,2.0
Mammals (mamm),LOCATION_OF,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.65e-07,128.27,5,15,0,6.67,2.0
Mammals (mamm),LOCATION_OF,Calcium (bacs),PART_OF,Protoplasm (celc),2.61e-06,51.77,5,41,0,5.61,2.0
Mammals (mamm),LOCATION_OF,Calcium (bacs),PART_OF,Coronary artery (bpoc),7.56e-07,51.55,5,1,0,1.2,2.0
Mammals (mamm),LOCATION_OF,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),1.65e-07,139.78,5,23,0,6.09,2.0
Vitamin D (phsu),ASSOCIATED_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,257.07,48,10,0,12.08,8.0
Dual-Energy X-Ray Absorptiometry (diap),ISA,Assessment procedure (hlca),TREATS,AIDS related complex (dsyn),2.46e-06,46.04,10,5,0,7.5,4.0
Vitamin D (phsu),INHIBITS,Angiogenesis (ortf),AFFECTS,Malignant neoplasm of prostate (neop),3.29e-11,235.75,6,10,0,9.6,7.0
Vitamin D (phsu),INHIBITS,Angiogenesis (ortf),AFFECTS,tumor growth (neop),6.77e-10,163.92,6,17,0,8.12,7.0
Pregnancy (orgf),ASSOCIATED_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.29e-11,251.09,6,10,0,9.6,8.0
Alendronate (opco),ISA,Diphosphonates (phsu),TREATS,Osteoporosis (dsyn),1.03e-06,32.56,85,25,0,32.35,4.0
Alendronate (opco),ISA,Diphosphonates (phsu),DISRUPTS,Osteoclasts (cell),3.23e-21,42.56,85,23,0,29.22,5.0
Alendronate (opco),ISA,Diphosphonates (phsu),TREATS,Bone pain (sosy),8.34e-16,57.19,85,13,0,14.99,4.0
Alendronate (opco),ISA,Diphosphonates (phsu),TREATS,Malignant neoplasm of prostate (neop),1.34e-98,112.02,84,60,1,102.86,4.0
Alendronate (opco),ISA,Diphosphonates (phsu),PREVENTS,Neoplasm Metastasis (neop),4.05e-06,59.37,85,5,0,5.29,5.0
Alendronate (opco),ISA,Diphosphonates (phsu),PREVENTS,loss; bone (patf),3.95e-30,48.37,85,28,0,37.22,5.0
Alendronate (opco),ISA,Diphosphonates (phsu),TREATS,loss; bone (patf),4.18e-09,42.4,85,10,0,11.18,4.0
Alendronate (opco),ISA,Diphosphonates (phsu),INHIBITS,Bone Resorption (ortf),1.62e-26,37.53,85,37,0,53.11,5.0
Alendronate (opco),ISA,Diphosphonates (phsu),TREATS,Multiple Myeloma (neop),1.26e-14,40.82,85,17,0,20.4,4.0
Alendronate (opco),ISA,Diphosphonates (phsu),TREATS,Bone Diseases (dsyn),1.82e-13,38.19,85,18,0,21.81,4.0
Alendronate (opco),ISA,Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),8.77e-112,56.42,85,104,0,154.47,4.0
Alendronate (opco),ISA,Diphosphonates (phsu),PREVENTS,Secondary malignant neoplasm of bone (neop),1.14e-11,54.2,85,10,0,11.18,5.0
Alendronate (opco),ISA,Diphosphonates (phsu),TREATS,Hypercalcemia (dsyn),3.25e-06,35.24,85,11,0,12.42,4.0
Alendronate (opco),ISA,Diphosphonates (phsu),TREATS,Neoplasm Metastasis (neop),1.7e-42,53.94,85,36,0,51.25,4.0
Calcitriol (horm),INHIBITS,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),5.68e-11,215.87,6,15,0,8.4,8.0
Calcitriol (horm),INHIBITS,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,139.37,6,41,0,6.88,3.0
Calcitriol (horm),INHIBITS,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,139.16,6,1,0,1.17,3.0
Calcitriol (horm),INHIBITS,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),5.68e-11,227.39,6,23,0,7.57,13.0
dihydroxy-vitamin D3 (orch),STIMULATES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.25e-07,235.53,4,35,0,4.46,8.0
dihydroxy-vitamin D3 (orch),STIMULATES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.25e-07,226.55,4,28,0,4.57,4.0
25-hydroxyvitamin D (strd),ISA,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,261.86,202,35,0,41.06,5.0
25-hydroxyvitamin D (strd),ISA,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,252.88,202,28,0,31.88,4.0
Vitamin D (phsu),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,256.65,37,14,0,19.3,8.0
Vitamin D (phsu),STIMULATES,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,255.88,36,12,1,16.0,12.0
Vitamin D (phsu),STIMULATES,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,268.15,37,6,0,6.97,8.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Neoplasm Metastasis (neop),1.82e-06,21.62,48,10,0,12.08,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Adenocarcinoma of the prostate metastatic (neop),2.76e-06,107.87,48,4,0,4.33,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),USES,Punch (medd),7.46e-08,17.3,48,42,0,78.75,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),PRECEDES,Implantation procedure (topp),2.42e-08,41.58,48,7,0,8.02,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Atypical proliferation (patf),4.5e-10,69.51,48,7,0,8.02,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),METHOD_OF,Core needle biopsy (diap),1.18e-07,35.33,48,7,0,8.02,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),USES,"Reagents, Immunoassay, Tumor Marker, Enzyme, Prostate Specific Antigen (irda)",2.08e-50,94.41,48,35,0,60.52,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),ISA,Diagnosis (hlca),2.08e-50,19.4,48,123,0,66.73,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Prostate carcinoma (neop),2.08e-50,84.87,48,48,0,96.0,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Benign prostatic hypertrophy (neop),4.13e-29,103.04,48,18,0,24.75,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Carcinoma (neop),1.01e-47,31.72,48,46,0,90.08,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),METHOD_OF,Magnetic Resonance Imaging (diap),4.71e-47,45.69,48,37,0,65.52,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),ISA,Procedures (hlca),2.08e-50,25.45,48,147,0,63.67,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Adenocarcinoma (neop),2.08e-50,33.49,48,92,0,73.04,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,High-Grade Prostatic Intraepithelial Neoplasia (neop),9.07e-39,100.8,48,24,0,36.0,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),USES,Guide device (medd),7.16e-08,52.63,48,6,0,6.75,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Small cell carcinoma of lung (neop),1.31e-08,26.14,48,10,0,12.08,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),AFFECTS,Malignant neoplasm of prostate (neop),2.62e-44,107.89,48,27,0,42.19,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),ISA,diagnostic procedure (diap),4.63e-13,23.82,48,17,0,23.02,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,CAP - NOS (fndg),1.15e-18,89.46,48,12,0,15.0,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),PRECEDES,Radical prostatectomy (topp),1.47e-20,95.6,48,13,0,16.52,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),USES,Probes (medd),3.74e-11,26.03,48,13,0,16.52,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,"[M]Adenocarcinoma, metastatic, NOS (neop)",3.83e-08,27.47,48,9,0,10.69,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),NEG_DIAGNOSES,Malignant neoplasm of prostate (neop),2.19e-37,104.05,48,23,0,34.02,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),METHOD_OF,Early Diagnosis (diap),6.82e-22,27.43,48,24,0,36.0,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),ADMINISTERED_TO,Physicians (humn),3.01e-07,27.49,48,8,0,9.33,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),ADMINISTERED_TO,Urologist (humn),1.58e-35,71.05,48,24,0,36.0,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Prostate cancer metastatic (neop),7.38e-24,97.05,48,15,0,19.69,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,Malignant neoplasm of prostate (neop),2.08e-50,93.89,48,763,0,51.02,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),DIAGNOSES,"Carcinoma, Transitional Cell (neop)",7.9e-11,27.31,48,12,0,15.0,2.0
Entire iliac crest (bpoc),LOCATION_OF,Biopsy (diap),METHOD_OF,Cancer Diagnosis (diap),3.62e-45,66.78,48,31,0,51.02,2.0
Cholecalciferol (phsu),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,260.76,20,10,0,15.0,4.0
Blood specimen (bdsu),LOCATION_OF,Alkaline Phosphatase (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.75e-08,129.18,6,12,0,9.0,2.0
Blood specimen (bdsu),LOCATION_OF,Alkaline Phosphatase (aapp),PREDISPOSES,Secondary malignant neoplasm of bone (neop),2.76e-08,75.87,6,8,0,10.5,2.0
Renal Osteodystrophy (dsyn),ISA,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),4.56e-09,137.77,10,6,0,9.6,5.0
"PTH protein, human|PTH (aapp)",ASSOCIATED_WITH,Metabolic syndrome (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),5.64e-07,179.67,4,16,0,5.0,8.0
"PTH protein, human|PTH (aapp)",ASSOCIATED_WITH,Metabolic syndrome (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),5.65e-07,186.58,4,7,0,6.29,8.0
Vitamin D (phsu),PREVENTS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,277.65,26,10,0,13.85,21.0
Vitamin D3 Receptor (gngm),PART_OF,Colon (bpoc),LOCATION_OF,Malignant neoplasm of prostate (neop),6.65e-08,277.59,5,5,0,10.0,2.0
Vitamin D (phsu),ASSOCIATED_WITH,Disease Progression (patf),COEXISTS_WITH,Prostate cancer metastatic (neop),2.76e-06,277.61,11,4,0,5.45,8.0
Vitamin D (phsu),ASSOCIATED_WITH,Disease Progression (patf),COEXISTS_WITH,Malignant neoplasm of prostate (neop),3.78e-21,270.81,11,50,0,13.42,8.0
Vitamin D Deficiency (dsyn),PREDISPOSES,Anemia (dsyn),COEXISTS_WITH,Iron deficiency anemia (dsyn),4.65e-09,178.55,5,9,0,7.78,9.0
dihydroxy-vitamin D3 (orch),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,257.38,60,14,0,17.27,8.0
dihydroxy-vitamin D3 (orch),INTERACTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,256.61,60,13,0,15.82,10.0
dihydroxy-vitamin D3 (orch),INTERACTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,268.88,60,6,0,6.6,8.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.13e-12,210.44,7,14,0,10.5,2.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.13e-12,209.67,7,13,0,10.77,2.0
Adipose tissue (tisu),LOCATION_OF,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,221.94,7,6,0,11.14,2.0
Calcitriol (horm),AFFECTS,Cell Growth (celf),PROCESS_OF,Cancer Model (emod),4.71e-06,238.57,8,4,0,6.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,high-risk group (popg),1.85e-11,261.59,6,19,0,7.89,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),OCCURS_IN,Participant (humn),4.71e-06,259.18,6,4,0,6.67,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Rats, Sprague-Dawley (mamm)",2.76e-06,277.59,6,4,0,6.67,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Aggressive behavior (mobd),1.99e-11,267.36,6,8,0,10.5,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Aggressive behavior (mobd),2.7e-09,264.44,6,6,0,12.0,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Adenocarcinoma (neop),1.85e-11,262.25,6,10,0,9.6,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Chronic inflammation (patf),1.85e-11,268.39,6,9,0,10.0,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Elderly man (aggp),1.52e-09,277.59,6,6,0,12.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Uterus (bpoc),2.7e-09,264.44,6,6,0,12.0,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Diabetes Mellitus (dsyn),1.85e-11,271.02,6,13,0,8.77,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Disease Progression (patf),1.85e-11,271.02,6,13,0,8.77,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Population Group (popg),1.85e-11,312.15,6,33,0,7.09,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Prostate (bpoc),1.85e-11,267.75,6,50,0,6.72,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Benign prostatic hypertrophy (neop),1.85e-11,266.65,6,37,0,6.97,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Surgical Patients (podg),2.7e-09,264.44,6,6,0,12.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Prostatic Diseases (dsyn),1.85e-11,270.34,6,35,0,7.03,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Veterans (popg),1.85e-11,259.19,6,32,0,7.12,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,organ donor (popg),4.71e-06,259.18,6,4,0,6.67,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Secondary malignant neoplasm of bone (neop),1.85e-11,277.6,6,10,0,9.6,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Cell Cycle (celf),8.04e-11,266.09,6,7,0,11.14,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,parathyroid hormone-related protein (aapp),5.29e-11,277.6,6,7,0,11.14,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Couples (humn),2.7e-09,264.44,6,6,0,12.0,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Androgens (horm),1.85e-11,263.43,6,11,0,9.27,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Cell Death (celf),2.76e-06,277.59,6,4,0,6.67,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,father (humn),1.85e-11,255.02,6,40,0,6.9,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Transgenic (mamm)",1.85e-11,260.55,6,22,0,7.64,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Tumorigenesis (neop),1.85e-11,265.32,6,13,0,8.77,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Population at Risk (popg),1.85e-11,269.92,6,11,0,9.27,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Clinicians (humn),4.71e-06,259.18,6,4,0,6.67,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Pathogenesis (patf),1.85e-11,271.19,6,40,0,6.9,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,member (popg),1.85e-11,277.6,6,14,0,8.57,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Prostate cancer metastatic (neop),2.76e-06,277.59,6,4,0,6.67,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,cohort (popg),2.7e-09,264.44,6,6,0,12.0,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Electromagnetic Energy (npop),1.14e-07,262.25,6,5,0,9.17,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Androgen Receptor|AR (aapp),2.7e-09,264.44,6,6,0,12.0,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Ethnic group (popg),1.85e-11,270.34,6,35,0,7.03,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,"Transcription, Genetic (genf)",1.52e-09,277.59,6,6,0,12.0,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm progression (neop),1.85e-11,262.87,6,21,0,7.71,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,African race (popg),1.85e-11,259.89,6,21,0,7.71,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Homosexuals (popg),7.44e-09,246.9,6,6,0,12.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Breast (bpoc),1.85e-11,269.92,6,11,0,9.27,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Xenograft Model (emod),1.85e-11,264.02,6,138,0,6.26,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Solid tumor (neop),1.85e-11,272.02,6,77,0,6.47,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Carcinogenesis (neop),1.85e-11,273.6,6,22,0,7.64,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Germ-Line Mutation (genf),1.92e-11,277.6,6,8,0,10.5,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Asians (popg),1.85e-11,260.76,5,57,1,5.44,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Recipient, Transplant (podg)",1.85e-11,261.36,6,28,0,7.29,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Prostatic Neoplasms (neop),1.85e-11,277.6,6,10,0,9.6,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Males (popg),1.85e-11,298.54,6,27,0,7.33,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Cancer of Urinary Tract (neop),1.99e-11,267.36,6,8,0,10.5,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Urologist (humn),1.85e-11,269.23,6,20,0,7.8,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Solid organ (bpoc),1.14e-07,262.25,6,5,0,9.17,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),1.85e-11,268.36,6,351,0,6.1,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Donor person (humn),5.29e-11,277.6,6,7,0,11.14,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Oxidative Stress (comd),1.52e-09,277.59,6,6,0,12.0,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,General Population (popg),1.85e-11,267.93,6,51,0,6.71,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Black African (popg),1.91e-07,251.29,6,5,0,9.17,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Koreans (ethnic group) (popg),6.49e-08,277.59,6,5,0,9.17,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,network (popg),1.85e-11,263.43,6,11,0,9.27,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,High-Risk Cancer (neop),5.29e-11,277.6,6,7,0,11.14,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Couples (humn),1.85e-11,264.45,6,18,0,8.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Malignant neoplasm of kidney (neop),3.41e-08,300.61,6,5,0,9.17,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Caucasoid Race (popg),1.85e-11,263.78,6,124,0,6.29,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Malignant disease (dsyn),1.85e-11,272.03,6,31,0,7.16,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,gene polymorphism (genf),1.85e-11,273.92,5,23,1,6.09,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Nude (mamm)",1.85e-11,260.57,6,66,0,6.55,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Racial group (popg),1.85e-11,271.47,6,28,0,7.29,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Transgenic Model (emod),1.85e-11,270.2,6,57,0,6.63,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Hospital specialist (humn),1.85e-11,255.68,6,16,0,8.25,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Modulus (invt),1.85e-11,272.75,6,18,0,8.0,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,African American (popg),1.85e-11,264.26,6,170,0,6.21,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Health Personnel (humn),1.85e-11,257.87,6,11,0,9.27,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,High Risk Populations (popg),1.85e-11,273.22,6,20,0,7.8,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Control Groups (humn),1.85e-11,266.1,6,28,0,7.29,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Tumorigenesis (neop),1.92e-11,277.6,6,8,0,10.5,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,cohort (popg),1.85e-11,265.07,6,76,0,6.47,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Participant (humn),1.85e-11,270.49,6,95,0,6.38,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Brothers (humn),1.85e-11,248.01,6,38,0,6.95,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Neoplasm Metastasis (neop),1.85e-11,268.08,6,26,0,7.38,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PART_OF,Lobe (bpoc),2.76e-06,277.59,6,4,0,6.67,3.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,tumor growth (neop),1.85e-11,271.46,6,14,0,8.57,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),OCCURS_IN,cohort (popg),1.85e-11,277.6,6,20,0,7.8,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PRODUCES,Testosterone (strd),6.49e-08,277.59,6,5,0,9.17,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Metabolic syndrome (dsyn),1.85e-11,239.68,6,10,0,9.6,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Gene Expression (genf),6.49e-08,277.59,6,5,0,9.17,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Physicians (humn),1.85e-11,269.23,6,20,0,7.8,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Prostatic Neoplasms (neop),1.85e-11,270.51,6,12,0,9.0,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),COEXISTS_WITH,Advanced cancer (neop),2.76e-06,277.59,6,4,0,6.67,8.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),ISA,Urologic Diseases (dsyn),1.85e-11,277.6,6,14,0,8.57,5.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,spouse (humn),4.71e-06,259.18,6,4,0,6.67,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),AFFECTS,Disease Progression (patf),1.85e-11,271.84,6,15,0,8.4,7.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Survivors (podg),1.85e-11,241.04,6,430,0,6.08,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,Long-Term Survivors (podg),1.85e-11,236.68,6,20,0,7.8,1.0
Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),PROCESS_OF,"Mice, Inbred C57BL (mamm)",2.7e-09,264.44,6,6,0,12.0,1.0
Treatment Protocols (topp),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.9e-13,254.41,7,10,0,11.9,4.0
Vitamin D3 Receptor (gngm),AFFECTS,Cell Proliferation (celf),PROCESS_OF,"Mice, Nude (mamm)",3.11e-11,181.67,12,13,0,23.08,1.0
Vitamin D (phsu),PREVENTS,Oxidative Stress (comd),COEXISTS_WITH,Benign prostatic hypertrophy (neop),2.78e-08,231.55,5,6,0,9.17,9.0
Vitamin D (phsu),PREVENTS,Oxidative Stress (comd),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.59e-09,270.78,5,25,0,6.0,9.0
Vitamin D (phsu),PREVENTS,Oxidative Stress (comd),AFFECTS,Malignant neoplasm of prostate (neop),1.59e-09,277.6,5,11,0,7.27,7.0
Proximal metaphysis (bpoc),PART_OF,Bone structure of tibia (bpoc),PART_OF,"Mice, Nude (mamm)",7.52e-14,55.67,39,10,0,12.56,3.0
Vitamin D Deficiency (dsyn),PRODUCES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.85e-11,272.63,6,35,0,7.03,8.0
Vitamin D Deficiency (dsyn),PRODUCES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.85e-11,263.65,6,28,0,7.29,4.0
Vitamin D (phsu),ASSOCIATED_WITH,Anemia (dsyn),COEXISTS_WITH,Iron deficiency anemia (dsyn),1.79e-12,208.37,7,9,0,12.44,8.0
X Chromosome (celc),LOCATION_OF,Endopeptidases (aapp),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.71e-06,128.34,33,4,0,4.48,2.0
X Chromosome (celc),LOCATION_OF,Endopeptidases (aapp),PART_OF,integral to membrane (celc),2.9e-39,81.23,33,32,0,63.03,2.0
X Chromosome (celc),LOCATION_OF,Endopeptidases (aapp),ASSOCIATED_WITH,Neoplasm progression (neop),5.74e-08,76.91,33,7,0,8.48,2.0
vitamin therapy (topp),TREATS,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.9e-13,254.41,7,10,0,11.9,4.0
Calcium (bacs),COEXISTS_WITH,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,153.5,7,9,0,12.44,5.0
Calcitriol (horm),ISA,Steroid hormone (horm),ASSOCIATED_WITH,Carcinogenesis (neop),4.05e-06,214.3,9,5,0,7.78,5.0
Calcitriol (horm),ISA,Steroid hormone (horm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),7.33e-16,269.23,9,10,0,17.1,5.0
Animal Model (anim),LOCATION_OF,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),2.08e-38,263.83,20,35,0,31.43,2.0
Animal Model (anim),LOCATION_OF,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),2.08e-38,254.85,20,28,0,34.29,2.0
Management procedure (hlca),TREATS,Bone Diseases (dsyn),COEXISTS_WITH,Malignant neoplasm of prostate (neop),1.37e-07,123.62,5,6,0,9.17,4.0
Calcium (bacs),INHIBITS,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.4e-07,141.72,5,9,0,7.78,5.0
Vitamin D (phsu),AFFECTS,Cell Proliferation (celf),PROCESS_OF,"Mice, Nude (mamm)",3.11e-11,196.02,46,13,0,16.67,1.0
Vitamin D3 Receptor|VDR (aapp),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.41e-26,239.91,14,35,0,19.6,8.0
Vitamin D3 Receptor|VDR (aapp),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.41e-26,230.93,14,28,0,21.0,4.0
Calcifediol (phsu),INTERACTS_WITH,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.78e-21,272.65,11,35,0,14.46,8.0
Calcifediol (phsu),INTERACTS_WITH,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),3.78e-21,263.67,11,28,0,15.32,4.0
"PTH protein, human|PTH (aapp)",ASSOCIATED_WITH,Vitamin D Deficiency (dsyn),PREDISPOSES,Malignant neoplasm of prostate (neop),3.77e-16,262.15,11,10,0,19.09,8.0
Prophylactic treatment (topp),USES,Cholecalciferol (phsu),TREATS,Malignant neoplasm of prostate (neop),4.71e-06,242.32,10,4,0,5.6,4.0
zoledronic acid (phsu),PREVENTS,loss; bone (patf),PROCESS_OF,Cancer Patient (humn),6.79e-07,69.77,11,5,0,7.27,1.0
Vitamin D (phsu),TREATS,melanoma (neop),PART_OF,Prostate (bpoc),3.41e-26,211.24,14,33,0,19.94,3.0
Vitamin D (phsu),TREATS,melanoma (neop),PART_OF,Breast (bpoc),3.41e-26,176.74,14,26,0,21.54,3.0
Vitamin D (phsu),TREATS,melanoma (neop),PART_OF,Ovary (bpoc),2.27e-08,169.93,14,8,0,12.57,3.0
Vitamin D (phsu),TREATS,melanoma (neop),PART_OF,Colon (bpoc),8.81e-10,166.96,14,10,0,17.14,3.0
Trochanter (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Prostate (bpoc),1.31e-11,79.52,9,12,0,15.75,2.0
Trochanter (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,"Preservation, Biological (lbpr)",1.31e-11,56.93,9,63,0,10.29,2.0
Trochanter (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Malignant neoplasm of prostate (neop),2.69e-09,108.22,9,6,0,10.0,2.0
Trochanter (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Bladder stenosis (anab),1.31e-11,48.86,9,17,0,13.76,2.0
Trochanter (bpoc),LOCATION_OF,Neck (blor),LOCATION_OF,Surgical margins (bpoc),1.31e-11,81.91,9,12,0,15.75,2.0
zoledronate (opco),ISA,Diphosphonates (phsu),TREATS,Osteoporosis (dsyn),2e-06,11.02,8,25,0,10.56,4.0
zoledronate (opco),ISA,Diphosphonates (phsu),DISRUPTS,Osteoclasts (cell),9.72e-07,21.02,8,23,0,10.78,5.0
zoledronate (opco),ISA,Diphosphonates (phsu),TREATS,Bone pain (sosy),9.72e-07,35.65,8,13,0,12.92,4.0
zoledronate (opco),ISA,Diphosphonates (phsu),TREATS,Malignant neoplasm of prostate (neop),9.72e-07,90.48,7,60,1,7.82,4.0
zoledronate (opco),ISA,Diphosphonates (phsu),PREVENTS,Neoplasm Metastasis (neop),5.02e-06,37.82,8,5,0,8.12,5.0
zoledronate (opco),ISA,Diphosphonates (phsu),PREVENTS,loss; bone (patf),9.72e-07,26.83,8,28,0,10.29,5.0
zoledronate (opco),ISA,Diphosphonates (phsu),TREATS,loss; bone (patf),9.76e-07,20.85,8,10,0,14.4,4.0
zoledronate (opco),ISA,Diphosphonates (phsu),INHIBITS,Bone Resorption (ortf),9.72e-07,15.99,8,37,0,9.73,5.0
zoledronate (opco),ISA,Diphosphonates (phsu),TREATS,Multiple Myeloma (neop),9.72e-07,19.28,8,17,0,11.76,4.0
zoledronate (opco),ISA,Diphosphonates (phsu),TREATS,Bone Diseases (dsyn),9.72e-07,16.65,8,18,0,11.56,4.0
zoledronate (opco),ISA,Diphosphonates (phsu),TREATS,Secondary malignant neoplasm of bone (neop),9.72e-07,34.88,8,104,0,8.62,4.0
zoledronate (opco),ISA,Diphosphonates (phsu),PREVENTS,Secondary malignant neoplasm of bone (neop),9.72e-07,32.66,8,10,0,14.4,5.0
zoledronate (opco),ISA,Diphosphonates (phsu),TREATS,Hypercalcemia (dsyn),4.22e-06,13.7,8,11,0,13.82,4.0
zoledronate (opco),ISA,Diphosphonates (phsu),TREATS,Neoplasm Metastasis (neop),9.72e-07,32.4,8,36,0,9.78,4.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),USES,alpha Tocopherol (phsu),3.36e-06,126.33,4,17,0,4.94,6.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),AFFECTS,Malignant neoplasm of prostate (neop),4.79e-07,200.41,4,5,0,7.2,7.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),USES,Soy Proteins (phsu),4.21e-07,132.44,4,10,0,5.6,6.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),METHOD_OF,cancer prevention (topp),8.25e-07,174.83,4,5,0,7.2,16.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),USES,lycopene (phsu),3.65e-07,133.75,4,22,0,4.73,6.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),USES,Androgens (horm),3.65e-07,139.69,4,28,0,4.57,6.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),USES,Testosterone (strd),3.65e-07,129.45,4,46,0,4.35,6.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),PREVENTS,Malignant neoplasm of prostate (neop),3.65e-07,199.01,4,9,0,5.78,22.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),TREATS,Malignant neoplasm of prostate (neop),3.65e-07,197.34,4,20,0,4.8,4.0
Gastrectomy (topp),PRECEDES,Supplementation (topp),USES,Iron (phsu),6.82e-07,123.73,4,3,0,5.25,6.0
methyl 4-azidophenylacetimidate (orch),COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),3.27e-22,244.59,38,14,0,19.16,8.0
methyl 4-azidophenylacetimidate (orch),COEXISTS_WITH,Vitamin D3 Receptor (gngm),PREDISPOSES,Malignant neoplasm of prostate (neop),1.47e-20,243.82,38,13,0,17.45,9.0
methyl 4-azidophenylacetimidate (orch),COEXISTS_WITH,Vitamin D3 Receptor (gngm),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),1.5e-09,256.09,38,6,0,6.95,8.0
TRPV6 (gngm),PART_OF,Intestines (bpoc),LOCATION_OF,Adverse effects (patf),2.58e-09,147.39,9,12,0,15.75,2.0
TRPV6 (gngm),PART_OF,Intestines (bpoc),LOCATION_OF,Toxic effect (inpo),1.6e-16,147.12,9,58,0,10.4,2.0
Vitamin D Deficiency (dsyn),OCCURS_IN,cohort (popg),LOCATION_OF,Single Nucleotide Polymorphism (nusq),1.23e-12,177.07,15,30,0,22.5,2.0
Vitamin D Deficiency (dsyn),OCCURS_IN,cohort (popg),LOCATION_OF,Prostate-Specific Antigen (aapp),1.15e-28,256.83,15,45,0,20.0,2.0
Vitamin D Deficiency (dsyn),OCCURS_IN,cohort (popg),LOCATION_OF,FLVCR1 (gngm),3.27e-22,254.51,15,14,0,27.07,2.0
Vitamin D Deficiency (dsyn),OCCURS_IN,cohort (popg),LOCATION_OF,ERG gene|ERG (aapp),7.62e-13,266.02,15,8,0,12.27,2.0
Vitamin D Deficiency (dsyn),OCCURS_IN,cohort (popg),USES,Tissue Microarray (resd),1.59e-06,186.58,15,7,0,10.27,6.0
Vitamin D Deficiency (dsyn),OCCURS_IN,cohort (popg),LOCATION_OF,Insulin-Like Growth Factor I (aapp),7.16e-08,188.39,15,8,0,12.27,2.0
Vitamin D Deficiency (dsyn),OCCURS_IN,cohort (popg),LOCATION_OF,KLK3 gene|KLK3 (aapp),1.4e-17,229.19,15,12,0,21.6,2.0
Vitamin D Deficiency (dsyn),OCCURS_IN,cohort (popg),USES,Gleason grading system for prostatic cancer (clas),1.79e-22,259.89,15,14,0,27.07,6.0
keratinocyte (cell),LOCATION_OF,Calcitriol (horm),ISA,Dihydroxycholecalciferols (phsu),2.35e-07,170.0,13,9,0,15.23,2.0
Dairy Products (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),2.21e-06,76.3,4,12,0,5.33,1.0
Dairy Products (food),PREDISPOSES,Carcinoma of the Large Intestine (neop),PROCESS_OF,Survivors (podg),2.21e-06,71.16,4,34,0,4.47,1.0
Supplementation (topp),USES,Vitamin D (phsu),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),4.91e-57,257.11,1253,35,0,35.98,6.0
Supplementation (topp),USES,Vitamin D (phsu),TREATS,Malignant neoplasm of prostate (neop),1.36e-44,248.13,1253,28,0,28.63,4.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),ASSOCIATED_WITH,Malignant neoplasm of prostate (neop),8.97e-13,144.2,8,15,0,12.27,8.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),PART_OF,Protoplasm (celc),2.44e-06,67.7,8,41,0,9.56,3.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),PART_OF,Coronary artery (bpoc),5.91e-07,67.48,8,1,0,1.12,3.0
"PTH protein, human|PTH (aapp)",INTERACTS_WITH,Calcium (bacs),PREDISPOSES,Malignant neoplasm of prostate (neop),8.97e-13,155.71,8,23,0,10.78,10.0
